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Summary 
Patients with end stage renal disease (ESRD) have a 20-100 fold risk of premature 
cardiovascular death compared to age matched controls from the general population. 
These patients have many ‘conventional’ cardiovascular risk factors such as diabetes, 
ischaemic heart disease, hypertension, cigarette smoking and hyperlipidaemia. 
However, the relationship between the presence of these risk factors and cardiovascular 
outcomes is less clear in ESRD than in the general population. In the cases of 
hyperlipidaemia and hypertension a paradoxical relationship has been demonstrated 
where lower cholesterol or blood pressure is associated with an increased risk of 
cardiovascular events. One factor previously demonstrated to be associated with poor 
prognosis is the presence of uraemic cardiomyopathy, found in approximately 70% of 
ESRD patients at initiation of dialysis therapy, usually defined echocardiographically as 
the presence of left ventricular (LV) abnormalities, including left ventricular 
hypertrophy (LVH), LV dilatation and LV systolic dysfunction. However, 
echocardiography makes assumptions regarding LV geometry, which is frequently 
distorted in patients with ESRD. Furthermore any errors in measurements are amplified 
by the changes in hydration status which occur during the dialysis cycle, leading to 
changes in LV chamber dimensions. For these reasons, cardiac magnetic resonance 
imaging (CMR), by providing high fidelity measurements, potentially offers a ‘volume 
independent’ method of quantifying LV dimensions. Furthermore, by using gadolinium 
based contrast agents, tissue abnormalities particularly myocardial fibrosis, indicated by 
late gadolinium enhancement (LGE) may by identified.  
 
The work contained in this thesis examines the relationship between cardiac 
dimensions, as defined by CMR and cardiovascular risk factors (both conventional and 
specific to uraemia).  In a study of 145 patients with ESRD using CMR with 
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gadolinium, two specific pathological processes were demonstrated. First, the presence 
of subendocardial LGE indicating previous myocardial infarction was associated with 
the presence of conventional cardiovascular risk factors such as previous ischaemic 
heart disease and diabetes. Patients with subendocardial LGE frequently had LV 
systolic dysfunction. Second, diffuse LGE, representing fibrosis throughout the LV wall 
was identified in patients with LVH. This was an unexpected finding and appears 
specific to uraemia. Using CMR, isolated LV dilatation was rare. These findings 
suggest that in uraemia two forms of cardiomyopathy exist- LV systolic dysfunction 
due to underling myocardial ischaemia and LVH which is a true ‘uraemic 
cardiomyopathy’ associated with diffuse myocardial fibrosis. Attempts were made to 
reassess the relationship between CMR and echocardiographic measures of cardiac 
dimensions. In keeping with a previous study, it was demonstrated that M-mode 
echocardiography overestimates LV mass compared to CMR in this population. Thus, 
CMR may be used to optimise echocardiographic formulae to calculate LV mass. 
Furthermore, it appeared that either by echocardiography or by CMR the chief 
determinant of LVH in this population was blood pressure, in particular systolic blood 
pressure. This has implications for treatment as recent studies aimed at correcting 
anaemia, previously associated with LVH, either to reduce LV mass or to improve 
survival, have generally demonstrated increased cardiovascular events with higher 
haemoglobin. Therefore, if LV mass is a goal of treatment, attempts should be made to 
reduce blood pressure further in this population. 
 
The patients studied in these investigations were candidates for renal transplantation, 
the definitive treatment for chronic renal failure. Cardiovascular disease is the leading 
cause of death both in patients on the renal transplant list, as well as post successful 
transplantation. There is a great deal of interest in identifying patients at high 
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cardiovascular risk, to allow strategies to be adopted to minimise this risk, frequently by 
undertaking invasive investigation such as coronary angiography. In a survival study of 
300 potential renal transplant recipients, factors associated with increased risk of 
mortality were increased age, ischaemic heart disease whilst receipt of a renal transplant 
was protective. Although the presence of LGE was associated with poorer outcome, this 
finding was not independent of other variables. One interesting finding was that patients 
with greater exercise tolerance, measured objectively using the full Bruce exercise test 
had better outcomes. This observation represents a simple pragmatic method to risk-
stratify such patients. A study using the biomarker brain natriuretic peptide (BNP) a 
peptide released from the LV in response to stretch and hypertrophy, in 114 patients, 
demonstrated that whilst BNP has potential as a diagnostic tool for the presence of 
uraemic cardiomyopathy, in particular LVH, this peptide added little prognostic value.   
 
As familiarity with CMR techniques developed, it became clear that vascular function 
could be investigated with this imaging modality. Previous studies using alternative 
measures of vascular function have suggested that arterial stiffness is an important 
predictor of long term outcome in patients with ESRD. A study of 147 uraemic patients 
using aortic distensibilty and aortic volumetric arterial strain as CMR measures of aortic 
stiffness demonstrated that both these parameters were associated with an increased risk 
of cardiovascular events and mortality. To date there do not appear to be any similar 
outcome studies using these measures, although a number of authors have noted an 
association between aortic distensibilty and cardiovascular risk factors. These factors 
may represent potential targets for therapy aimed at reduction of cardiovascular risk in 
patients with ESRD.  
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One unfortunate development during the period during which these studies were 
undertaken, was the emergence of a link between exposure to gadolinium based contrast 
agents and nephrogenic systemic fibrosis (NSF), a potentially life threatening skin 
disorder in patients with advanced renal failure. This finding lead to the cessation of 
contrast CMR studies. A retrospective investigation of factors present in patients in 
North Glasgow affected by NSF, confirmed that patients with NSF were more likely to 
have undergone contrast based imaging than unaffected patients, frequently undergoing 
multiple scans, with high doses of gadodiamide used. Until this issue is clarified, future 
scans using these agents in this population should be undertaken with caution. 
 
These studies have characterised for the first time the relationship between both uraemic 
cardiomyopathy and uraemic arterial stiffness and both cardiovascular risk factors and 
long term outcome. CMR measures of cardiac dimensions and vascular function 
represent future targets for interventions aimed at reducing cardiovascular risk in 
patients with advanced renal failure.  
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Chapter 1 
 
 
Introduction 
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1.1  Epidemiology of cardiovascular disease in end stage renal failure 
Premature cardiovascular disease is the leading cause of death in patients with end stage 
renal disease (ESRD) requiring dialysis therapy with approximate risk age adjusted 
cardiovascular risk and cardiovascular mortality rates around 20 times those of the 
general population(1;2). Prior to the development of haemodialysis (and subsequently 
peritoneal dialysis) as treatment for advanced renal failure, pericarditis and pericardial 
effusions were common and often fatal cardiac manifestations of the syndrome of 
terminal uraemia.  With the advent of dialysis therapy, it became evident that premature 
cardiovascular disease was reported as cause of death in a disproportionately large 
number of patients on dialysis programmes, despite the young age of patients selected 
for dialysis treatment during the early years of this treatment. In 1974, the Seattle group 
led by Belding Scribner, a pioneer in early haemodialysis treatment, reported the 
presence of accelerated atherosclerosis in patients treated with dialysis treatment(3). 
Whilst undeniably a contributory factor to the excess cardiovascular mortality in ESRD 
patients, this is unlikely to be the sole mechanism, and further analysis of the 
relationship between conventional cardiovascular risk factors and outcome in this 
population reveals stark differences between patients with ESRD and the general 
population. 
 
Using data from the United States Renal Data Services (USRDS), approximately 60% 
of deaths amongst dialysis patients in the United States can be attributed to myocardial 
infarction, cardiac arrest, cerebrovascular disease and other cardiac causes(4), with 
similar figures reported to European renal registries. Whilst the most common mode of 
cardiovascular death in the general population is myocardial infarction, one striking 
finding in the ESRD population is the extremely high proportion of deaths attributed to 
sudden (and therefore presumed arrhythmic) cardiac death (Figure 1.1).  
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Figure 1.1 
Cause specific death rates for all dialysis patients by age, 1995-97 from the USRDS 
report 1999.  
 
One dilemma here is the difficultly is ascertaining the cause of death in such patients, to 
then identify reversible risk factors to improve treatment. Nonetheless, as this is a 
consistent finding, it suggests differences in the pathogenesis of fatal cardiovascular 
events in patients with ESRD compared to those in the general population. Moreover, 
although many ‘conventional’ cardiovascular risk factors are present in patients with 
ESRD, the relationship between these risk factors and outcome is less clear than in the 
general population, and additionally there are cardiovascular risk factors either specific 
to the uraemic milieu which carry a more influential role on future cardiovascular 
events than in the general population. Table 1.1 lists some of these risk factors which 
will be discussed in greater detail. 
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Risk factors for CVD – gen. population Risk factors for CVD - ESRD 
Older age Haemodynamic and metabolic factors of CRF 
Hypertension Proteinuria 
Hyperlipidaemia ↑extracellular fluid (ECF) volume 
Diabetes Electrolyte imbalance 
Physical inactivity Anaemia 
Previous MI/CAD/PVD/CVD Homocysteine 
Smoking ↑PTH/calcium-phosphate  
Oxidative stress Arterial calcification 
LVH/LVSD Inflammation 
 
Table 1.1 
Risk factors for cardiovascular disease in the general population and in ESRD 
 
1.2 Risk factors for cardiovascular disease in the general population and in 
ESRD 
In the later part of the 20th century it became clear from an abundance of large clinical 
trials, that by intervention on a specific risk factor, previously identified from 
observational studies, the risk of future cardiovascular events could be reduced. Focus 
has directed on which patients derive most benefit from these interventions, frequently 
dependent on their baseline probability of a certain event occurring. For example, in the 
case of lipid lowering therapy post myocardial infarction(5), the clinical benefit is now 
clear and has translated into widespread changes in clinical practice.  As the same 
evidence is not present in the ESRD population, it is tempting to extrapolate these 
findings from trials in the general population to this group. However, these 
epidemiological associations from observational studies do not demonstrate the same 
relationship in ESRD as in the general population and to date interventional trials aimed 
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at such risk factors in ESRD patients have given conflicting results. It is also clear that 
some of these risk factors are closely interrelated (e.g. haemodynamic/ metabolic factors 
of chronic renal failure and extracellular fluid volume). A number of the factors 
displayed in Table 1.1 are discussed.  
 
1.2.1  Hypertension 
In the general population, it has been demonstrated that lowering blood pressure in 
patients with hypertension reduces cardiovascular risk(6;7). Initially studies suggested 
that the agent used to treat blood pressure may not be as important as the blood pressure 
target itself, with certain exceptions. Treatment with diuretics(8), calcium channel 
antagonists(9), beta blockers(10), angiotensin converting enzyme inhibitors(11) and 
angiotensin receptor blockers(12) have all been shown to be effective at reducing risk of 
cardiovascular events in hypertensive individuals. To date, no minimum blood pressure 
target has been identified and although there is some evidence from observational 
studies that a ‘U’ or ‘J’ shaped curve relationship between diastolic blood pressure and 
outcome exists(13), suggesting that low diastolic blood pressure may compromise 
perfusion of vascular beds distal to a stenotic vessel. Nonetheless, this is less of a 
problem in clinical practice, where frequently achieving target blood pressure is more of 
an issue. Additionally, it has been clearly demonstrating that reduction of blood 
pressure is a major modifiable risk factor in patients with chronic kidney disease, both 
in preventing progression to ESRD and in preventing cardiovascular events(14;15). 
The story is more complex in patients with ESRD. Several observational studies have 
demonstrated that low blood pressure is independently associated with increased 
mortality in ESRD. Zager et al demonstrated that whilst pre-dialysis blood pressure was 
unrelated to cardiovascular mortality, a clear ‘U’ shaped curve relationship between 
post-dialysis blood pressure was seen with post-dialysis systolic blood 
43 
pressure>180mmHg and <110mmHg both associated with adverse outcome(16). 
Similar findings have been demonstrated in other observational studies, with Port et al 
also observing that a low pre-dialysis blood pressure being associated with 
mortality(17). However, intriguingly Mazzuchi et al observed that once incident 
dialysis patients were followed up for greater than two years, risk of early mortality 
(after < 2years on dialysis therapy) demonstrated a ‘U’ shaped relationship with pre-
dialysis systolic blood pressure (patients with systolic blood pressure >160mmHg or 
<110mmHg were most at risk), whilst later mortality (after >2 years on dialysis therapy) 
demonstrated a linear relationship with increasing blood pressure(18). The inference 
from this study is that low blood pressure in incident dialysis patients may represent left 
ventricular systolic dysfunction, hence increasing these patients risk of early death.  
 
There few trials to inform how best to achieve blood pressure targets in ESRD, and 
observational data supports the use of long-duration dialysis sessions, with slow 
ultrafiltration as pioneered by Charra et al in Tassain, France(19). More recent data 
have shown similar benefits with nocturnal haemodialysis (allowing for longer 
treatment sessions)(20). There is a pressing need for large randomised controlled trials 
in ESRD (both haemodialysis and peritoneal dialysis) to determine both optimal blood 
pressure targets and strategies to achieve those targets, with either dialysis, 
pharmacological intervention or a combination of these methods. 
 
1.2.2 Hyperlipidaemia 
In the general population, hypercholesterolaemia and dyslipidaemia are interchangeable 
in terms of prevalence and risk implication. In ESRD, however, this is not the case. 
ESRD patients typically have either normal or slightly increased low-density lipoprotein 
(LDL), increased very low-density lipoprotein (VLDL) and intermediate-density 
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lipoprotein (IDL) leading to elevated triglyceride levels, and decreased levels of high-
density lipoprotein (HDL). There are also qualitative changes in dyslipidaemia with a 
shift to a more atherogenic LDL particle size toward a small, dense apo-B-rich LDL 
predominance(21). The prevalence of dyslipidaemia in chronic kidney disease patients 
is very high. In one study of patients of both haemodialysis and peritoneal dialysis 
patients, the prevalence of dyslipidaemia was approximately 67%(22), where 
dyslipidaemia was defined as at least one abnormal lipid parameter. In fact, peritoneal 
dialysis seems to be associated with a relatively more atherogenic lipid profile than 
haemodialysis(23).  
 
In the general population the relationship between hyperlipidaemia (dyslipidaemia) and 
cardiovascular disease (predominantly coronary artery disease) is well established and 
there are proven benefits of lipid-lowering with statins(5;24-28). Only limited 
epidemiological and even more limited interventional, data exist on the relationship 
between dyslipidaemia and cardiovascular disease in ESRD. In patients receiving 
maintenance haemodialysis, reports suggest either no relationship or paradoxical 
correlations, the so called “reverse epidemiology”, where a lower total cholesterol level 
has been associated with a higher risk of death (29-31), or conversely, a higher serum 
cholesterol level has been found in long-term dialysis survivors(32). These studies have 
often used registry data, and either all cause mortality or unspecified CV mortality. 
Similar inverse, “J” or “U”-shaped relationships between lipid levels and all cause 
mortality have been reported in other populations and are thought to reflect a high 
prevalence of co-morbid disease (specifically malignancy and associated malnutrition) 
in patients with low cholesterol levels. These observations highlight the need for 
interventional trials and may have led to under-treatment of dyslipidaemia. Amongst 
patients starting dialysis, almost 40% are diabetic and 25% have known coronary artery 
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disease and 30% of dialysis patients have cholesterol levels higher than 
5.18mmol/L(33). Despite these observations, and studies showing effective lipid-
lowering and safety of statins, less than 10% of patients commencing maintenance 
dialysis receive statins(34;35). The impetus now lies in clarifying the therapeutic 
benefit, and unravelling the mechanisms that underlie the cholesterol paradox.   
 
The “4D Trial” (Deutsche Diabetes Dialyse Studie) perhaps unexpectedly, failed to 
show a significant reduction in cardiovascular events in haemodialysis patients given 
atorvastatin for a median of four years(36). It was a randomised, placebo-controlled 
study in 1,255 type II diabetic patients on chronic haemodialysis, who had been on 
dialysis for less than two years. Atorvastatin lowered mean LDL-cholesterol levels by 
42%, to 1.9 mmol/L. However, there was no significant reduction in the primary end 
point (a composite of cardiac death, nonfatal myocardial infarction, and fatal or nonfatal 
stroke).  The investigators speculated that the negative results could be in part due to a 
different pathogenesis of vascular events in diabetic patients with ESRD compared to 
other groups, and that the intervention was too late in the natural history of such 
complex disease. Atorvastatin therapy did, however, lower the incidence of myocardial 
infarction. Thus, an alternative explanation is that in the complex mixture of 
cardiovascular disease that affects patients with ESRD the relationship between 
cholesterol and myocardial infarction is present (and lipid-lowering reduces this end-
point) but that myocardial infarction is not the dominant cardiovascular end-point.  
 
This hypothesis has been explored in patients with ESRD who received renal 
transplants in the Assessment of LEscol in Renal Transplantation (ALERT) trial. In this 
related population, all lipid parameters are associated strongly with the development of 
myocardial infarction but much less so with cardiac death, which is more dependent on 
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left ventricular hypertrophy (LVH) and hypertension(37). The differences in cardiac 
outcomes in the 4S study in patients with conventional CVD, the 4D study and the 
ALERT study are illustrated in Table 1.2. The 4S (Scandinavian Simvastatin Survival 
Study) study randomised patients to simvastatin 40mg or placebo post myocardial 
infarction and demonstrated a significant reduction in both myocardial infarction and 
cardiovascular death(5). In the general population (4S) patients are more likely to have a 
non-fatal MI than a cardiac death, whereas in patients receiving haemodialysis the 
relationship is reversed. Additionally it is clear that the cardiac event rate in the 4D 
exceeds even a very high risk group such as post myocardial infarction patients. In the 
general population, a minimum threshold for lowering LDL has not yet been defined 
and safety concerns regarding intensive statin therapy have not been founded. To date 
only less aggressive statin therapy has been trialled in the ESRD population and 
although the risk of adverse affects such rhabdomyolysis in this population is higher, so 
far the safety record in these clinical trials has been good.  
 
LDL-cholesterol 
 n 
mmol/L 
baseline 
mmol/L 
change 
% change 
CD+MI 
annual 
rate 
Non-
fatal 
MI % 
CD+MI % 
reduction 
CD % of 
reduction 
4S 4444 4.9 1.7 -35 5.2 16.9 34 42 
ALERT 2102 4.1 1.0 -32 2.0 5.2 35 38 
4D 1255 3.1 1.2 -42 8.2 11.8 14 19 
 
Table 1.2 
Comparison of the 4S study with the 4D and ALERT studies. Abbreviations n= number 
of patients studied, CD – cardiac death, MI – myocardial infarction 
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1.2.3  Diabetes mellitus 
Diabetic nephropathy is the cause of ESRD in 15-30% of patients with approximately 
equal proportions of patients having type I and type II diabetes(38).  Extra-renal 
complications of diabetes include macrovascular disease and microvascular disease. The 
overall risk of death from myocardial infarction in a patient with diabetes is 
approximately three times that of the general population, with younger patients at higher 
risk(39). However the development of nephropathy, heralded by the presence of 
albuminuria, enhances the risks of further macrovascular complications as well as the 
risk of progressing to ESRD(40). Data from the Diabetes Control and Complications 
trial has shown that tight diabetic and blood pressure control reduce the risk of 
progression to ESRD and cardiovascular events in type I diabetics(41;42). However in 
the United Kingdom Prospective Diabetes Study tight glycaemic control was not shown 
to reduce risk of myocardial infarction in type II diabetics(43). Better glycaemic control 
was shown to reduce risk of microvascular complications and better blood pressure 
control has been demonstrated to reduce risk of cardiovascular events and progression 
of diabetic nephropathy(44). Once established on dialysis therapy, the survival for 
diabetic patients is considerably worse than for patients with other causes of ESRD with 
a median survival on dialysis survival of 2.5 years(45). This is mainly attributable to the 
excess risk of vascular disease. Studies screening diabetic patients for kidney 
transplantation have suggested that over half of diabetic renal transplant candidates will 
have at least one greater than 50% coronary artery stenosis(46).  
 
Once established on dialysis therapy, the options for type I diabetic patients include 
both simultaneous kidney-pancreas transplantation and kidney only transplantation with 
or without pancreas after kidney transplantation. Islet cell transplantation has been 
performed successfully but the long success has to date been relatively disappointing 
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with <50% of patients insulin independent at 2-3 years(47). Although less widely 
established than kidney only transplants, kidney-pancreas transplantation in suitable 
recipients has been demonstrated to have good outcomes for the patient with 85% 1 
year graft (kidney and pancreas) survival. Crude analyses have suggested that 
simultaneous kidney-pancreas transplantation offers a survival advantage compared to 
cadaveric renal transplantation for type I diabetic patients with ESRD(48). 
 
1.2.4  Ischaemic heart disease 
Although sudden cardiac death is a more dominant manifestation of cardiovascular 
disease in patients with ESRD, there is no question that the prevalence and severity of 
ischaemic heart disease in the ESRD is a key factor in explaining the dramatically 
increased risk of cardiovascular death in this population. In some patients, the 
underlying cause of ESRD will share a common pathogenesis as that of accelerated 
atherosclerosis (e.g. in diabetic nephropathy or atherosclerotic renal artery stenosis). It 
is difficult to accurately categorise what proportion of excess cardiovascular morbidity 
can be attributed to obstructive coronary artery disease in ESRD patients. Some of the 
sudden cardiac deaths, out of hospital, may be due to acute myocardial infarction, whilst 
others may be inappropriately labelled as myocardial infarction when primary 
arrhythmia was the underlying cause. Studies assessing the prevalence of coronary 
artery disease in patients with advanced renal disease have tended to focus on potential 
renal transplant candidates who tend to have less co morbidity than the whole ESRD 
population. Nonetheless, Sharma et al reported that in a series of 126 consecutive 
patients screened with coronary angiography significant coronary artery disease in at 
least one vessel was found in 30% of patients(49). On the other hand, symptomatic 
angina is common in patients with ESRD with angiographically normal coronary 
arteries.  Rostand et al reported that of 44 ESRD patients with symptomatic angina, 
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only 53% had obstructive coronary artery disease at angiography(50). Explanations for 
this phenomenon include subendocardial ischaemia due to left ventricular hypertrophy 
(LVH), microvascular dysfunction with impaired vasodilator reserve and/or limitations 
of oxygen delivery.  
 
About 20% of deaths in dialysis patients are attributed to acute myocardial infarction. In 
patients with ESRD, acute myocardial infarction is associated with extremely poor 
survival. Herzog et al reported a 1-yr 59% mortality and 2-yr 73% mortality in 34,189 
dialysis patients with acute myocardial infarction in the US from 1977 to 1995(51). In 
the ‘post thrombolysis’ era, 1-yr and 2-yr mortalities of have improved little at 62% and 
74% in 1990–95, and 2-yr mortality of 78% in 1991–97(52). Although ESRD is a risk 
for poor outcome post myocardial infarction, ESRD patients are less likely to receive 
treatments proven to improve outcome in this setting such as aspirin, thrombolytics and 
beta blockers(53). Additionally, the presence of advanced kidney failure is frequently an 
exclusion criterion for clinical trials in myocardial infarction. Therefore, the  poor 
outcome of ESRD patients with myocardial infarction may be partially attributable to 
undertreatment, either due to fear of potential complications such as haemorrhage, 
particularly from arteriovenous fistulae used for dialysis, and the unavailability of 
clinical trial outcome data due to the exclusion of ESRD patients from all AMI trials. 
 
In ESRD patients with critical coronary artery stenosis there is a relative survival 
advantage associated with coronary artery bypass grafting compared to percutaneous 
coronary intervention (angioplasty or stent) in dialysis patients. USRDS data reports 
that for dialysis patients receiving their first coronary revascularisation procedure in 
1995–98: 4836 dialysis patients treated with angioplasty, 4280 with angioplasty plus 
stent, and 6668 coronary artery bypass grafting, the 2-yr all-cause survival was 48% in 
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both percutaneous coronary intervention groups and 56% after coronary artery bypass 
grafting(54). In a multivariate analysis, the risk of all-cause death was 20% lower for 
bypass grafting compared to percutaneous intervention and 6% lower for stenting 
compared with angioplasty. This must be balanced with the higher than normal in 
hospital mortality for bypass (4.1% for stenting, 6.4% for angioplasty and 8.6% for 
bypass grafting). However, the restenosis rates of coronary stents are unknown in 
dialysis patients, but are likely to be no lower than in the general population, and 
probably higher. Drug eluting stents (using sirolimus or paclitaxel) have offered 
promising results with extremely low restenosis rates (0% at 6 months for patients 
receiving sirolimus- coated stents for native coronary lesions compared to a 26.6% 
restenosis rate in the Randomized Study with the Sirolimus- Coated Bx Velocity 
Balloon-Expandable Stent in the Treatment of Patients with De Novo Native Coronary 
Artery Lesions (RAVEL) trial)(55). Whether these results will translate to benefits in 
the dialysis population is unclear, particularly in light of some evidence suggesting that 
late stenosis after one year is more common with both sirolimus-eluting stents and 
paclitaxel-eluting stents than with bare-metal stents(56).  
 
Whilst in patients with critical coronary disease revascularisation is imperative, the 
presence of renal failure is a predictor of adverse outcome after percutaneous coronary 
intervention. Rubenstein et al compared the immediate and long-term outcomes of 362 
renal failure patients (creatinine >132.6 µmol/L, 27 dialysis patients) with 2972 patients 
with normal renal function undergoing PCI in 1994–97(57). The in-hospital mortality 
was significantly higher in the patients with renal dysfunction (10.8% for the renal 
patients and 1.1% in the controls) with significantly more blood transfusions in the renal 
patients. The 1-yr actuarial survival was significantly lower at 75% for the renal group 
compared to 97% for the matched controls. These data suggest that once a patient with 
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advanced renal disease develops a significant burden of atherosclerotic coronary artery 
disease, there is paucity of randomised controlled data to inform best practise. Current 
observational evidence suggests that outcomes are considerably poorer than the general 
population both in the setting of acute myocardial ischaemia as well as for coronary 
revascularisation. 
 
1.2.5  Physical inactivity 
Evidence from observational studies of the general population suggests that increased 
physical activity is associated with reduced cardiovascular mortality.  Physical activity 
is frequently limited in ESRD patients. One epidemiological study from the Dialysis 
Morbidity and Mortality Wave 2 study has demonstrated that limitations in physical 
activity are common among new patients with ESRD in the United States and correlate 
highly with increased mortality risk. Frequent exercise of up to 4 to 5 times per week 
correlate with improved survival. Daily exercise was not associated with any additional 
protective benefit(58). Although direct benefits of an interventional exercise programme 
on long term outcome are difficult to demonstrate, in a small single centre study of 
haemodialysis patients, Mustata et al demonstrated that a 3 month exercise programme 
improved arterial stiffness, a surrogate marker of increased cardiovascular risk in 
ESRD. A typical class consisted of a 5- to 10-minute warm-up period, 40 to 50 minutes 
of conditioning exercise (either treadmill running or exercise bicycle), and a 5- 10-
minute cool-down(59). It is not clear how this approach would translate to the entire 
ESRD population. 
 
1.2.6  Cigarette smoking 
Of potentially modifiable risk cardiovascular risk factors in ESRD patients, perhaps less 
attention has been paid to cigarette smoking than other factors. In the USRDS Wave 2 
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study studying 4024 new dialysis patients smoking at the time of inception of dialysis 
was associated with a 37% increase in mortality, even after adjustment for co-morbidity. 
Ex-smokers had event rates similar to non smokers(60). Cigarette smoking also 
accelerates the progression of chronic renal failure. There are no trials to support which 
smoking cessation strategy is most effective in ESRD, but meta-analyses suggest that 
nicotine replacement therapy is part of an effective strategy in the general 
population(61). 
 
1.2.7  Oxidative stress 
Conditions predisposing to atherosclerosis, including hypercholesterolemia, diabetes 
mellitus, cigarette smoking and chronic kidney disease are associated with increased 
oxidative stress. The atherogenicity of low-density lipoprotein (LDL) is greatly 
increased upon oxidative modification(62) as, once oxidised, LDL is taken up by 
scavenger receptors on monocytes, leading to the conversion of monocytes into foam 
cells, one of the earliest steps in the development of atherosclerosis. Reactive oxygen 
species can also directly promote LDL oxidation, stimulate vascular smooth muscle cell 
proliferation and migration(63). Reactive oxygen species also activate several matrix 
metalloproteinases, which contribute to atherosclerotic plaque instability and rupture, 
thereby precipitating acute cardiovascular events(64). Oberg et al demonstrated that 
biomarkers of oxidative stress (plasma protein carbonyl group content, plasma free F2-
isoprostane content, plasma protein reduced thiol content) were significantly elevated in 
patients with chronic renal failure compared to healthy subjects(65). Haemodialysis 
(HD) may induce oxidative stress, primarily through membrane bio-incompatibility and 
endotoxin challenge. One study examining the relationship between haemodialysis and 
cardiovascular disease on serum malondialdehyde levels, a marker of oxidative stress 
found mean serum malondialdehyde levels were significantly elevated in dialysis 
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patients with cardiovascular disease(66). However to date no study exists examining the 
relationship between oxidative stress and long term outcome in ESRD patients.  
 
A number of studies have addressed the issue of whether using antioxidant therapy 
would reduce the risk of cardiovascular events, both in patients at high risk of 
cardiovascular events in the general population and in ESRD. The Heart Protection 
Study randomised 20,536 UK adults (aged 40-80) with coronary disease, other 
occlusive arterial disease, or diabetes to receive antioxidant vitamin supplementation 
(600 mg vitamin E, 250 mg vitamin C, and 20 mg beta-carotene daily) or matching 
placebo. None of these interventions produced any significant reductions in the 5-year 
mortality from, or incidence of, any type of vascular disease, cancer, or other major 
outcome(67). Similarly in the Heart Outcomes Prevention Evaluation  (HOPE) Study 
treatment with vitamin E had no apparent effect on cardiovascular outcomes(68). By 
contrast in the Cambridge Heart Antioxidant Study (CHAOS) in patients with 
angiographically proven coronary atherosclerosis, alpha-tocopherol (vitamin E) 
substantially reduced the rate of non-fatal myocardial infarction at one year(69). This 
study is out of keeping with the larger trials with longer follow up.  
 
Interestingly in ESRD, alpha-tocopherol decreases LDL oxidation in ESRD patients. 
The benefit appears to be greater in patients on PD, which may be of clinical importance 
given the greater atherogenicity of lipid abnormalities in peritoneal dialysis(70). 
Building on this observation, the Secondary Prevention with Antioxidants of 
Cardiovascular disease in End stage renal disease study (SPACE), assigned 
haemodialysis patients with cardiovascular disease to high dose (800 IU/day) oral 
vitamin E or placebo.  Vitamin E reduced the risk of the composite cardiovascular 
disease endpoints (myocardial infarction (fatal and non-fatal), ischaemic stroke, 
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peripheral vascular disease and unstable angina)(71). A similar large scale trial of 
antioxidant therapy as primary cardiovascular disease prevention is required in ESRD. 
 
1.2.8  Uraemic cardiomyopathy as a cardiovascular risk factor 
Cardiac abnormalities, specifically hypertrophy of the left ventricular wall, were first 
noted in ESRD by Richard Bright in 1827, where he postulated that it was caused by 
‘the unusual efforts to which the heart has been impelled’(72). The presence of uraemic 
cardiomyopathy is strongly associated with adverse outcome in patients will ESRD. 
Echocardiographic studies report three patterns of cardiomyopathy – left ventricular 
hypertrophy (LVH) and LV dilatation and left ventricular systolic dysfunction (LVSD) - 
that affect up to 90% of patients starting dialysis therapy(73). Each is associated with 
reduced survival compared with unaffected patients; effects that persist even after 
successful transplantation(74). Parfrey et al have demonstrated that the 
echocardiographic prevalence of LVH is 50-80%, with left ventricular dilatation in 20-
40% and LVSD present in approximately 16% of patients in incident ESRD 
patients(75). When followed up over a 2 year period, these abnormalities were 
associated with a cumulatively poorer survival compared to those patients with normal 
ventricles after adjustment for other variables such as age, diabetes and ischaemic heart 
disease(76). Data from the USRDS registry has demonstrated similar findings with 
LVH a risk factor for poor outcome in incident dialysis patients(77). A schematic 
diagram of the potential relationships between ischaemic heart disease, sudden cardiac 
death and LVH is demonstrated in Figure 1.2. 
 
LVH develops early in the course of chronic kidney disease and is associated with 
stiffening of the LV wall, a precursor to diastolic heart failure(78;79). The various 
permissive factors promoting LVH in uraemia will be discussed in detail in Chapter 5 
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but hypertension, anaemia, hyperparathyroidism and hypoalbuminaemia have all been 
associated with its development(80). Volume status is a key factor in determining blood 
pressure in ESRD and may make definition of LV chamber dimensions difficult(81).  
 
Histological analysis of the heart in animal models of experimental renal failure shows 
that LVH is associated with an increase in cardiomyocyte volume(82). This, in turn, 
results in increased oxygen diffusion distance and subsequent cardiomyocyte ischaemia. 
Cardiomyocyte number may increase initially but subsequently is reduced(83). In sub-
totally nephrectomised rats, reduced capillary density per volume of myocardium is 
seen(84). Similar findings have been demonstrated in post mortem specimens of 
patients with ESRD(85). It is likely that apoptosis is triggered and increased fibrosis 
follows progressive myocyte death(82). Electrophysiological abnormalities in calcium 
handling have been demonstrated with abnormal sarcoplasmic calcium uptake, and 
increased cytosolic calcium concentrations of calcium in diastole(86-88). These 
electrophysiological changes lower the threshold for arrhythmia and underpin the 
evolution of diastolic heart failure. 
 
LVH may be considered an adaptive process in response to increased myocardial work 
due to pressure and volume overload. Pressure overload tends to cause increased wall 
thickness with an unchanged or reduced LV cavity diameter (concentric hypertrophy), 
whilst volume overload promotes LV dilatation, with additional changes in wall 
thickness as an adaptive mechanism to reduce wall stress(89;90). This phenomenon is 
called eccentric hypertrophy. Both eccentric and concentric remodelling are common in 
ESRD patients. These remodelling processes are initially beneficial as dilatation allows 
an increase in stroke volume without increased inotropy, as well as permitting 
maintenance of stroke volume and cardiac output in the presence of decreased 
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contractility(91).  Physiological hypertrophy may additionally occur in response to 
increased cardiac work, and the increase in LV mass is appropriate to LV volume such 
as in highly conditioned athletes(92). However, in dialysis patients the degree of 
hypertrophy may be inappropriate for the given ventricular stresses, either volume or 
pressure load, both of which are dramatically elevated(76). This has led to the term 
‘inadequate hypertrophy’, and LVH may be either a precursor to the evolution of 
cardiac failure or arrhythmia in ESRD patients(93). 
 
 
Figure 1.2 Schematic view of the relationship between ischaemic heart disease, LVH 
and sudden cardiac death in ESRD. Abbreviations CRF- chronic renal failure, RRT –
renal replacement therapy, Tx - transplant 
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1.2.9  Sudden cardiac death 
Sudden cardiac death is the cause of up to 60% of cardiovascular deaths in patients with 
ESRD. The risk of such an event increased with increasing time spent on renal 
replacement therapy. Although, high risk patients potentially can be identified- patients 
with LVH or LVSD, previous ischaemic heart disease or potentially using biomarkers 
such as brain natriuretic peptide (BNP) or troponin T(94), no proven strategy exists to 
reduce risk of this catastrophic event. Haemodialysis specific risks include pre-dialysis 
hyperkalaemia and intra-dialytic or post dialysis hypokalaemia.  In a large retrospective 
analysis of dialysis related cardiac arrests (in centre up to 2 hours post dialysis), a low 
potassium dialysate (0 or 1 mmol/L) was identified as a risk factor for cardiac arrest. 
More cardiac arrests took place on Mondays, suggestive that fluid overload may also be 
a risk factor, after the ‘long gap’ of 2 days since the antecedent dialysis session(95). 
Evidence is emerging from patients with ischaemic heart disease and cardiac failure that 
implantable cardiac defibrillators, as a prophylaxis for sudden cardiac death, improve 
survival(96). Currently these are underused in the ESRD post cardiac arrest despite 
apparent association with improved survival(97). A prospective trial of implantable 
defibrillators for reduction of mortality in dialysis patients is warranted.   
 
1.2.10  Haemodynamic and metabolic factors of CRF 
Additional to electrolyte shifts related to dialysis, alterations in volume status and hence 
blood pressure, may cause haemodynamic instability in the dialysis patient. Intermittent 
haemodialysis leads to rapid changes in fluid and solute status. Hypotension in 
particular, is a common cardiovascular complication of haemodialysis, which may vary 
in severity from minor, if troublesome side-effects such as nausea or dizziness, through 
to more severe cardiac or cerebral ischaemia. The pathogenesis of haemodialysis related 
hypertension is multi-factorial. The initial trigger is hypotension as the patient is 
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connected to the dialysis circuit. The main determinants of blood pressure control, 
which are deranged in ESRD, are intravascular volume preservation, vasoconstriction 
leading to increased systemic vascular resistance and maintenance of cardiac output by 
appropriate inotropic and chronotropic response(98).  
 
During haemodialysis, fluid is removed from the intravascular space by ultrafiltration. 
As intravascular pressure drops, fluid is drawn from the interstitial space in an attempt 
to maintain intravascular volume. This however is incomplete and limited by the 
relative increase in extravascular osmotic pressure. Blood volume decreases leading to 
hypotension(99). Factors influencing this include ultrafiltration rate(100), fluid status of 
the patient(101), dialysate sodium(102), dialysate buffer(103), temperature(104), 
venous compliance and food intake which may lead to splanchnic blood pooling(105).  
 
The appropriate response to dialysis related hypovolaemia is normally to increase 
systemic vascular resistance, by constriction of precapillary vessels. However in ESRD 
this mechanism is blunted. Although autonomic neuropathy affecting efferent 
sympathetic pathways may contribute to this disturbance (primarily found in diabetic 
patients), the dialysis treatment itself is a greater factor for impaired vascular response 
in this setting.  Haemodialysis appears to be associated with impaired vascular reactivity 
during hypovolaemia. The secretion of vasoconstrictive peptides such as 
catecholamines, vasopressin and renin is less pronounced with haemodialysis compared 
to say haemofiltration or isolated ultrafiltration(106). Other factors associated with 
vasodilatation related to haemodialysis include excess secretion of cytokines such as 
tumour necrosis factor-α and interleukin-1, perhaps related to the degree of 
biocompatibility of the dialysis membrane, although this remains 
controversial(107;108). The temperature of the dialysate in the extracorporeal circuit is 
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an additional feature influencing haemodynamic stability and control of systemic 
vascular resistance. Both the blood pressure response and vascular reactivity are 
improved with the use of cool (35-360C) compared to standard (37-380C) dialysate 
(104;109). This may either be due to reduced cutaneous vasodilatation, which may 
occur in a bid to reduce ‘excessive’ heat when warmer standard dialysate is used or the 
constrictive effect of blood vessels to maintain a constant core temperature when a 
cooler dialysate is used.   
 
Maintenance of cardiac output in response to hypovolaemia related to dialysis is mainly 
dependent on pre-existing cardiac function which is discussed elsewhere. Left 
ventricular diastolic or systolic dysfunction where present impair the heart’s ability to 
maintain cardiac output. Other factors such as autonomic neuropathy and drug therapy 
with beta-blockade may impair the chronotropic response. Cardiac function may 
paradoxically improve during dialysis due to a combination of fluid removal reducing 
after load, the removal of postulated cardiodepressor uraemic toxins (or acidosis) or due 
to the use of increased dialysate calcium which has a positive inotropic effect(110;111). 
Factors specific to dialysis which may reduce cardiac output include impaired 
ventricular filling due to reduced venous return. The presence of the arteriovenous 
fistula used for dialysis access causes increased cardiac output, promoting LVH and 
may lead to high output cardiac failure(112). 
 
For the period when the patient is not on dialysis therapy, the relationship between 
volume status, blood pressure and systemic vascular response is complex with debate 
about the relative importance of increased peripheral resistance and increased 
intravascular volume on the development of hypertension in ESRD. In one pilot study 
from our group, cardiac output was lower in haemodialysis patients than in a small 
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group of normal subjects, because of a lower stroke volume in the dialysis group(113). 
As the blood pressure was the same, calculated peripheral resistance was thus higher in 
the dialysis group compared with controls. In the dialysis group there is a very 
convincing relationship between end diastolic volume (a reflection of intravascular 
volume), cardiac output and blood pressure. No such relationship was found between 
calculated peripheral resistance and any blood pressure variable, suggesting that 
intravascular volume plays a larger role than increased vascular resistance in the 
determination of blood pressure in patients on haemodialysis, or is at least the most 
variable factor. This is consistent with the effects of reduction of intravascular volume 
(‘dry weight’) and improved blood pressure control on dialysis(114;115). Although 
there was no correlation between systemic vascular resistance and blood pressure 
parameters, systemic vascular resistance was higher in haemodialysis patients. Thus, for 
a given cardiac output, the achieved blood pressure is substantially greater in 
haemodialysis patients than in controls. Whether this increase in systemic vascular 
resistance is a functional consequence of increased vascular tone or of structural 
changes in the vessel wall is unclear, although it is clearly important as vasodilators are 
likely to be effective against the former, whereas reversal of strategies structural 
changes (e.g. associated with calcification) are likely to be more difficult. 
 
1.2.11 Proteinuria 
Microalbuminuria (30 to 300mg/day) was first identified as risk factor for 
cardiovascular disease in patients with diabetes in 1984(116). Subsequently, data from 
the Framingham studies have shown that proteinuria is a risk factor for cardiovascular 
mortality in the general population(117). Similar findings have emerged from other 
large epidemiological studies that either proteinuria or microalbuminuria are not only 
predictive of progression of renal disease but also of future cardiovascular events(118). 
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Analyses from the Prevention of Vascular and End Stage Renal Disease (PREVEND) 
study shows clearly that urinary albumin acts as a continuous risk factor for 
cardiovascular events with no lower limit(119). Microalbuminuria and proteinuria have 
been accepted to represent a consequence of renal damage. However, Deckert et al 
proposed in 1989 that albumin leakage is a reflection of widespread vascular damage, 
with the kidney as a ‘window’ to the vasculature(120). This hypothesis has been 
reinforced by studies demonstrating that microalbuminuria is associated with changes in 
endothelial dysfunction in patients with diabetes(121). The Irbesartan in Patients with 
Type 2 Diabetes and Microalbuminuria (IRMA-2) study, evaluating the effect of the 
angiotensin II antagonist irbesartan, demonstrated that reduction of albuminuria in 
microalbuminuric hypertensive patients with type II diabetes was associated with renal 
protection and some degree of cardiovascular protection although this study was not 
powered to address the effect on cardiovascular events(122). From the standpoint of the 
patient with ESRD, as albuminuria or proteinuria are both markers of cardiovascular 
risk and of progression of renal disease towards ESRD, it seems likely that proteinuria 
is a cardiovascular risk factor, which whilst present in some patients in the general 
population, is grossly overrepresented in patients at the onset of dialysis therapy.  
 
1.2.12  Anaemia 
The presence of anaemia, secondary to erythropoietin deficiency is an almost universal 
finding in patients with ESRD. This is strongly associated with increased mortality and 
morbidity in patients on maintenance haemodialysis(123). Anaemia has been 
consistently linked with the development and progression of cardiac structural changes 
in patients with chronic renal failure. In patients with chronic renal failure, haemoglobin 
starts to fall as glomerular filtration rate drops to between 25 and 50 ml/min and Levin 
et al demonstrated that in patients with advanced pre-dialysis renal failure each 0.5g/dL 
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fall in haemoglobin was associated with a increased LV mass(124). However, the 
outcome of studies directed at haemoglobin correction, either to reduce progression of 
LVH or to reduce cardiovascular events have generally been associated with increased 
mortality in patients randomised to achieve a higher haemoglobin with erythropoietin 
therapy(125-128).  Lower haemoglobin is likely to be found in ‘sicker’ patients with 
more evidence of inflammation and malnutrition, and therefore it is not surprising that 
anaemia is associated with increased mortality. What is less clear is what the target 
haemoglobin should be in dialysis patients, and the optimum time to commence 
correctional therapy with erythropoietin. The relationship between haemoglobin and 
uraemic cardiomyopathy and outcome is further discussed in Chapter 5. 
 
1.2.13  Homocysteine 
Homocysteine is a sulphur containing amino acid, formed during the conversion of 
methionine to cysteine. The concept of homocysteine being atherogenic arose from the 
observation that patients with homocystinuria, an autosomal recessive condition, 
characterised by the accumulation of homocysteine experienced premature 
cardiovascular death. Epidemiological studies have demonstrated an association 
between hyperhomocysteinaemia and atherosclerotic vascular disease. Normal 
metabolism of homocysteine is either by transsulfuration to cysteine (vitamin B6 
dependent) or remethylation to methionine (vitamin B12 and folate dependent). In renal 
failure it is suggested that remethylation is impaired leading to accumulation of 
homocysteine. Hyperhomocysteinaemia has been associated with increased risk of 
cardiovascular events in patients with ESRD in a number of observational studies(129-
131).  
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One large trial of B vitamin (2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of 
vitamin B12) supplementation in the general population to reduce cardiovascular events 
was disappointing, with no significant reduction in risk(132). In dialysis patients, 
despite evidence that reduction of serum homocysteine levels can be achieved with folic 
acid, randomised controlled trials have demonstrated that folic acid supplementation in 
ESRD is not associated with reduction of cardiovascular events(133) or a reduction in 
atheroma progression(134). Indeed, further analysis have suggested paradoxically that 
some patients with higher homocysteine levels are at reduced risk(133;135) forwarding 
the hypothesis, that homocysteine levels may be a nutritional marker in dialysis patients 
in the absence of inflammation, a frequent confounder of other markers of  
interpretation of nutritional status (albumin) in ESRD. This represents a further example 
of the ‘reverse epidemiology’ (akin to cholesterol) of cardiovascular risk factors where 
conventional cardiovascular risk factors in the general population have the reverse 
relationship with outcome in the ESRD population. 
 
1.2.14  Hyperparathyroidism, calcium-phosphate metabolism and arterial 
calcification 
Hyperparathyroidism is one of the hallmarks of chronic renal failure and is a result of 
chronic hyperphosphataemia and hypocalcaemia. Secondary and tertiary 
hyperparathyroidism result in the spectrum of renal bone disease including osteitis 
fibrosa cystica and mixed renal osteodystrophy. Observational studies demonstrate that 
as well as being a risk factor for fractures (136), raised serum PTH levels are a risk 
factor for mortality in dialysis patients(137;138). It is now recognised that parathyroid 
hormone (PTH) has potentially negative cardiovascular effects. In animal models of 
uraemia PTH has been demonstrated to promote cardiac interstitial fibrosis and 
arteriolar thickening(139). PTH has also been shown to stimulate cardiac accumulation 
64 
of calcium in myocytes leading to scarring(140). The role of PTH in promoting LVH is 
further discussed in Chapter 5. 
 
Like hyperparathyroidism, hyperphosphataemia is almost inevitable in patients with 
ESRD and registry data supports that even mild hyperphosphataemia is an independent 
predictor of mortality in dialysis patients(137;138;141). Although poor phosphate 
control may be a reflection of under dialysis, it has become clear that phosphorus 
retention promotes vascular calcification, perhaps by inducing transformation of 
vascular smooth muscle cells into an osteoblast-like phenotype(142). Total body 
calcium or calcium phosphate product as well as PTH have been recognised to be the 
other key determinants of vascular calcification. Other clinical factors consistently 
associated with the development of vascular calcification include age, duration on renal 
replacement therapy, PTH, homocysteine and degree of inflammation(143-147).  
 
Although patients with ESRD, if left untreated, would be calcium deficient due to 
failure of synthesis of 1,25-dihydroxyvitamin D3, the combination of treatment with 
vitamin D analogues to suppress PTH, combined with calcium containing phosphate 
binders may lead to overall normalised or high body calcium levels. The presence and 
degree of coronary artery calcification, demonstrated in young adult dialysis patients by 
electron beam computed tomography, has been associated with ingestion of large 
amounts of calcium containing phosphate binders and a greater elevation in the calcium-
phosphate product(144). Until fairly recently, options for controlling phosphate with 
phosphate binding medication were limited to compounds containing either calcium or 
aluminium. The non-calcium containing binder sevelamer hydrochloride has been 
demonstrated to be associated with a lesser degree of progression of coronary artery 
calcification in patients new to haemodialysis therapy, compared to those taking 
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calcium containing phosphate binders(143). It has been suggested that this reduction in 
vascular calcification using non calcium containing phosphate binders may translate 
into a survival benefit for these patients(148). 
 
1.2.15  Inflammation and C-Reactive protein 
Chronic inflammation is indicated by raised serum C-reactive protein (CRP), a hepatic 
derived acute phase protein. CRP is raised in response to a number of conditions where 
inflammation may be present including infection, trauma, infarction and malignancy. 
The acute phase response is driven by cytokines including interleukin-1, interleukin-6, 
interferon-gamma, tumour necrosis factor-α, and transforming growth factor-β.  In 
healthy individuals elevated CRP is a risk factor for future coronary events(149;150) as 
well as in patients with diabetes(151), whilst in patients with acute myocardial 
infarction, CRP predicts mortality within the first 30 days post infarct (152). Whether 
CRP is simply an additional marker for established coronary risk factors, such as 
dyslipidaemia or perhaps the inflammatory nature of the high risk atherosclerotic 
coronary plaque, or represents a further additive risk factor is less clear.  The is no doubt 
that raised CRP correlates with the cluster of atherogenic risk factors found in the 
metabolic syndrome(153). Supporting the notion that CRP is directly atherogenic, in 
vitro studies have demonstrated the presence of CRP in atherosclerotic coronary 
plaque(154), whilst CRP and matrix metalloproteinase co-localise in the endothelial 
layer and macrophage-rich areas in atherosclerotic plaques suggesting that CRP has a 
role in rupture of the ‘vulnerable’ plaque(155). Finally, statins have been demonstrated 
to lower serum CRP, with greatest clinical benefit derived in patients with a larger 
magnitude of CRP reduction in response to therapy(156).  
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Patients with ESRD tend to have higher CRP levels, and this is predictive of 
cardiovascular outcome in both haemodialysis and peritoneal dialysis 
patients(157;158)whilst higher levels interleukin-6 have also been associated  with 
increased mortality(159). Possible explanations for elevated CRP in ESRD include 
direct inflammatory effects of uraemia, chronic infection of vascular access, the 
presence of indwelling peritoneal or vascular dialysis catheters, bio-incompatibility of 
haemodialysis membranes or peritoneal dialysis fluids or impurities of water supply 
used for dialysis.  
 
The association between atherosclerosis and inflammation (together with associated 
poor nutritional status) in dialysis patients have given rise to the hypothesis of the so 
called malnutrition, inflammation, and atherosclerosis (MIA) syndrome(160). If truly 
present this relationship may explain the cholesterol paradox in ESRD patients. One 
intriguing study addressing this issue performed by Liu and colleagues followed up 823 
chronic haemodialysis patients for a median of 2.4 years, and categorised the study 
population into 2 subgroups based on the presence or absence of inflammation and/or 
malnutrition (defined as achievement of specified cut-offs for any of serum albumin, 
CRP and interleukin-6)(35). Overall, 77% of the patients had evidence of 
inflammation/malnutrition, which was associated with older age, increased co-
morbidity, prevalent CV disease, diabetes, and lower total cholesterol levels. A U-
shaped association between cholesterol levels and mortality was seen in the overall 
cohort and in the subgroup with inflammation/malnutrition. However, in the absence of 
inflammation/malnutrition, total cholesterol was positively associated with all-cause 
mortality and even more strongly associated with CV mortality. These results give 
insights into novel methods to address the frequently perplexing issue of the reverse 
epidemiology of cardiovascular disease in patients with renal failure. 
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1.3 Assessment of uraemic cardiomyopathy with echocardiography 
Echocardiography involves the application of ultrasound in the frequency range of 2 to 
10 MHz. The technique requires an ultrasound transducer consisting of a series of 
piezoelectric crystals, that when electrically activated, emit ultrasound energy. 
Returning ultrasound energy is converted by the piezoelectric crystal into 
radiofrequency energy which is processed to digital information by high-speed by 
digital converters within the ultrasound platform.  
 
The simplest image is the M-mode echocardiogram. An M-mode echocardiogram is 
acquired by interrogating returning ultrasound signals along a single plane with the 
images generated recorded on a scrolling video screen. The operator can select this 
plane to obtain an M-mode image. This plane line can be swept through an area of 
cardiac anatomy and the image then displayed as a series of concurrent M-mode images. 
M-mode echocardiography was once the foundation of anatomical diagnosis but has 
been to an extent abandoned in favour of 90-degree two-dimensional scanning. 
However, M-mode does confer higher temporal resolution than two-dimensional 
echocardiography and may provide a higher degree of resolution than two-dimensional 
scanning. In general, however, its clinical role, as a stand-alone technique, has been 
largely supplanted by two-dimensional echocardiography. It remains widely used as a 
method for estimation of LV mass, both for clinical practise as well as in interventional 
studies. Conventionally “cube” methods, which using M-mode septal, posterior wall, 
and left ventricular internal dimensions have been used to measure LV mass. These 
methods assume normal ventricular geometry. More recently, several two-dimensional 
methods have been shown to provide enhanced accuracy, especially in abnormally 
shaped ventricles(161). 
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Echocardiography provides an excellent method for quantification of ventricular 
function. Linear measurements such as LV wall thickness, internal chamber dimensions, 
and derived parameters such as fractional shortening traditionally have been obtained 
from M-mode echocardiography. Normal values for adults are well established(162-
164). Global ventricular function and cardiac volumes can be measured with a variety of 
methods using two-dimensional echocardiography, with Simpson’s rule being the most 
commonly used for quantification of ventricular volume. Determination of left 
ventricular volume requires manual tracings of the endocardial border in diastole and 
systole. Once the chamber volumes have been determined, ejection fraction can be 
calculated. Echocardiographic methods will be discussed in greater detail in Chapters 2 
and 4.  
 
Echocardiographic abnormalities have been described in patients with ESRD as early as 
the 1970s. Initially, as uraemic pericarditis was one of the cardinal features of advanced 
presentation of ESRD, echocardiography was a key tool in the diagnosis and 
management of haemorrhagic pericardial effusions.  However, abnormal thickening of 
the LV wall as well as valvular calcification, were soon demonstrated 
echocardiographically(165) and the prognostic implications of these findings emerged 
with the expansion of dialysis programmes. Studies from the Canadian dialysis 
population have demonstrated the importance of LV abnormalities as discussed 
previously(73;76). However, as echocardiographic measurement of LV mass and 
function is dependent on LV chamber dimensions, care must be taken in assessing LV 
structure and performance in patients with ESRD. It is well-established that changes in 
volume status in these patients during both the inter- and intra-dialytic period result in 
substantial changes in LV chamber dimensions(81;166), with any potential error in 
echocardiographic measures being amplified by the assumptions of cubed formulae.  
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Additionally changes in volume status affect both pre- and after-load. To what extent 
the changing loading conditions contribute to a change in LV function parameters is 
difficult to determine. A lower ejection fraction after dialysis may result from a decrease 
in contractility either de novo or in response to myocardial ischaemia invoked by the 
haemodynamic demands of dialysis, but also from a decreased preload, an increased 
after load or a combination thereof. 
 
A ‘volume-independent’ assessment of LV dimensions in ESRD is an extremely 
attractive concept. Newer echocardiographic techniques such as 3-dimensional 
echocardiography may be promising but are untested in this population. Whilst LV 
chamber dimensions remain subject to the hydration status of the patient regardless of 
imaging method, by using a high resolution method such as cardiac magnetic resonance 
imaging (CMR) to delineate myocardial dimensions, the presence of structural 
cardiovascular disease may be more accurately defined in this population.   
 
1.4 Cardiovascular magnetic resonance imaging 
Rapid progress has been made with CMR over the past decade, and this has become 
established as a reliable and clinically important technique for assessment of cardiac 
structure and function. Furthermore, by using contrast based techniques, myocardial 
perfusion and viability can be assessed. CMR is non-invasive and avoids the use of 
ionising radiation. Progress in CMR technology may further widen its clinical 
application in coronary artery imaging, assessment of valvular heart disease and 
identification of vulnerable atheromatous coronary plaque. 
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1.4.1 Principles of cardiac magnetic resonance imaging 
CMR (and all magnetic resonance imaging) is based on the principle of nuclear 
magnetic resonance. Images are generated from signals produced by protons (hydrogen 
nuclei). The human body consists of mainly of water, an abundant source of hydrogen 
ions. The proton behaves like a small magnet when placed in a magnetic field, aligning 
itself with the field and precessing with a frequency that depends on the magnetic field 
strength. Protons align parallel and anti-parallel to the direction of the primary field, 
with a small excess of parallel protons that gives rise to a net magnetisation vector. This 
net vector can be rotated by application of a second temporary radiofrequency (RF) 
pulse. Once this pulse ceases, the magnetisation vector recovers to its former position, 
releasing a signal in the form of radio waves. This relaxation of the net vector is 
attributable to two distinct but simultaneous processes, longitudinal (T1) and the 
transverse (T2) relaxations(167;168) A pulse sequence consists of a series of RF pulses 
of varying duration or strength and application of magnetic-field gradients that are 
adjusted to highlight desired tissue characteristics. 
 
Basic pulse sequences used in CMR are spin-echo and gradient-echo sequences. Spin-
echo sequences are often used for assessment of cardiac morphology, and flowing blood 
normally appears black. Gradient-echo sequences have a lower soft-tissue contrast 
compared with spin-echo, and flowing blood is represented by high signal intensity and 
turbulence as areas of signal void. Gradient-echo sequences are used to assess valvular 
lesions, shunts, and great vessels as well as for measurement of ventricular function and 
wall-motion characteristics. Flowing blood across a magnetic gradient can be encoded 
to quantify flow. These phase-encoded velocity maps are based on the principle that 
magnetic vectors of flowing protons acquire a phase shift that is proportional to flow 
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velocity. This technique is used to assess flow volumes and velocity profiles across 
valves and shunts.  
 
Cardiac and respiratory motion artefact can cause difficulty acquiring CMR images. 
Using breath-hold electrocardiograph-gated techniques to acquire images minimises 
such artefacts. The presence of cardiac arrhythmias such as atrial fibrillation may 
interfere with synchronised data acquisition.  
 
1.4.2 Cardiac magnetic resonance imaging for assessment of cardiac function 
Unlike echocardiography, where LV mass and dimensions are derived from one- or 
two-dimensional data, using assumptions of cardiac geometry, with CMR, actual 
myocardial mass and volumes are obtained. A Simpson’s rule algorithm is still used, but 
acquired using three-dimensional data from a series of thin slices with no geometric 
assumptions. Therefore, CMR has become established as the ‘gold standard’ non-
invasive reference standard for cardiac function and mass. Data are acquired using  
bright blood gradient-echo sequences, obtained during a 15- to 20-s breath-hold, are 
used to cover the entire left ventricle (LV) with short-axis views from the mitral plane 
and slice thickness of 10 mm. In these studies a TrueFISP (fast imaging with steady-
state precession) sequence is used. Individual CMR scanner manufacturers have their 
own nomenclature for the various imaging sequences, with TrueFISP being that used 
for this pulsed gradient-echo sequence by Siemens (Erlangan, Germany). The actual 
CMR protocol used is described in detail in Chapter 2. 
 
Using these techniques, published normal reference ranges for cardiac dimensions and 
function have been generated(169). As CMR sequences evolve, it is important to use the 
appropriate reference range for the sequence used to acquire the data as small but 
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statistically significant differences in LV dimensions have been described between 
images acquired of the same patients with TrueFISP and FLASH (fast low-angle shot), 
an alternative gradient-echo sequence(170). 
 
 
1.4.3 Gadolinium based contrast agents for cardiac magnetic resonance imaging 
All the currently approved CMR contrast agents use gadolinium which has 
paramagnetic properties. Gadolinium based contrast acts as an extracellular contrast 
agent with a ‘fast wash in/slow wash out’ characteristics. Gadolinium itself is toxic, and 
therefore is chelated to a variety of molecules depending on the agent used. This chelate 
has some effect on the pharmacokinetics of the agent and in the case of Gd-BOPTA 
(Multihance), further changes the paramagnetic properties of the product. The molecular 
weights of these agents range between 650 and 2,000 Daltons and their mechanism of 
action is to shorten T1 relaxation of tissue within the magnetic field.  
 
During the first pass after rapid intravenous injection of contrast, extracellular agents 
diffuse into the interstitium of the tissues, except in the brain and testes. Approximately 
40% of intravenously injected extracellular agents diffuse from the blood into the 
interstitium during the first pass(171). By tracking a bolus as it transits through a region 
of interest, time-intensity curves can be generated and used to determine myocardial 
perfusion. In the presence of altered interstitial tissue architecture, e.g. due to oedema, 
necrosis, fibrosis or inflammation (or any combination of these factors), passage of the 
gadolinium chelate will be delayed through the myocardial tissue. This will be indicated 
by the presence of late gadolinium enhancement (LGE), when this tissue is imaged, 
typically achieved approximately 5 minutes after bolus injection. Over a period 
typically lasting several minutes, the agent diffuses back into the blood pool, from 
which it is excreted by the kidneys.  
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Gadolinium based agents currently in use for cardiac imaging include Omniscan 
(gadodiamide, GE Healthcare, UK), Magnevist (gadopentetate dimeglumine, Gadovist, 
Schering AG, Berlin, Germany), MultiHance (gadobenate dimeglumine, Bracco, Bracco 
S.p.A., Milan, Italy), Gadovist (gadobutrol, Schering AG, Berlin, Germany),  
OptiMARK  (gadoversetamide, Tyco Healthcare, Hazelwood, Minnesota, United 
States) and ProHance (gadoteridol, Bracco, Princeton, New Jersey, United States). 
 
1.4.4 Cardiac magnetic imaging for assessment of ischaemic heart disease 
CMR is an excellent technique for defining the presence and extent of both acute and 
chronic myocardial infarction. Like echocardiography, wall motion abnormalities may 
be present on cine images, suggestive of ischaemic myocardial damage. On first-pass 
perfusion images with contrast, an area of hypo-enhancement is seen within the 
infarcted region, correlating with microvascular obstruction inside the infarct zone 
(172), Figure 1.3. In the presence of chronic myocardial infarction the presence of LGE 
5 to 30 min after contrast injection is seen using a turbo FLASH inversion-recovery 
sequence, Figure 1.4. In acute infarction, LGE reflects myocardial necrosis and 
abnormal contrast molecule kinetics within infarcts with associated tissue oedema, 
whereas in chronic infarction, it reflects increased concentration of gadolinium non-
viable, infarcted scar tissue(173;174). Combining the extent of LGE, may indicate the 
presence of viable ‘hibernating’ myocardium. A myocardial segment with a wall motion 
abnormality and no LGE may represent myocardial hibernation which may recover with 
revascularisation, whilst non viable myocardium typically has >75% thickness of tissue 
demonstrating LGE(175). 
 
Coronary angiography with CMR is an attractive concept and may yet become a non-
invasive diagnostic method. Currently, the small size of coronary arteries, their complex 
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course, and constant motion with cardiac contraction and respiration has made 
angiography technically difficult. CMR however can evaluate coronary blood flow of 
myocardial perfusion with first-pass contrast enhanced imaging before and after 
pharmacologically induced hyperaemia, usually with adenosine. This method has a have 
high diagnostic accuracy for detection of coronary artery disease with myocardial 
perfusion reserve having a sensitivity, specificity, and diagnostic accuracy of 90%, 
83%, and 87%, respectively, for detection of a  >75%, coronary artery stenosis(176). 
This technique clearly has great potential for non invasive diagnosis of coronary artery 
disease. 
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Figure 1.3  
First pass imaging demonstrating an area of hypoenhancemnt (arrowed) in keeping with 
a myocardial perfusion deficit in a patient with a recent lateral myocardial infarction 
 
Figure 1.4  
Late gadolinium enhancement representing infarcted myocardial tissue in the lateral 
wall of the left ventricle in the same patient as Figure 1.3 
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1.4.5 Cardiac magnetic resonance imaging for assessment of cardiomyopathy 
CMR allows accurate definition of cardiac structure, function and geometry in the 
presence of cardiomyopathy. Furthermore, the ability of contrast enhanced CMR to 
detect areas of tissue fibrosis has allowed detailed study of myocardial composition in a 
number of cardiomyopathies characterised by the presence of fibrotic tissue (usually 
collagen) within the myocardium. To date there has been extremely limited study of 
uraemic cardiomyopathy with CMR, with one small study with CMR from our own 
group describing LVH morphologically in haemodialysis patients. Other 
cardiomyopathies have been analysed in more detail. Hypertrophic cardiomyopathy has 
been intensively studied with CMR (Figure 1.5) and CMR allows both demonstration of 
the degree of hypertrophy, the phenotypic expression of the pathological fibrosis(177), 
degree of left  ventricular outflow tract obstruction, systolic anterior motion of the 
mitral valve and can monitor after surgical and pharmacologic interventions(178) or 
alcohol septal artery ablation(179).  
 
Other cardiomyopathies involving myocardial fibrosis where CMR may be useful in 
either the diagnosis or long term management include arrhythmogenic right-ventricular 
cardiomyopathy and dilated cardiomyopathy. In arrhythmogenic right-ventricular 
cardiomyopathy CMR can demonstrate fatty infiltration of the right ventricle and by 
detecting characteristic high signal intensity of fat on spin-echo images within the right 
ventricular myocardium, the presence of fat in the right ventricular wall can be 
demonstrated and then confirmed with fat suppression techniques. Diffuse and focal 
thinning and local aneurysms of the right ventricle can be also be detected (180;181). 
Areas of myocardial fibrosis have been described in dilated cardiomyopathy, and CMR 
may be a useful method of discriminating dilated from ischaemic cardiomyopathy in 
patients with heart failure of unknown aetiology(182).  
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Inflammatory and infiltrative cardiomyopathies have also been described using CMR. 
In sarcoidosis, infiltrates in myocardium can be are seen as areas of amplified T2 signal 
intensity (attributable to inflammation, oedema, and granulomas), which enhance after 
administration of gadolinium. CMR can non-invasively assess response to steroid 
treatment(183). In acute myocarditis contrast enhancement is present in approximately 
90% of patients and correlates with active inflammation defined by histopathology 
(Figure 1.6)(184). In cardiac amyloidosis, CMR initially allows accurate demonstration 
of the presence of thickening of the right atrial and right ventricular wall. Following 
administration of gadolinium in patients with cardiac amyloid, CMR shows a 
characteristic pattern of global subendocardial late enhancement coupled with abnormal 
myocardial and blood-pool gadolinium kinetics(185). Additionally, endomyocardial 
fibrosis (also termed Loeffler’s endocarditis), which is characterised by extensive 
subendocardial fibrosis, apical thrombus formation, and progressive diastolic 
dysfunction can be quantified using CMR(186).  
 
Recently, the ferromagnetic properties attributable to the deposition of iron in 
myocardial tissue have been exploited to initially assess the degree of iron overload in 
the heart of patients with thalassaemia. Myocardial iron loading is assessed with the use 
of myocardial T2* relaxation characteristics at CMR. This approach has subsequently 
been used to guide iron chelation therapy in these patients and myocardial T2* has been 
used as an end point in a clinical trial demonstrating superiority of combination 
chelation treatment with deferiprone and deferoxamine in comparison to deferoxamine 
monotherapy, in thalassaemia major patients with mild to moderate cardiac iron 
loading(187). 
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1.4.6 Contraindications to cardiac magnetic resonance imaging 
Patients with claustrophobia may not tolerate study with CMR. The presence of a 
cardiac pacemaker or implantable cardiac defibrillator remains an absolute 
contraindication to study with CMR. There are some reports of patients with 
pacemakers undergoing CMR without adverse outcome, but this should be only be 
carried out in a controlled environment, with facilities for both close monitoring and 
reprogramming of the pacemaker immediately available, and for the purpose of general 
clinical and research use, a pacemaker remains an absolute contraindication to 
scanning(188). The presence of intraocular metallic shards (e.g. welders) and intra-
cerebral clips or shunts are also contraindications to scanning. Metallic implants can 
lead to artefacts, which might degrade images. Most cardiac prosthetic valves and 
coronary stents presently in use are safe for CMR at available clinical field strengths.  
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Figure 1.5  
Extensive chaotic myocardial collagen deposition indicated by late gadolinium 
enhancement in a patient with hypertrophic cardiomyopathy 
 
Figure 1.6  
Patchy late gadolinium enhancement demon demonstrated in both the septum and 
lateral walls of the left ventricle in a patient with acute myocarditis 
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1.5 Redefinition of uraemic cardiomyopathy with cardiovascular magnetic 
resonance imaging 
Despite the dramatically increased cardiovascular risk in ESRD, the relationship 
between risk factors, interventions and outcome is unclear. One of the few factors to 
have consistently been demonstrated to indicate poor outcome is uraemic 
cardiomyopathy, defined by echocardiography. However, as discussed, it is possible 
that some echocardiographic abnormalities widely present in ESRD, such as LVH may 
be at best overestimated, as suggested by the one previous  report using CMR, or even 
artefactual(189). Although a variety of myocardial tissue abnormalities have been 
described either in animal models of uraemia or in post mortem studies of ESRD 
patients, no method has been able to non invasively describe this histopathological 
finding in vivo. The previous studies of other cardiomyopathies, with some similar 
histological correlates suggest that CMR has the potential to perform this function. 
Furthermore, very few CMR studies have been able to assess the long term implications 
of either morphological ventricular abnormalities or whether the presence of LGE 
confers increased risk of cardiovascular events or mortality.  
 
All these factors suggest that there would be benefits from studying a cohort of patients 
with ESRD using CMR. Hopefully, by more accurately characterising cardiac 
abnormalities in this patient group, novel therapeutic targets for intervention may be 
identifies. The relationship between ischaemic heart disease and uraemic heart disease is 
imprecise. If systolic dysfunction, is due primarily to uraemia, then increasing doses of 
dialysis may be beneficial, on the assumption that myocardial contractility is suppressed 
by some (potentially undiscovered or least not yet causally linked) ‘uraemic factor’. 
Renal transplantation is a definitive treatment for uraemia, but unfortunately the current 
supply of cadaveric organs is outstripped by demand. On the other hand, if as in the 
81 
general population, ischaemic heart disease is the leading cause of systolic dysfunction, 
then evidenced based medical therapy with inhibitors of the renin angiotensin system 
and beta blockade would be an appropriate strategy. The question of lipid lowering 
therapy remains unresolved, but requires further study. Many of these agents are 
currently underused in the ESRD population, and often poorly tolerated. 
 
One further intriguing notion would be to predict the patients at highest risk of sudden 
cardiovascular death. The recent finding that the presence of myocardial fibrosis 
demonstrated by CMR was associated with increased risk of ventricular arrhythmia in 
patients with dilated cardiomyopathy(190), suggests that CMR may have a role in risk 
stratification for such patients. The same may apply in ESRD, with the highest risk 
patients being candidates for implantable cardiac defibrillators.  
 
Finally as CMR technology evolves, new methods for imaging and analysis emerge, 
dependent on the clinical needs of the cohorts of patients examined. Often these 
techniques may be applicable, across a wider range of patients than previously 
envisaged. As a unique group of patients at very high cardiovascular risk, patients with 
ESRD may have distinct differences in both cardiac and vascular function, allowing 
insights into factors responsible for the pathogenesis of cardiovascular disease in the 
general population. Abnormalities in these factors which are severely distorted in 
ESRD, such as arterial stiffness, may be expressed more subtly in the general 
population. Studying a cohort of ESRD patients may allow novel CMR methods to be 
developed to investigate cardiac and vascular markers of cardiovascular risk, to the 
advantage of research into cardiovascular disease in the general population. 
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1.6 Aims of this project 
The principal aims of this project were: 
• To establish the presence and prevalence of left ventricular abnormalities 
(‘uraemic cardiomyopathy’), in a cohort of patients with ESRD using CMR 
• To establish the relationship between uraemic cardiomyopathy and conventional 
cardiovascular risk factors 
• Establish the prognostic impact of the presence of uraemic cardiomyopathy 
described by CMR 
 
Secondary aims: 
• To compare conventional methods of defining uraemic cardiomyopathy such as 
echocardiography with CMR  
• To examine whether vascular function could be assessed using CMR 
• To determine methods of identifying patients with uraemic cardiomyopathy, in 
particular left ventricular hypertrophy using the conventional method of 
echocardiography 
 
1.6.1 Hypothesis 
The studies performed are designed to test the hypothesis that specific left ventricular 
and vascular abnormalities can be identified in patients with ESRD and that these 
abnormalities have an influence on long term survival of these patients. 
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1.7 Outline of the studies contained within this thesis 
Seven principal studies were performed and are detailed in Chapters 3-9:  
 
Chapter 3 : A study of ventricular dimensions and function in uraemia with 
contrast enhanced cardiac magnetic resonance imaging.  
Chapter 4 : A comparative study of echocardiography and electrocardiography 
with cardiac magnetic resonance imaging.  
Chapter 5 : A study of the determinants of uraemic cardiomyopathy.  
Chapter 6 : Survival of patients undergoing cardiovascular screening for renal 
transplantation.  
Chapter 7 : A study of the diagnostic utility of brain natriuretic peptide in end 
stage renal disease.  
Chapter 8 : A study of vascular function with cardiovascular magnetic 
resonance imaging in end stage renal disease. 
Chapter 9 : A study of dermatological complications of contrast enhanced 
magnetic resonance imaging. 
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Chapter 2 
 
Materials and Methods 
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2.1  Introduction 
The principal technique used for this thesis was cardiovascular magnetic resonance 
imaging (CMR). This was supplemented with electrocardiography (ECG), 
echocardiography and exercise tolerance testing.  In this chapter the background, 
methods, apparatus and protocols used for these techniques will be outlined. 
 
2.2  Ethics Committee approval 
The studies performed in this thesis were approved by the North Glasgow Hospitals 
University NHS Trust Ethics Committee. All subjects gave written informed consent, 
the forms being approved by the Ethics Committee. 
 
2.2.1 Subjects 
Patients with advanced renal failure were recruited from the renal transplant assessment 
clinic at the Western Infirmary. At inception of the study, patients attending the renal 
transplant assessment clinic were required to be established on dialysis therapy. The 
study extended to those patients anticipated to commence dialysis therapy within six 
months in keeping with changes in British Transplant Society recommendations 
regarding eligibility for cadaveric renal transplantation. Therefore using KDOQI 
classification all patients studied would be classified as chronic kidney disease stage 
5(191). As cardiovascular disease is the leading cause of both early (with 30 days of 
surgery) and late patient death with a functioning renal transplant, patients considered to 
be at increased cardiovascular risk for renal transplantation were referred for 
cardiovascular screening by the renal transplant co-ordinator. At this point, patients 
were asked if they were willing to undergo CMR by the investigator (PM). Patients 
were considered to be at increased cardiovascular risk if any of the following criteria 
were present, in keeping with published guidelines(192): 
86 
• Age ≥50 
• Presence of diabetes mellitus 
• History of cigarette smoking 
• Previous history of ischaemic heart disease 
• Previous history of peripheral or cerebrovascular disease 
• Strong family history of cardiovascular disease 
• Documented history of left ventricular abnormalities 
• ECG or previous cardiac stress test suggestive of underlying ischaemic heart 
disease 
• The opinion of the consultant transplant surgeon or consultant nephrologist  
 
All subjects who underwent CMR gave written informed consent and this strategy was 
approved by the consultant nephrologists and surgeons involved in the transplant 
assessment process with the protocol approved by the local ethics committee. All 
patients underwent conventional cardiovascular risk factor assessment including history, 
clinical examination, ECG and blood sampling. A history of IHD was defined as 
previous myocardial infarction or angina pectoris, and hypercholesterolaemia was 
defined as fasting total serum cholesterol >5.0 mmol/L or use of statin therapy. The 
decision to list a patient for transplantation was not influenced by CMR findings, and 
was made by an independent transplant surgeon and nephrologist taken on the basis of 
clinical findings and additional investigations such as exercise testing, myocardial 
perfusion scanning and coronary angiography as clinically indicated. Due to ethical 
concerns regarding the potential risks of invasive procedures such as coronary 
angiography, this was only performed as clinically indicated as judged by an 
independent cardiologist, and not as part of study protocol. 
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2.2.2 Exclusion criteria 
Exclusion criteria were contraindications to magnetic resonance scanning (permanent 
pacemaker, implanted ferromagnetic objects, pregnancy, and extreme claustrophobia). 
Two otherwise eligible patients were also screened and excluded with a documented 
history or echocardiographic evidence of hypertrophic cardiomyopathy and one further 
patient with a history of thalassaemia and repeated blood transfusions was excluded; 
both of which have been associated with characteristic CMR findings(177;187). There 
was no evidence of other cause of cardiomyopathy (e.g. amyloidosis, Fabry’s disease, 
sarcoidosis, iron overload) in study patients based on clinical (original renal disease, 
serum ferritin, and clinical review) and echocardiographic findings. 
 
2.3  Cardiovascular Magnetic Resonance Imaging  
 
2.3.1 CMR scan 
CMR was performed using a 1.5 Tesla MRI scanner (Siemens Sonata, Erlangan, 
Germany). As described previously CMR provides a high fidelity, volume independent 
method for assessing cardiac dimensions and function. To minimise influence of 
hydration status on ventricular chamber dimensions CMR scanning was performed on 
the post-dialysis day in patients on haemodialysis, and with patients at their ‘dry 
weight’ in patients on peritoneal dialysis, according to clinical charts. All scanning was 
performed by the investigator (PM) or a cardiac radiographer (Tracey Steedman, 
Glasgow CMR Unit, Western Infirmary, Glasgow). 
 
2.3.2 Contrast agent 
The paramagnetic contrast agent used was gadolinium-diethylentriaminepentaacetate 
(Gd-DTPA-BMA, Omiscan, Amersham, United Kingdom). The initial dose used was 
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0.2mmol/kg from September 2003 to March 2004. All studies after March 2004 used 
0.1mmol/kg. The change in dose was made to allow for reduction in scan time and to 
minimise any potential side effects associated with use in patients with advanced renal 
failure. 
 
2.3.3 CMR protocol- image acquisition 
 
2.3.3.i  Patient positioning 
Patients were positioned head first and supine in the scanner. Breath hold instructions 
were relayed via headphones and relaxing music played if desired. A chest coil was 
employed to optimise image acquisition.  
 
2.3.3.ii  Left ventricular mass and function 
An ECG gated breath hold fast imaging with steady-state precession (trueFISP) 
sequence was used to acquire cine images in long axis planes followed by sequential 
short axis left ventricular cine loops (8mm slice thickness, 2mm gap between slices) 
from the atrio-ventricular ring to the apex. In full the protocol is as follows:  
1. The initial sequence was a multi-slice breath-hold localiser in end expiration. 
From these images select the best axial image depicting the left ventricle and 
septum was selected 
2. This image was used to plan a vertical long axis localiser (VLA) along the long 
axis of the ventricle from the mid-point of the mitral valve to the apex.  From the 
resulting VLA scan the horizontal long axis (HLA) localiser was planned, again 
using the mid-point of the mitral valve and the apex of the ventricle to orientate 
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3. From this HLA view, three short axis (SA) localiser slices were produced, with 
the orientation selected as close as possible to parallel to the mitral valve plane. 
The anatomical landmark of the atrio-ventricular groove was used as a guide  
4. The resulting SA images allow the three long axis views to be set. These were 
the 4-chamber, 2-chamber and left ventricular outflow tract (LVOT) views. Cine 
studies were acquired in these orientations 
5. From the cine 4-chamber study acquired the short axis stack was planned. The 
first of these cine slices was positioned in an orientation across the mitral valve 
plane, again using the atrio-ventricular groove as an anatomical land-mark. The 
slice position would then be incremented and repeated until LV was completely 
covered 
Imaging parameters, which were standardized for all subjects, included repetition time 
(TR)/echo time (TE)/ flip angle (FA)/ voxel size /field of view (FoV) - 3.14 ms/ 1.6 ms/ 
600/ 2.2 x 1.3 x 8.0 mm/340 mm.  
 
2.3.3.iii Aortic distensibilty and compliance 
Aortic distensibilty was assessed from cine MR images in the transverse plane of the 
ascending aorta were obtained at the level of the main pulmonary artery utilising a 
trueFISP sequence (TR=3.2 ms, TE=1.6 ms, FA=60°, FoV 276x340mm, pixel 
dimensions 2.3x1.3mm, slice thickness=7 mm). The approximately 10 second breath-
hold CMR sequence resulted in prospective images with a temporal resolution of at 
least 22.5ms. During image acquisition, blood pressure was measured using a non-
ferromagnetic brachial artery sphygmomanometer cuff (Schiller instruments, Baar, 
Switzerland).  
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2.3.3.iv Phase encoded (Flow sensitive) CMR imaging of aortic blood flow 
To generate flow measurements along the aorta a fast low angle shot (FLASH) gradient-
echo pulse sequence (TR=41 ms, TE=3.2 ms, FA=30°, matrix size=192x256, Pixel 
Dimensions 1.5x1.5, slice thickness= 5 mm) was applied perpendicular to the aorta at 2 
levels: at the level of the crossing of the pulmonary artery through the ascending (in the 
same plane as the compliance sequence) and descending aorta and at the level of the 
diaphragm. This resulted in multiphase image pairs of modulus- and velocity encoded 
images with a temporal resolution of approximately 20.7 ms. 
 
2.3.3.v  Contrast enhanced CMR images 
Further images were acquired 10 minutes after a manual injection of a peripheral bolus 
of Gd-DTPA-BMA via a intravenous cannula flushed with 10ml of 0.9% saline.  A 
breath-hold segmented turboFLASH inversion-recovery sequence, using identical slice 
positions as the cines was used. Standardised settings were used for contrast-enhanced 
imaging including specific parameters of TR/TE/flip angle/voxel size/FoV/number of 
segments - 11.6 ms/4.3 ms/20°/2.2 x 1.3 x 8.0 mm/ 23. Inversion time for the 
turboFLASH sequence was optimized on an individual patient basis. Successful nulling 
of normal myocardium was deemed to have been achieved once the LV myocardium 
appeared black and homogenous. Generally, an inversion time of between 150 and 280 
ms was required.  
 
2.3.3.vi CMR scan duration 
Standard LV mass and function took approximately 20-25 minutes. Measures of 
vascular function required a further 5 minutes and acquisition of contrast enhanced 
images added an additional 10 minutes to scan time. Overall, scan time was 
approximately 30–40 minutes, with a maximum time of 45minutes. 
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2.4 CMR Analysis 
 
2.4.1 Analysis of left ventricular function 
LV function was analysed from the left ventricular short axis cine loops. Epicardial and 
endocardial borders were traced manually and end-systolic and end-diastolic contours 
with end-systolic and end-diastolic volumes and LV mass were calculated using 
conventional analysis software (Argus, Siemens, Erlangen). Volumes and LV mass 
were also indexed to body surface area with body surface area calculated using the 
Dubois formula: 
Body Surface Area = 0.20247 x Height(m)0.725 x Weight(kg)0.425 
Left ventricular ejection fraction (LVEF) was calculated as: 
 
 
2.4.2 Definition of left ventricular abnormalities 
LVSD was defined as LV ejection fraction (LVEF) <55%, with LVH defined as left 
ventricular mass index (LV mass/body surface area; LVMI) greater than 84.1 g m-2 
(male) or 76.4 g m-2  (female), LV dilatation defined as end diastolic volume/body 
surface area greater than 111.7 ml m-2 (male) or 99.3 ml m-2 (female) or end systolic 
volume greater than 92.8 ml (male) or 70.3 ml (female) based on based on published  
mean normal LV dimensions for healthy volunteers plus two standard deviations(169). 
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Figure 2.1 
 
Figure 2.2 
Figure 2.1  Vertical long axis (2-chamber) image in end diastole in a patient with left 
ventricular hypertrophy with line demonstrating plane used to plan horizontal long axis 
(4-chamber) cine 
Figure 2.2  Horizontal long axis (4-chamber) image in end diastole in the same 
patient with line demonstrating plane used to plan short axis (4-chamber) cine 
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Figure 2.3  
Short axis view of the left ventricle in end diastole with the left ventricular (LV) and 
right ventricular (RV) cavities indicated. The papillary muscles (Pap) are arrowed 
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Figure 2.4  
End diastolic (left) and end systolic (right) short axis views of the left ventricle with the 
endocardial (red) and epicardial (green) borders contoured using the Argus analysis 
package 
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2.4.3 Contrast-enhanced image analysis 
Myocardial fibrosis was documented as indicated by the presence of late gadolinium 
enhancement (LGE). Images were assessed for the presence, pattern, and volume of 
gadolinium enhancement. Patients were classed as having positive LGE, if LGE was 
seen on at least two (of three) views: short axis view, long axis view, and reverse phase 
sequences, to exclude artefact. Artefact on the contrast-enhanced images was excluded 
by the acquisition of ‘reverse phase’ images through slice planes which appeared to 
demonstrate intra-myocardial contrast enhancement. This technique involves the 
reversal of the phase encoding and frequency-encoding directions as the phase-encoding 
direction is particularly prone to artefacts caused by cardiac motion or chest wall 
movement. Only areas of contrast enhancement that persisted on these reversed phase 
images were included in subsequent quantification of areas of contrast enhancement. 
Areas of contrast enhancement were first identified visually and this area was contoured 
by manual planimetry to calculate volume of enhanced myocardial tissue. Volume of 
LGE mass was calculated by multiplying LGE volume by myocardial density (1.04 g 
cm-3) and is used as the absolute measured value of contrast-enhancing tissue seen. 
 
2.4.4 Computerised assessment of areas of late gadolinium enhancement 
Mean signal intensities (+/- standard deviation) for areas of contrast enhancement and 
for an adjacent reference area of non-enhancing myocardium again using the Argus 
package. LGE was defined as an area of visually identified contrast enhancement with a 
mean signal intensity that was greater than one standard deviation higher than the mean 
signal intensity of an adjacent area of reference ventricular myocardium, which 
although nulled had a mean signal intensity significantly above zero. No manual 
alteration of image brightness/intensity settings was made during this process to ensure 
objective visual assessment of LGE. Patterns of gadolinium enhancement were analysed 
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both subjectively and objectively based on mean signal intensity. LGE volume was 
determined by manual planimetry of any areas of contrast enhancement meeting these 
criteria.  
 
2.4.5 Analysis of vascular function 
 
2.4.5.i  Aortic distensibilty 
To calculate aortic distensibilty, the aortic volumes were measured by manual tracing of 
the cross sectional area of the vessel lumen using the Argus analysis software, which 
was multiplied by the slice thickness. Aortic distensibilty was calculated according to 
the following formula:  
 
where (Aortic volume)max and (Aortic volume)min are the maximal and minimal 
calculated aortic volumes obtained during the cardiac cycle (Figure 2.5). 
Aortic volumetric arterial strain (VAS- non pressure dependent) is calculated from the 
formula: 
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2.4.5.ii  Measurement of pulse wave velocity  
2.4.5.ii (a) Assessment of aortic length 
Aortic length was measured using software developed by Dr. Gang Gao (Department of 
Computing Science, University of Glasgow). Briefly, a threshold algorithm is used to 
convert the original image to a binary map with the threshold value selected both 
manually and automatically. The binary map highlights the aortic region since the aorta 
appears significantly brighter than other soft tissues around it. To locate the aorta, 
further manual refinements are required.  Once the aortic midline is defined, the aorta is 
‘skeletonised’, to isolate the aortic length to be measured (Figure 2.6). 
 
2.4.5.ii (b) Interpretation of flow velocity curves to calculate time difference 
between points along the aorta 
Initial measurement of blood flow and velocity was made using the Argus CMR 
analysis software (Figure 2.7). These files were saved for off line plotting, 
normalisation and interpretation. The time difference of initial flow acceleration 
between two regions of interest was calculated from normalised velocity curves using 
off-line software (Origin, OriginLab Corporation, Northampton, MA, USA). The 
upstroke velocity is approximately linear and usually contains three or more sample 
points. The location of the best cross-correlation of two partial upstroke velocity curves 
was used to estimate the time delay (Figure 2.8).  
 
2.4.5.ii (c) Calculation of pulse wave velocity 
Pulse wave velocity was then calculated using the equation: 
Pulse wave velocity = Distance/Time 
where distance is the distance between the points along the aorta and time is the time 
difference in flow between those points. 
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Figure 2.5 
Ascending aorta (AAo) and descending aorta (DAo) shown in cross section, with 
ascending aortic contour traced for distensibilty and volumetric arterial strain 
measurement 
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Figure 2.6.1 Figure 2.6.2 
 
Figure 2.6 Using Cardiowarp to measure aortic length 
Figure 2.6.1 Sagittal planning view through the aorta with planes for measurement of 
blood flow and aortic distensibilty indicated 
Figure 2.6.2 The aortic midline has been accurately defined and skeletonised 
Figure 2.6.3 The measured aorta with regions of interest (ROI) 1-3 indicated where 
blood flow velocity will be subsequently measured 
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Figure 2.7 
Ascending aorta (AAo) and descending aorta (DAo) shown in cross section, with 
ascending aortic contour traced for aortic blood flow measurement 
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Figure 2.8 
Representative plot of normalised blood flow plotted against time. ∆t is the time delay 
subsequently used to calculate pulse wave velocity 
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2.5  CMR Analysis – duration 
Approximate time required analysing left ventricular mass and function was 15 minutes 
per patient, with a further five minutes required to analyse late gadolinium images.  
Analysing the measures of vascular function took somewhat longer, with 20 minutes 
required for all the Argus based analysis and a further 10 minutes per patient to perform 
the PC based graph construction. 
 
2.6 Coronary angiography 
A proportion of patients underwent coronary angiography as part of assessment for 
renal transplant listing. The decision to perform angiography and interpretation of the 
angiogram was made by a cardiologist blinded to CMR findings, and was made on 
clinical grounds, based on symptoms, LVSD, or positive stress test (exercise test or 
myocardial perfusion scanning). CMR was performed within 3 months (before or after) 
of angiography. Patients were classified as having normal coronary arteries, 
mild/moderate coronary artery disease (presence of coronary plaque or up to 70% 
stenosis of any epicardial coronary artery) or severe coronary artery disease (presence of 
>70% stenosis of any epicardial coronary artery). Total atheromatous plaque burden 
was calculated by adding the percentages of the most severe lesion in each artery (thus 
the range was 0–400% as four vessels- left main stem, left anterior descending, right 
coronary and circumflex arteries were studied)(193). 
 
2.7  Echocardiography 
 
2.7.1 Echocardiography – general 
In all cases echocardiography was carried out on the same day as CMR, either 
immediately prior to, or after the CMR scan. Echocardiography was performed using an 
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Acuson 128 machine (Siemens Medical, Bracknell, UK) by a single cardiac technician 
(Tony Cunningham, Clinical Research Initiative, University of Glasgow) and stored on 
videotape for off line analysis. 
 
2.7.2 Echocardiography protocol – image acquisition 
Patients were placed in the left lateral position and scanned from several different 
intercostal spaces. Standard trans-thoracic views were recorded from parasternal and 
apical transducer positions as listed below:  
Parasternal Approach 
Long-axis plane 
Root of aorta—aortic valve, left atrium, left ventricular outflow tract 
Body of left ventricle—mitral valve   
Left ventricular apex   
Right ventricular inflow tract—tricuspid valve   
Short-axis plane 
Root of the aorta—aortic valve, pulmonary valve, tricuspid valve, right ventricular 
outflow tract, left atrium, pulmonary artery, coronary arteries 
Left ventricle—mitral valve   
Left ventricle—papillary muscles 
Left ventricle—apex   
Apical Approach 
Four-chamber plane 
Four chamber   
Four chamber with aorta   
Long-axis plane 
Two chamber—left ventricle, left atrium and with aorta    
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Pulsed wave, continuous wave Doppler, 2-D M-mode, and colour flow mapping were 
used in each position as appropriate to assess valve flow patterns, diastolic function, 
anatomy, dimensions and regurgitation respectively. Analysis of LV mass was 
performed as described in chapter 4. Further characterisation of LVH into concentric 
and eccentric LVH was dependent on measurements of regional wall thickness (RWT): 
RWT = [(2 x PWTd) / LVIDd) 
Concentric hypertrophy was present if the RWT ≥0.45 in the presence of LVH with 
eccentric hypertrophy present if RWT was <0.45 in the presence of LVH. 
 
2.8 Electrocardiogram 
A standard 12-lead ECG was recorded at 25 mm s-1 and 1 mV cm-1 standardisation. The 
ECG was considered abnormal if any of the following criteria were met in any of the 
standard limb leads or praecordial leads, except AVR or V1: pathological Q waves, 
LVH by Sokolow–Lyon criteria or Cornell index, ST depression 1 mm, ST elevation 1 
mm, T wave inversion or bundle branch block (QRS 120 ms). 
 
2.9 Exercise tolerance testing 
All patients able to perform treadmill exercise underwent treadmill exercise testing 
according to standard Bruce protocol. The 12 lead ECG was recorded continuously and 
the following documented: exercise time to limiting symptom, maximal ST segment 
change, maximal heart rate, maximal systolic blood pressure, limiting symptoms. The 
test was stopped if any of the following occurred: limiting symptoms (angina, shortness 
of breath, dizziness, lethargy), ST depression 3 mm, ventricular tachycardia, drop in 
blood pressure 30 mmHg, rise in systolic blood pressure 230 mmHg.  The test was 
described as inconclusive if stopped before 85% predicted heart rate could be achieved 
with no cardiac symptoms or significant changes at that stage. 
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Figure 2.9  
M-mode echocardiogram of the left ventricle of a patient with left ventricular 
hypertrophy. IVS (interventricular septum), LVPW (left ventricular posterior wall), 
LVESD (left ventricular end systolic diameter), LVEDD (left ventricular end diastolic 
diameter) 
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Figure 2.10.1 
 
Figure 2.10.2 
Figure 2.10.1 
 End diastolic 4-chamber view of the left ventricle with the endocardial surface 
contoured 
Figure 2.10.2  
End systolic 4-chamber view of the left ventricle with the endocardial surface contoured
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2.10  Blood sampling 
Prior to CMR scanning 30ml of venous blood was drawn and analysed in the hospital 
biochemistry and haematology laboratories for haemoglobin, electrolytes, urea, 
creatinine and glucose. A proportion of this blood was centrifuged and frozen within 20 
minutes of collection to -70ºC. Serum brain natriuretic peptide was measured using by a 
one step radioimmunoassay (ShionoRIA, Shinogi, Japan).  Plasma total cholesterol, 
low-density lipoproteins, high-density lipoproteins, triglycerides and high sensitivity C-
reactive protein were assessed using standard biochemical methods.  
 
2.11 Follow up 
Follow up data were collected from date of the CMR scan to 30th September 2006 using 
electronic patient records from the Western Infirmary Glasgow and Glasgow Royal 
Infirmary Renal Units.  
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Chapter 3 
 
A study of ventricular dimensions and function in uraemia with contrast enhanced 
cardiac magnetic resonance imaging 
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3.1 INTRODUCTION 
The burden of cardiovascular disease in uraemia has been outlined in Chapter 1 and its 
relationship with subsequent mortality and morbidity has been highlighted. As 
discussed, despite the presence of many ‘traditional’ cardiovascular risk factors for 
atherosclerosis and subsequent development of coronary artery disease as well as those 
risk factors specific to uraemia in patients with ESRD; the relationship between these 
risk factors and outcome is less clear than in the general population. However, based on 
data from the early 1990s, the presence of uraemic cardiomyopathy, defined 
echocardiographically by the presence of left ventricular abnormalities, specifically 
LVH, left ventricular dilatation and left ventricular systolic dysfunction have been 
shown to be associated with poor outcome in this patient group(76). At the inception of 
the study, no large scale studies existed to establish whether these relationships between 
cardiac dimensions and outcome held true using the more accurate method of CMR to 
assess cardiac dimensions. Moreover data were limited on the use of CMR in patients 
with ESRD, with only one small pilot study published, from our own group using a 1 
Tesla scanner with less sophisticated scanning protocols(189). 
 
This study was designed to accurately characterise left ventricular mass and function in 
a cohort of patients with ESRD, firstly compared to controls and additionally to explore 
the relationship between CMR markers of myocardial fibrosis, indicated by late 
gadolinium enhancement (LGE), and uraemic cardiomyopathy.  
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3.2 METHODS 
 
3.2.1 CMR technique and analysis 
All patients and controls were studied with the CMR technique described in detail in 
Chapter 2 (2.3.2). Controls did not have contrast enhanced studies with Gd-DTPA-
BMA performed. Blood pressure was recorded at the time of scanning. 
 
3.2.2 Statistical methods 
Left ventricular dimensions, age and blood pressure were compared between control 
groups and patients with ESRD by t-test or Mann-Whitney-U as appropriate. In patients 
with ESRD undergoing contrast enhanced CMR the prevalence of conventional 
cardiovascular risk factors and LV abnormalities between those patients with, and 
without, the presence of myocardial fibrosis indicated by CMR were analysed by Chi-
squared or Fisher’s exact test (as appropriate) for categorical data and paired t-test and 
Mann–Whitney–U testing, respectively, for continuous data. Correlations between 
volume of myocardial fibrosis and cardiac dimensions were assessed with Pearson and 
Spearman correlation co-efficient as appropriate. All analyses were performed using the 
SPSS 11.5 statistical software package (SPSS Inc., Chicago, IL., USA). 
 
3.3  RESULTS 
 
3.3.1 Patient and control demographics 
Patient demographics and drug therapy at the time of scan are shown in Table 3.1. 
Seven (3.9%) patients consented to be studied but did not complete CMR scanning due 
to claustrophobia and were not included in the analysis. 172 patients (38 with advanced 
renal failure not on dialysis therapy and 134 established on dialysis) and 20 control 
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subjects were studied. The groups of controls and uraemic patients had a similar age and 
sex distribution. No significant differences in patient demographics or ventricular 
dimensions or function were exhibited between patients with advanced renal failure not 
yet on dialysis therapy and those established on renal replacement therapy and therefore 
these patients were combined as a single ‘uraemic’ group. Systolic and diastolic blood 
pressures were higher in uraemic patients than controls as expected.  
 
3.3.2 Left ventricular dimensions 
Left ventricular dimensions are shown in Table 3.2 for the uraemic patients and 
controls. Overall there was no significant difference in left ventricular end diastolic or 
systolic dimensions between uraemic patients and controls but, as expected, uraemic 
patients had significantly higher left ventricular mass. As an entire group uraemic 
patients did not show a reduction in systolic function as indicated by left ventricular 
ejection fraction compared to controls. Representative CMR images of control and 
uraemic patients are shown in Figures 3.1 - 3.4. 
 
3.3.3 Reproducibility of measurement of left ventricular dimensions 
A proportion of scans (n=20) were reanalysed in a blinded fashion. The intra-observer 
variability of measurements for ejection fraction, LV mass/BSA, end diastolic 
volume/BSA and end systolic volume/BSA were 4.2%, 5.3, 5.3% and 8.8%  
respectively, in keeping with previous studies within our group(189). 
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 Uraemic Control p value 
Number 172 20 - 
Male (%) 107 (62.2) 12 (60.0) 0.847 
Age (years) 51.9 (11.1) 48.8 (9.1) 0.366 
Height (m) 168.7 (10.0) 170.4 (9.0) 0.390 
Weight (kg) 74.8 (16.2) 74.8 (10.6) 0.984 
SBP (mmHg) 140 (25) 116 (10) <0.001 
DBP (mmHg) 82 (13) 75 (8) 0.013 
10 Renal Disease  -  
 Diabetes 47 (27.3) 
 APKD 19 (11.0) 
 GN 34 (19.8.) 
 CPN 19 (11.0) 
 Renovascular 7 (4.1) 
 Unknown/Other 46 (26.7) 
  
RRT time (months) 7 (47.8)   
Smoker    
 Never 97 (56.4) 13 (65.0)  
 Current 51 (29.7) 2 (10.0) 0.123 
 Ex 24 (14.0) 5 (25.0)  
Previous IHD 30 (17.4) - - 
TIA/CVA 14 (8.1) - - 
PVD 12 (7.0) - - 
Table 3.1 
Background demographics for uraemic patients and controls. Results are show as mean 
with standard deviation in parenthesis or number with percentage in parenthesis as 
appropriate except for RRT time which is displayed as median and inter quartile range. 
Tests of significance are t-test and Chi-squared between groups  
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 Uraemic Control p value 
LV ejection fraction (%) 66.6 (11.6) 67.4 (4.6) 0.753 
LV mass (g) 169.1 (61.4) 123.1 (29.4) 0.001 
End diastolic volume (ml) 145.0 (59.5) 137.0 (33.0) 0.556 
End systolic volume (ml) 51.7 (36.5) 45.4 (15.3) 0.444 
Stroke volume (ml) 91.3 (33.6) 91.7 (20.1) 0.961 
LV mass/BSA (g m-2) 91.3 (29.4) 65.7 (12.9) <0.001 
End diastolic volume/BSA (ml m-2) 78.6 (29.9) 72.7 (14.8) 0.398 
End systolic volume/BSA(ml m-2) 28.0 (19.1) 24.2 (7.3) 0.391 
Stroke volume/BSA (ml m-2) 49.6 (16.7) 48.6 (8.9) 0.792 
 
Table 3.2 Left ventricular dimensions in uraemic patients and controls. Results are 
show as mean with standard deviation in parenthesis. Test of significance is t-test  
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Figure 3.1 
Short axis mid left ventricular cavity view of images of the left and right ventricle of a 
normal control subject in end diastole (left) and end systole (right) 
 
    
Figure 3.2 
Short axis mid left ventricular cavity view of images of the left and right ventricle of a 
patient with ESRD on haemodialysis with marked left ventricular hypertrophy in end 
diastole (left) and end systole (right) 
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Figure 3.3 
Horizontal long axis view of images of the left and right ventricle of a normal control 
subject in end diastole (left) and end systole (right) 
 
   
 
Figure 3.4 
Horizontal long axis view of images of the left and right ventricle of the ESRD patient 
also shown in Figure 3.2 in end diastole (left) and end systole (right) 
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3.4 Contrast enhanced studies 
Contrast enhanced CMR studies were performed in 145 uraemic patients.  Contrast was 
not administered for the CMR scan for the following reasons: concern over precipitating 
decline in renal function in patient with rapidly deteriorating native renal function 
(n=17), concern of decline in renal function in rapidly deteriorating renal transplant 
function (4), patient choice (5) and poor venous access (1). The CMR protocol for 
image acquisition is described in detail in Chapter 2 (2.3.2.v), with analysis described in 
2.4.2. The dose of Gd-DTPA-BMA was 0.2mmol/kg used until March 2005, when it 
was reduced to 0.1mmol/kg, in light of recognition, that similar scan quality could be 
achieved with a lower dose (permitting reduced scan time and theoretically safer or less 
likely to provoke side effects).   
 
3.4.1 Baseline left ventricular dimensions in patients with and without positive 
myocardial late gadolinium enhancement 
Baseline patient demographics of patients undergoing contrast enhanced CMR are 
displayed in Table 3.3. Results are show as mean with standard deviation in parenthesis 
or number with percentage in parenthesis as appropriate except for RRT time which is 
displayed as median and inter quartile range.   
 
There was a high prevalence of conventional cardiovascular risk factors in the overall 
patient group with 18.6% having a history of ischaemic heart disease (IHD), 31.7% 
were diabetic (27.6% with diabetic nephropathy), 49.7% had hypercholesterolaemia 
(39.3% on statin therapy), and 47.6% had a positive smoking history. Overall, 49 
(33.8%) patients had evidence of late gadolinium enhancement (LGE) at CMR. Patients 
who had evidence of LGE (LGE positive) had greater LVMI (LGE positive – mean 
100.9 g m-2, LGE negative – mean 86.6g m-2, p<0.001), LV dilation (measured as end 
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diastolic volume: LGE positive – 168.2 ml, LGE negative – 129.2ml, p<0.001) and had 
greater evidence of LVSD (ejection fraction: LGE positive – mean 60.7%, LGE 
negative – mean 68.8%, p<0.001) than patients with no LGE. Representative images of 
patients with and without LGE (and its subtypes are displayed in Figures 3.5-3.10). As 
fundamental differences emerged between the functional, clinical and laboratory 
correlates of different subgroups of LGE further analysis of these factors was performed 
separately. 
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Male (%) 88 (60.7) 
Age (years) 51.9 (11.1) 
Height (m) 168.6 (10.0) 
Weight (kg) 74.6 (16.2) 
SBP (mmHg) 138.9 (25.3) 
DBP (mmHg) 82.4 (13.4) 
RRT 
 
 HD 75 (51.7) 
 PD 52 (35.9) 
 Pre-Dialysis 18 (12.4) 
Duration of RRT (months) 8 (52.5) 
10 Renal Disease 
 
 Diabetes 40 (27.6) 
 APKD 16 (11.0) 
 GN 29 (20.0) 
 CPN 15 (10.3) 
 Renovascular 6 (4.1) 
 Unknown/Other 39 (26.9) 
Smoker 
 
  Never 76 (52.4) 
 Current 46 (31.7) 
 Ex 23 (15.9) 
Diabetes 46 (31.7) 
  Type 1 28 (19.3) 
 Type 2 18 (12.4) 
IHD 27 (18.6) 
Hypercholesterolaemia 72 (49.7) 
Previous MI 16 (11.0) 
TIA/CVA 11  (7.6) 
PVD 12  (8.3) 
Table 3.3  
Background demographics for uraemic patients undergoing contrast enhanced CMR 
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3.4.2 Description and functional implications of subendocardial late gadolinium 
enhancement  
Further analysis of the pattern of LGE revealed crucial differences between patient 
groups. Broadly, there were two patterns of LGE. Firstly, subendocardial LGE 
involving the subendocardium was seen in 24 patients (16.6%). This finding is in 
keeping with the pattern of LGE previously described in patients with myocardial 
infarction (Figures 3.6-3.7). Subendocardial LGE was associated with significantly 
greater degree of ventricular dilatation (end systolic volume/BSA 47.1 vs. 22.9 ml m-2, 
p<0.001) as well as reduced systolic function indicated by left ventricular ejection 
fraction (54.1 vs.  68.8%, p<0.001) compared to patients who were LGE negative, with 
a corresponding greater proportion of patients with subendocardial LGE having left 
ventricular systolic dysfunction (54.2% vs. 8.3% of LGE negative, p<0.001). These 
results are presented in Table 3.4. In keeping with this pattern representing old 
myocardial infarction, the presence of subendocardial LGE was associated with a wall 
motion abnormality of the corresponding myocardial wall in nearly all cases when the 
pre-contrast cine images were reviewed (23 of 24 scans exhibited wall motion 
abnormalities in the areas affected by subendocardial LGE). In patients with 
subendocardial LGE there was a significant negative correlation between mass of 
myocardial tissue indicated by LGE and LVEF (Spearman’s R= -0.43, p=0.036).  
 
3.4.3 Clinical correlates of subendocardial late gadolinium enhancement 
Subendocardial LGE was associated with the presence of conventional cardiovascular 
risk factors (Table 3.5) and was found in significantly higher proportions in patients 
with a history of IHD (66.7% of patients with subendocardial LGE had a history of IHD 
vs. 8.3% of LGE negative patients, Chi- squared p<0.001), hypercholesterolaemia 
(79.2% of patients with subendocardial LGE had a history of hypercholesterolaemia vs. 
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48.3% of LGE negative patients, p=0.002), and a positive smoking history (79.2% of 
subendocardial LGE vs. 41.7% LGE negative patients had ever smoked, p=0.001). 
Diabetes was present in a significantly greater proportion of patients with 
subendocardial LGE compared to LGE negative patients (54.2% vs. 30.2, Chi-squared 
p=0.028). The presence of subendocardial LGE was not associated with significant 
differences in gender, dialysis modality or duration, or a difference in blood pressure 
compared to those patients who were LGE negative.  
 
3.4.4 Laboratory correlates of subendocardial late gadolinium enhancement 
There were no significant differences in haemoglobin, dialysis adequacy in 
haemodialysis patients, calcium, phosphate or albumin between patients with 
subendocardial LGE and LGE negative patients (Table 3.6). Although LDL cholesterol 
was non-significantly lower in these patients (2.2 vs. 2.9 mmol/L, p=0.054), a higher 
proportion of these patients were treated with statin therapy that LGE negative patients 
(60.9%% vs. 38.7%, p= 0.055). Serum parathyroid hormone was significantly higher in 
these patients compared to LGE negative patients (median 32.5 vs. 12.5 pg/mL, p = 
0.003). Unexpectedly in the small number of patients on peritoneal dialysis (n=5) with 
subendocardial LGE dialysis adequacy, as indicated by total weekly creatinine 
clearance, was greater in patients with subendocardial LGE (112.1 vs. 81.0 
L/week/1.73m2, p=0.009). This was primarily accounted for by greater residual renal 
function in these patients (64.7 vs. 31.1 L/week/1.73m2, p=0.010). The converse was 
true in patients on haemodialysis with patients with subendocardial LGE having 
numerically poorer dialysis adequacy, as indicated by higher urea reduction ratio 
compared to LGE negative patients (66.5 vs. 70.8%, p=0.084). 
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3.4.5 Description and functional implications of diffuse late gadolinium 
enhancement  
The second pattern, diffuse LGE, was less intense, without subendocardial dominance 
(Figures 3.8-3.10). Diffuse LGE was seen in 25 patients (17.2%). While this pattern was 
still ‘patchy’ and was therefore regional, this appears to represent regional areas of 
diffuse fibrosis within the left ventricle. These two patterns were not mutually exclusive 
and one patient, with severe LVH, diabetes, and coronary artery disease had both 
patterns of LGE. By contrast to subendocardial LGE, patients with diffuse LGE had no 
or minimal impairment of systolic function, compared to those without LGE (Table 
3.4). However, diffuse LGE was associated with significantly greater LV mass 
compared to patients without LGE (105.7 vs. 100.9 g m-2, p=0.003), and whilst the 
presence of LGE was also associated with a greater LV dilatation indicated by increased 
end diastolic volume (156.9 vs. 129.2 ml, p=0.023), this did not appear to have a 
negative impact on systolic function, with no overall reduction in ejection fraction (67.0 
vs. 68.8%, p=0.389). There were no significant differences between measures of LV 
dilatation between patients with diffuse LGE and LGE negative patients when 
ventricular dimensions were normalised to body surface area. Unlike subendocardial 
LGE, the correlation between the mass of diffuse LGE and LV dimensions or function 
was less clear with no significant correlation between mass of myocardial tissue 
indicated by diffuse LGE and any ventricular dimension. Additionally, no wall motion 
abnormalities were observed in any ventricular segments affected by diffuse LGE. 
 
3.4.6 Clinical correlates of diffuse late gadolinium enhancement 
There was no association between the presence of diffuse LGE and the presence of 
cardiovascular risk factors such as blood pressure, smoking history, gender or history of 
previous IHD, nor was this associated dialysis modality (Table 3.5). Patients with 
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diffuse LGE had been receiving treatment with renal replacement therapy for a 
significantly longer duration than LGE negative patients (median time 36.0 vs. 7.0 
months, p=0.036). 
 
3.4.7 Laboratory correlates of diffuse late gadolinium enhancement 
There were no significant differences in haemoglobin, dialysis adequacy or albumin 
between patients with diffuse LGE and LGE negative patients (Table 3.6). Systemic 
inflammation, as indicated by high sensitivity C-reactive protein was numerically higher 
in these patients (9.3 vs. 4.5 mg mL-1, p=0.087). Despite proportionally lower numbers 
of these patients being treated with statin therapy (29.2 vs. 38.7 of LGE negative 
patients, p=0.387), patients with diffuse LGE had significantly lower total cholesterol 
than LGE negative patients (4.2 vs. 5.0 mmol L-1, p=0.013) and LDL cholesterol (2.2 
vs. 2.9 mmol L-1, p=0.033). Additionally these patients had greater biochemical 
evidence of hyperparathyroidism than LGE negative patients (median PTH 30.5 vs. 
12.5 pg mL-1, p=0.029). Conversely, the overall calcium-phosphate product was 
significantly lower in patients with diffuse LGE (3.6 vs. 4.2 mmol L-1, p=0.044). 
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Figure 3.5 
Contrast enhanced images of the left ventricle in a patient with ESRD with no evidence 
of LGE. A short axis view (left) and a horizontal long axis view are shown (right). The 
myocardium has been successfully nulled (black) and in this patient ventricular 
dimensions and function are normal 
   
Figure 3.6 
Contrast enhanced images of the left ventricle in a patient with ESRD with evidence of 
subendocardial LGE indicating a large old inferior myocardial infarction (arrowed). A 
short axis view (left) and a horizontal long axis view are shown (right) 
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Figure 3.7 
Patient with an inferior myocardial infarction indicated by subendocardial LGE 
(arrowed left panel) and a corresponding basal inferior wall motion abnormality 
demonstrated by a dyskinetic basal inferior segment arrowed in end diastole (centre 
panel) and end systole (right panel) 
 
   
Figure 3.8 
Horizontal long axis (left) and short axis (right) view of the heart of a patient with 
severe left ventricular hypertrophy and septal diffuse LGE (arrowed). Coronary 
angiography in this patient was normal with large unobstructed coronary arteries 
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Figure 3.9 Vertical long axis (left) and short axis (right) view of the left ventricle in a 
further patient with severe left ventricular hypertrophy and septal and lateral wall diffuse LGE 
(arrowed). Coronary angiography in this patient was normal with large unobstructed coronary 
arteries and additionally the patient performed 11:30 minutes of a Bruce protocol exercise 
tolerance test with no ECG changes 
   
Figure 3.10 Short axis (left) Horizontal long axis (left) and view of a patient with moderate 
left ventricular hypertrophy and a lesser degree of septal diffuse LGE (arrowed). There is a 
minor degree of movement artefact on the left image. The patient was 30 years old with no 
angina and performed 12 minutes of a Bruce protocol exercise tolerance test with no ECG 
changes 
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3.4.8 Objective computerised analysis of identification and classification of late 
gadolinium enhancement 
Owing to the subjective nature of classification of pattern of gadolinium enhancement, 
objective measurement was made to compare signal intensity (or pixel intensity on the 
analysed images), of the region of interest of LGE compared to that of nulled 
myocardium. The mean signal intensity of nulled myocardium was 6.4 units compared 
to a mean value 25.5 for all LGE positive tissue (p<0.001, Table 3.5). Subendocardial 
LGE had significantly higher mean signal intensity than that of diffuse LGE (32.6 vs. 
18.1, p<0.001) demonstrating the distinct presence of diffuse LGE separate from any 
artefact in the acquisition of images, as well as potentially indicating the different tissue 
properties of subendocardial and diffuse LGE (Figure 3.11).   
 
3.4.9 Relationship between results of contrast enhanced studies and coronary 
angiography 
In total, 64 patients underwent coronary angiography (Table 3.6). Overall 39.1% had 
normal coronary arteries, with 28.1% having mild/moderate coronary artery disease 
(CAD) and 32.8% having severe CAD. A significantly greater proportion of patients 
with subendocardial LGE had severe CAD compared to LGE negative patients (82.4 vs. 
12.9%, p<0.001) and additionally had a significantly atheromatous disease burden score 
than either patients with diffuse LGE or LGE negative patients (Mann-Whitney-U test, 
p<0.001 for comparison with either group). By contrast, the majority of patients with 
diffuse LGE had either normal coronary arteries or mild/moderate CAD with only 
18.8% of these patients having severe CAD. 
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Figure 3.11 Box plot showing mean pixel intensity for subtypes of LGE pattern. Each 
box shows the median, quartiles, and extreme values within the LGE category  
128 
Variable All patients Gadolinium negative Gadolinium positive Subendocardial Gadolinium Diffuse Gadolinium 
Number (%) 145 96 (66.2) 49 (33.8) 24 (16.6) 25 (17.2) 
LVH (%) 80 (55.2) 46 (47.9) 34 (69.4) * 14 (58.3) 20 (80.0) † 
LV dilatation (%) 24 (16.6) 12 (12.5) 12 (24.5)  10 (41.7) † 2 (8.0) 
LVSD (%) 25 (17.2) 8 (8.3) 17 (34.7) ‡ 13 (54.2) ‡ 4 (16.0) 
EF (%) (SD) 66.1 (11.8) 68.8 (8.5) 60.7 (15.1) ‡ 54.1 (14.9) ‡ 67.0 (12.7) 
LV mass (g) 168.3 (60.5) 157. 7 (60.6) 189.0 (55.4) † 177.3 (53.9) 200.2 (55.5) †  
LV mass/BSA(g m-2) 91.4 (28.6) 100.9 (27.1) 86.6 (28.2) † 95.4 (28.5) 105.7 (25.5) †  
ESV(ml) 51.3 (35.4) 41.6 (25.4) 70.4 (43.9) ‡ 87.8 (47.7) ‡ 53.6 (32.8) 
ESV/BSA (ml m-2) 27.7(18.3) 22.9 (13.3) 37.2 (22.8) ‡ 47.1 (24.4) ‡ 28.4 (17.1) 
EDV (ml) 142.4 (58.0) 129.2 (53.9) 168.2 (57.5) ‡ 180 (61.5) ‡ 156.9 (52.2) *  
EDV/BSA(ml m-2) 77.2 (28.6) 71.3 (27.1) 89.1 (28.2) ‡ 96.2 (30.1) ‡ 82.8 (25.5) 
Mass of LGE (g) - - 8.2 (5.4) 9.3 (6.4) 7.2 (4.3) 
Myocardial Signal Intensity  6.4 (1.8) 25.5 (14.5) ‡ 32.6 (16.7) ‡ 18.1 (5.8) ‡ 
Table 3.4 Left ventricular dimensions displayed by subtype of LGE. Data are expressed as number with percent of specific subtype of 
late gadolinium enhancement (LGE) in parenthesis; all data are mean and standard deviation in parentheses  or number and percentage are 
shown as appropriate. Percentages shown are as a proportion of that subtype of LGE. Tests of significance compared to patients with 
negative LGE: *- p<0.05, †p<0.01, ‡p<0.001 
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Variable All patients Gadolinium negative Gadolinium positive Subendocardial Gadolinium Diffuse Gadolinium 
Number (%) 145 96 (66.2) 49 (33.8) 24 (16.6) 25 (17.2) 
Age (years) 51.9 (11.1) 51.1 (11.6) 53.4 (10.1) 54.4 (9.7) 52.4 (10.6) 
Sex (% male) 88 (60.7) 56 (58.3) 32 (65.3) 16 (66.7) 16 (64.0) 
Haemodialysis (%) 75 (51.7) 45 (46.9) 30 (61.2) 13 (54.2) 17 (68.0) 
Duration of RRT 8.0 (52.5) 7 (22.0) 25 (100.5) 12.0 (97.0) 36.0 (98.5) * 
History of IHD (%) 27 (18.6) 8 (8.3) 19 (38.8) ‡ 16 (66.7) ‡ 3 (12.0) 
History of MI (%) 16 (11.0) 2 (2.1) 14 (28.6) ‡ 14 (58.3) ‡ 0 (0) 
Diabetes (%) 46 (31.7) 29 (30.2) 17 (34.7) 13 (54.2) * 4 (16.0) 
Hypercholesterolaemia (%) 72 (49.7) 42 (43.8) 30 (61.2)* 19 (79.2) † 11 (44.0) 
Positive smoking history (%) 69 (47.6) 40 (41.7) 29 (59.2)* 19 (79.2) † 11 (44.0) 
SBP (mmHg) 138.9 (25.3) 137.3 (22.9) 141.9 (29.5) 144.6 (26.8) 139.2 (32.2) 
DBP (mmHg) 82.4 (13.4) 82.5 (12.1) 82.3 (15.7) 85.7 (14.7) 79.0 (16.2) 
Table 3.5 Clinical characteristics of patients as grouped by presence and subtype of LGE. Numbers displayed are absolute number with 
percentage of group of LGE subtype or as mean and standard deviation as appropriate except for RRT time which is displayed as median 
and inter quartile range. Tests of significance are Chi-squared or t-test/Mann-Whitney-U as appropriate with significance indicated as * - 
p<0.05, † - p<0.01, ‡ - p<0.001 compared to LGE negative group 
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Variable All patients Gadolinium negative Gadolinium positive Subendocardial Gadolinium Diffuse Gadolinium 
Number (%) 145 96 (66.2) 49 (33.8) 24 (16.6) 25 (17.2) 
Haemoglobin (g dL-1) 11.6 (1.7) 11.6 (1.8) 11.3 (1.4) 11.5 (1.6 ) 11.8 (1.6) 
Cholesterol (mmol L-1) 4.8 (1.2) 5.0 (1.2) 4.3 (0.9) * 4.5 (1.1) 4.2 (0.7) * 
Triglycerides (mmol L-1) 2.3 (1.4 2.3 (1.2) 2.4 (1.9) 2.7 (2.6) 2.1 (1.0) 
VLDL (mmol L-1) 1.1 (0.6) 1.1 (0.5) 1.1 (0.8) 1.2 (1.1) 1.0  (0.5) 
LDL (mmol L-1) 2.7 (1.1) 2.9 (1.0) 2.2 (1.0) † 2.2 (1.2)  2.2 (0.9) *  
HDL(mmol L-1) 1.1 (0.4) 1.1 (0.4) 1.0 (0.5) 1.0 (0.4) 1.0 (0.5) 
CRP (mg L-1) 4.8 (10.7) 4.5 (8.2) 9.2 (29.0) 7.8 (31.5) 9.3 (28.5) 
PTH (pg mL-1) 16.7 (35.0) 12.5 (27.0) 31.0 (51.6) † 32.5 (57.6) † 30.5 (53.8) * 
Corrected Calcium (mmol L-1) 2.4 (0.2) 2.4 (0.2) 2.3 (0.2) 2.3 (0.1) 2.3 (0.2) 
Phosphate (mmol L-1) 1.7 (0.5) 1.8 (0.5) 1.7 (0.5) 1.8 (0.5) 1.6 (0.4) 
Ca-P product 4.1 (1.2) 4.2 (1.2) 3.9 (1.3) 4.3 (1.5) 3.6 (1.0) * 
Albumin (g L-1) 39.2 (4.5) 39.1 (4.4) 39.5 (4.8) 39.9 (5.4) 40.1 (4.1) 
URR (%) 70.5 (7.5) 70.8 (7.5) 70.0 (7.7) 66.5 (8.4) 73.0 (5.6) 
CrCl (L/week/1.73m2) 85.5 (25.1) 81.0 (21.7) 97.8 (30.4) 112.1 (28.4) † 83.6 (27.6) 
Table 3.6 Laboratory characteristics of patients grouped by presence and subtype of LGE. Numbers displayed are absolute number with 
percentage of LGE group subtype or as mean and standard deviation as appropriate. CRP and PTH are displayed as median and inter 
quartile range. URR is for HD patients. Weekly creatinine clearance is for patients on peritoneal dialysis. Tests of significance are Chi-
squared or t-test/Mann-Whitney-U as appropriate with significance indicated as * - p<0.05, † - p<0.01, ‡ - p<0.001 compared to LGE 
negative group 
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Variable 
All 
patients 
LGE 
negative 
Subendocardial 
LGE 
Diffuse LGE 
Number (%) 64 31 (48.4) 17 (26.6) 16 (25.0) 
Normal angiogram (%) 25 (39.1) 18 (58.1) 0 (0) 7 (43.8) 
Mild/moderate CAD (%) 18 (28.1) 9 (29.0) 3 (17.6) 6 (37.5) 
Severe CAD (%) 21 (32.8) 4 (12.9) 14 (82.4) ‡ 3 (18.8) 
Atheroma score 65 (164.3) 48 (100.0)  195 (155.5) ‡ 36.5 (134.0) 
   
Table 3.7 
Coronary angiography results by presence and subtype of LGE. Numbers displayed are 
absolute number with percentage of LGE group subtype. Median and inter quartile 
range are shown for atheroma score. Tests of significance are Chi-squared or Mann-
Whitney-U as appropriate with significance indicated as ‡ - p<0.001 compared to LGE 
negative group 
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3.5 DISCUSSION 
 
3.5.1 Uraemic cardiomyopathy defined by CMR 
Left ventricular abnormalities, previously described echocardiographically as ‘uraemic 
cardiomyopathy’ have been demonstrated to convey important prognostic implications 
in patients with ESRD. Epidemiological studies of patients with ESRD suggest that at 
inception of renal replacement therapy the majority of patients display some 
abnormality in left ventricular dimensions, geometry or function. This study was 
designed to reassess the prevalence of LV disorders using CMR, and furthermore 
explore the relationship between LV abnormalities and myocardial fibrosis indicated by 
late gadolinium enhancement. 
 
Firstly, as expected patients with ESRD had significantly higher left ventricular mass 
compared to controls. Using published reference ranges for LV dimensions with CMR, 
41.3% of this cohort of uraemic patients had normal LV dimensions, higher than 
reported echocardiographically. Whether this lower prevalence of LV disorders is due to 
a ‘healthier’ cohort of patients, as these patients were fit enough to be considered for 
renal transplantation, better treatment of hypertension and hence left ventricular 
hypertrophy, or due to genuine differences between measurements made with CMR 
versus echocardiography requires further study of direct comparison between CMR and 
echocardiography. Only 16.2% of patients in the uraemic cohort displayed evidence of 
left ventricular systolic dysfunction, which is in keeping with reported prevalence in 
echocardiographic studies of patients with ESRD as well as those few pilot studies that 
exist with CMR(75;113;189). Blinded analysis demonstrated that CMR measures of LV 
dimensions are more reproducible than has been reported with echocardiography(194). 
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This indicates that CMR may allow substantial reduction in numbers for interventional 
studies where LV mass or ejection fraction is a clinical end point(195). 
 
At the time of performing this study contrast enhanced CMR using gadolinium based 
contrast agents had become an established clinical tool in the management of patients 
with heart failure, cardiomyopathies and coronary artery disease. However, this 
represents the first published study using this technique in patients with ESRD. Other 
centres have performed smaller pilot studies, reported in abstract form, whose results 
appear similar to our own. The published literature has categorised uraemic 
cardiomyopathy defined by echocardiography into three subtypes – LVH, ventricular 
dilatation or systolic dysfunction (or a combination of these patterns) with each pattern 
associated with cumulatively worse survival(75;76). By contrast, the results of this 
study based on CMR findings, suggest that there are only two types of uremic 
cardiomyopathy. The first is due to underlying ischaemic heart disease where LV 
dilatation and systolic dysfunction are due primarily to previous myocardial infarction 
revealed by CMR. The second form, diffuse LGE found in patients with more severe 
LVH, is more specific to uraemia is consistent with fibrosis in the hypertrophied 
ventricle. 
 
Gd-DTPA-BMA is an extracellular contrast agent that diffuses into the interstitial space 
between cells and exhibits its effect by shortening the T1 relaxation of tissue in a 
magnetic field. There is greater space for Gd-DTPA-BMA accumulation both in areas 
of myocardial fibrosis and oedema. In areas of ischaemia or infarction, gadolinium leaks 
into the surrounding fibrotic or oedematous, tissue resulting in late gadolinium 
enhancement on CMR imaging(174). However, the presence of LGE is not specific and 
further subjective assessment of the pattern of LGE is required. LGE has also been 
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described in patients with myocarditis, dilated cardiomyopathy and other inflammatory 
cardiomyopathies(182-184). Importantly, LGE has been shown to represent collagen 
deposition in hypertrophic cardiomyopathy(177).  
 
3.5.2 Clinical implications of subendocardial LGE 
Subendocardial LGE, consistent with that described in myocardial infarction, follows a 
primarily subendocardial distribution. This reflects the perfusion of the subendocardium 
by end-arteries. Therefore, a high prevalence of myocardial infarction in this cohort of 
patients has been demonstrated indicated by subendocardial LGE. Patients with 
subendocardial LGE had greater evidence of LV systolic dysfunction, clearly 
highlighting the importance of underlying ischaemic heart disease as the cause for 
ventricular impairment in these patients. While this was associated with a previous 
history of ischaemic heart disease, eight patients (4.7% of the whole cohort or one third 
or all patients with CMR evidence of infarction indicated by subendocardial LGE) had 
CMR evidence of myocardial infarction, despite no preceding history, in keeping with 
studies suggesting that ESRD patients are more likely to have silent myocardial 
ischaemia(53). Subendocardial LGE was associated with many ‘classical’ risk factors 
for ischaemic heart disease, present in the general population such as diabetes and 
positive smoking history. Although a significantly higher number of these patients were 
labelled as hypercholesterolaemic, this may be due to the factor that a higher 
numerically proportion of patients were on statin therapy than LGE negative patients 
(60.9 vs. 38.7%, p=0.055). This however did not in turn lead to a significantly lowered 
total or LDL cholesterol compared to LGE negative patients, and consequently one may 
speculate that patients with subendocardial LGE may have had higher pre-treatment 
serum cholesterol than LGE negative patients.  
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The only risk factors specific to uraemia associated with subendocardial LGE were 
raised serum PTH levels and greater dialysis adequacy in patients on peritoneal dialysis. 
This second finding was unexpected and is unlikely to be of clinical significance given 
the extremely small numbers of peritoneal dialysis patients with subendocardial LGE. 
This finding may be explained by higher numbers of diabetic patients on peritoneal 
dialysis. These patients, at greatest cardiovascular risk are also likely to be commenced 
on renal replacement therapy at a higher residual GFR due to excessive symptoms of 
uraemia. Higher dialysis adequacy has not been shown to be associated with improved 
outcomes in peritoneal dialysis patients(196). By contrast, the presence of 
hyperparathyroidism contributes to accelerated cardiovascular disease in uraemia by 
two mechanisms. Firstly, it is likely that high levels of PTH are associated with arterial 
calcification, which in turn may be associated with atherosclerosis (particularly intimal 
calcification)(197). Of interest, in the current study, this was not associated with 
significant abnormalities in serum calcium, phosphate or calcium-phosphate product. 
Additionally, it has been shown that parathyroid hormone as a permissive factor 
promoting cardiac fibroblast activation and intercardiomyocytic fibrosis therefore 
promote LVH(139). This is likely to be important in the pathogenesis of diffuse LGE, 
which will be discussed later in this section. 
 
The data on coronary angiography explore further the relationship between results of 
contrast enhanced CMR, LGE and cardiomyopathy. First, in the absence of LGE 
patients were relatively unlikely to have significant coronary artery disease requiring 
intervention. Only 12.9% of these patients had severe coronary artery disease. As this 
technique represents a static scan, a negative CMR for LGE does not exclude the 
presence of critical coronary disease, but makes it less likely. Conversely, no patients 
with subendocardial LGE had a normal angiogram and the majority of these patients 
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had critical coronary stenosis, where coronary intervention with angioplasty or bypass 
surgery may be appropriate. Similarly, these patients have a significantly higher total 
atheroma burden than either LGE negative patients or those with diffuse LGE. 
 
The discovery of this high prevalence of myocardial infarction in ESRD patients is 
important given the poor long-term survival of these patients post-infarction and general 
trend towards under treatment in this patient group(53). Thus, the diagnosis of sub-
clinical myocardial infarction with CMR is likely to have prognostic and therapeutic 
implications and may be an indication for further assessment with angiography, 
particularly if the patient is being considered for renal transplantation. Furthermore, in 
patients with coronary artery disease requiring intervention, CMR can assess 
myocardial viability prior to revascularisation, allowing optimal identification of 
patients likely to benefit from coronary intervention(175).  
 
3.5.3 Other studies displaying myocardial ischaemia with subendocardial LGE at 
CMR 
Recent studies using similar CMR protocols to detect the presence of myocardial 
infarction, represented by the presence of subendocardial LGE, have focused on various 
goals such as early detection of myocardial infarction, detection of silent infarction, 
accurately characterising the location of infarcted tissue and most promisingly 
prediction of myocardial viability post revascularisation in patients with critical 
coronary artery lesions: 
• Kim et al used CMR to identify reversible myocardial dysfunction can be 
identified by contrast-enhanced MRI before coronary revascularisation (either 
surgical or by percutaneous intervention). Their results suggest that in areas of 
abnormal ventricular contraction, improvement in contractility can be predicted 
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by the percentage of that myocardial segment that is composed of tissue indicted 
by LGE. For instance, contractility increased in 256 of 329 segments (78 
percent) with no LGE before revascularisation, but in only 1 of 58 segments 
with LGE occupying more than 75 percent of tissue. The percentage of the left 
ventricle that was not enhanced before revascularisation was strongly related to 
the degree of improvement in the ejection fraction after revascularisation(175) 
• In a study of patients with dilated cardiomyopathy of unknown aetiology CMR 
differentiated between patients with ischaemic cardiomyopathy and idiopathic 
dilated cardiomyopathy. This has important implications for both secondary 
prevention in ischaemic heart disease and genetic screening for patients with 
idiopathic dilated cardiomyopathy which may have an underlying genetic 
basis(182) 
 
3.5.4 Clinical implications of diffuse LGE  
The second pattern of gadolinium enhancement demonstrated was a pattern of diffuse, 
less intense, LGE. This was an unexpected finding. This diffuse gadolinium 
enhancement is less striking than that seen in, for example, myocardial infarction or 
hypertrophic cardiomyopathy. However, it was reproducible and not due to artefact in 
the imaging process, and was associated with features of uraemic cardiomyopathy, most 
notably LVH. Coronary angiography revealed that that many patients with diffuse LGE 
had either no or minimal coronary artery disease. This was perhaps unexpected but 
suggests that diffuse LGE is not due to large vessel coronary artery disease. This does 
not exclude that it may be due to low grade ischaemia leading to fibrosis or to 
permissive factors in uraemia as discussed previously.   
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Diffuse gadolinium enhancement implies an additional pathological process, other than 
large vessel myocardial infarction. It may reflect diminished capillary blood supply with 
associated fibrosis, which is a prominent histopathological finding in the uraemic heart, 
or low-grade ischaemia. It may be that small vessel disease is also present in patients in 
the absence of epicardial atherosclerosis. Alternatively, this pattern of enhancement may 
most likely represent fibrosis throughout the hypertrophic ventricle, being evident in 
severe hypertrophy. Overall, the presence of gadolinium enhancement may not be due 
to a single process. To address whether uraemia or ventricular hypertrophy is a 
dominant factor in its pathogenesis, a larger study of gadolinium enhancement in 
patients with LVH due to hypertension and normal renal function is required.  
 
The clinical and laboratory correlates of diffuse LGE to an extent support the notion that 
LVH represents a form of cardiomyopathy more specific to uraemia than systolic 
dysfunction, which is primarily due to underlying ischaemic heart disease. Diffuse LGE 
was in particular associated with a significantly greater duration of renal replacement 
therapy than LGE negative patients. There were no associations with conventional risk 
factors for coronary artery disease such as smoking history, age, diabetes, blood 
pressure or hypercholesterolaemia. Indeed, despite lower proportions of patients with 
diffuse LGE being on statin therapy (29.2%), these patients had significantly lower 
serum total and LDL-cholesterol than LGE negative patients as well as higher (although 
non-significantly) C-Reactive protein. This suggests that these patients are at greater 
risk of the malnutrition-inflammation complex syndrome, which has been postulated in 
patients on dialysis therapy(160). Further support for this concept is illustrated by 
significantly lower serum phosphate levels in these patients which may suggest poor 
nutritional intake. Conversely lower phosphate levels are usually a marker of good 
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dialysis and have been previously associated with better outcome, therefore this result 
may be paradoxical(137). 
 
3.5.5 Other studies displaying diffuse LGE with contrast enhanced CMR 
Although no directly comparable reports of use of CMR in patients with ESRD exist, a 
number of authors have performed similar studies in other patient groups: 
• Recent data have emerged suggesting that areas of scarring similar to diffuse 
LGE are present in patients with adaptive LVH secondary to aortic stenosis. 
Although the terminology used by the authors for the description of the pattern 
of LGE is different in the study of aortic stenosis the images are remarkably 
similar(198) 
• Our own group have demonstrated areas of diffuse LGE in the interventricular 
septum in patients with right ventricular pressure overload due to primary 
pulmonary hypertension(199)  
• Patchy foci of midwall LGE have been described in patients with idiopathic 
dilated cardiomyopathy. In this study the authors speculate that these foci of 
midwall LGE probably reflect focal segmental fibrosis found at autopsy in 
patients with dilated cardiomyopathy(182) 
• A form of diffuse LGE has been described in patients with systemic amyloidosis 
and associated infiltrative cardiomyopathy(185) 
• LGE has also been reported in two storage diseases with myocardial 
involvement, namely glycogenosis and Anderson-Fabry disease(200;201). In 
Anderson-Fabry disease diffuse LGE was mainly localised to the basal 
inferolateral LV wall and was not involving the subendocardium 
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3.5.6 Other studies assessing myocardial tissue composition in ESRD 
A number of studies have reported tissue abnormalities in patients with ESRD: 
• Aoki et al performed endomyocardial biopsies in patients with no evidence of 
coronary artery disease and cardiac dysfunction and found evidence of 
myocardial fibrosis(202) 
• Post mortem studies have shown evidence of tissue fibrosis in patients with 
ESRD(85) 
• Animal models have demonstrated similar findings and explored factors which 
may promote tissue fibrosis in renal failure(203) 
• Using CMR spectroscopy it has been demonstrated that myocardial metabolism 
is altered in patients with ESRD. This abnormality is accentuated by diabetes 
and may be ameliorated by renal transplantation(204). Whether these metabolic 
abnormalities are related to myocardial fibrosis is unknown 
 
3.5.7 Limitations 
This study has some weaknesses. The patients studied were being considered for renal 
transplantation, who are fitter than the majority of patients with ESRD, and hence found 
a lower prevalence of systolic dysfunction than might be expected. To fully appreciate 
the burden of cardiovascular disease in patients with ESRD, it would be necessary to 
study the entire dialysis population. Therefore, selection bias cannot be excluded, and a 
higher prevalence of LVSD may be expected (but also an even higher prevalence of 
IHD) in an unselected cohort of dialysis patients. Coronary angiography (and 
endomyocardial biopsy) in all patients would provide additional information regarding 
the relationship between LGE and coronary artery disease, but is invasive, and therefore 
not without risk. This was not deemed ethically justifiable by the consultants 
responsible for the patients’ overall care. Hence correlation between angiographic and 
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CMR findings should be interpreted with caution. In analysis of LGE, using signal 
intensity, greater distinction between nulled myocardium and areas of LGE (using a 
signal intensity of LGE >2 standard deviations higher the mean intensity of an area of 
reference myocardium), would give greater distinction in image analysis, but may 
exclude definite areas of LGE. Future use of computer software to automatically detect 
areas of LGE will optimise detection of enhancement.  
 
3.5.8 Conclusions 
In this study, systolic dysfunction and ventricular dilatation are not present in the 
absence of late gadolinium enhancement and it is only patients with focal gadolinium 
enhancement that have significant ventricular dilatation and systolic dysfunction. This 
suggests that LVH is the only cardiomyopathy truly associated with uraemia (and 
presumably is a consequence of hypertension and other factors associated with renal 
failure) whilst systolic dysfunction is not due to uraemia, but to underlying ischemic 
heart disease. Therefore CMR represents an advance for cardiovascular investigation to 
guide invasive assessment, particularly in asymptomatic patients, undergoing evaluation 
for renal transplantation. The implication is that patients with systolic dysfunction 
require investigation of coronary heart disease. The prognostic implications of both 
subendocardial and diffuse LGE require further study.  
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Chapter 4 
 
 
A comparative study of echocardiography and electrocardiography with cardiac 
magnetic resonance imaging 
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4.1 INTRODUCTION 
Left ventricular function, dimensions and geometry have conventionally been assessed 
using echocardiography. As previously discussed, this technique is convenient and 
reproducible and conveys important prognostic and diagnostic information for patients 
with ESRD. However M-mode echocardiography, a one-dimensional technique, 
overestimates left ventricular mass in this population compared to CMR(189). The 
disparities between the two methods have also been demonstrated in other patient 
populations. The geometrical assumptions used by M-mode echocardiography have 
primarily been validated in normal hearts or in small studies compared to post mortem 
specimens(205;206). Echocardiography is operator dependent and is limited by the 
acoustic window which depends on cardiac geometry, body habitus and co-morbidity 
such as respiratory disease or obesity. No attempt has been made to derive a correction 
factor to optimise M-mode echocardiographic measures of left ventricular mass in this 
population.  
 
The electrocardiogram (ECG) is readily available, easy and inexpensive to acquire and 
is widely used in both research and clinical practise to diagnose left ventricular 
hypertrophy (LVH). Like echocardiography, ECG measures of LVH have prognostic 
value in patients with ESRD(207). However, the criteria used to classify LVH were 
derived from echocardiographic measures of left ventricular mass which may have 
limitations, particularly in groups where there is a high prevalence of LVH.  These 
studies were designed to:  
• Compare echocardiographic measures of left ventricular dimensions in patients 
in patients with ESRD with CMR 
• Use CMR to optimise echocardiographic formula to derive left ventricular mass 
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• Evaluate the Sokolow-Lyon voltage, Cornell sex-specific voltage, Sokolow-
Lyon product and Cornell product criteria against left ventricular mass index   as 
measured by CMR in a cohort of patients with ESRD 
• Use CMR to derive optimised ECG partition values for LVH in the ESRD 
population 
 
4.2 METHODS 
 
4.2.1 CMR and echocardiography 
All patients were studied with CMR technique and echocardiography performed on the 
same day described in detail in Chapter 2 (2.3.2). As some of the disparity between 
echocardiographic and CMR measures of LV dimensions may be due to changes in 
hydration status related to the dialysis cycle, only patients with ESRD established on 
dialysis therapy on with both echocardiographic and CMR data were studied.  
 
4.2.2 Echocardiogram- analysis 
Left ventricular (LV) dimensions were determined from two-dimensional guided M-
mode images, using American Society of Echocardiography leading edge 
recommendations. The mean of three measurements was taken. As the most widely 
used method the Penn (Devereux-Reichek) was used for the majority of analyses of LV 
mass. The utility of the following alternative formulae for calculation of left ventricular 
mass was also assessed(205;206;208;209): 
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where LVID - left ventricular internal diameter, IVST - interventricular septal thickness 
and PWT - posterior wall thickness. LVH was defined by conventional criteria (LVMI 
≥131 or 110 g/m2 in men and women, respectively). Systolic function was assessed by 
measuring LV ejection fraction (LVEF), calculated from end-systolic and end-diastolic 
volumes determined from the mean of three measurements in different cardiac cycles 
using modified biplane disc summation (Simpson’s rule).  
 
4.2.3 Electrocardiogram 
This was performed prior to echocardiography. ECG criteria were analysed in a blinded 
fashion. The following ECG criteria were tested: Sokolow-Lyon voltage(210), Cornell 
sex-specific voltage(211), Cornell product, and Sokolow-Lyon product(212). LVH was 
defined as a Sokolow-Lyon voltage amplitude of (SV1+RV5 or RV6)≥35 mV, a Cornell 
voltage of (RaVL+SV3)≥28 mV for men and ≥20 mV for women, and a Cornell 
product of [(RaVL+SV3)*QRS duration] ≥2440 mV ms. There is no recognised 
partition value for the Sokolow-Lyon product [(SV1+RV5 or RV6)*QRS duration]. 
 
4.2.4 Statistical methods 
Correlations between cardiac dimensions by the various methods were assessed with 
Pearson and Spearman correlation co-efficient as appropriate, with comparisons made 
using Bland-Altman plots. Receiver operator characteristic (ROC) curves were plotted 
Penn: = 1.04 x [(IVST + PWT + LVID)3 – LVID3] -13.6 
ASE: = 0.80 x [(IVST + PWT + LVID)3 – LVID3] + 0.6 
Troy = 1.05 x [(IVST + PWT + LVID)3 – LVID3] -13.6 
Teichholz: = 1.04 x {[7/(2.4 + IVST + PWT + LVID)] x (IVST + PWT + LVID)3 – 
[7/(2.4 + LVID)] x (LVID)3} 
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to assess diagnostic utility of tests for categorical variables. All analyses were 
performed using the SPSS 13.0 statistical software package (SPSS Inc., Chicago, IL., 
USA), except Bland-Altman plots and ROC curves which were performed with the 
MedCalc software package (MedCalc 8.1, MedCalc Software, Belgium). Derivation of 
revised echocardiographic formula was performed with OriginPro 7.0 software 
(OriginLab Corporation, Northampton, MA, USA). 
 
4.3 RESULTS OF ECHOCARDIOGRAPHIC STUDIES 
 
4.3.1 Patient demographics 
Echocardiography combined with CMR were available on 128 patients, of whom 28 
were excluded as not established on long term dialysis therapy (25 advanced renal 
failure not yet started dialysis, 3 failing renal transplant). Patient demographics for the 
100 patients studied at the time of scan are shown in Table 4.1. 15 (15.0%) patients had 
insufficient M-mode echocardiographic images to calculate LVM and 30 (30.0%) had 
inadequate images for calculation of LVEF by Simpson’s bi-plane method. 
 
4.3.2 Echocardiographic compared to CMR descriptions of uraemic 
cardiomyopathy 
Subdividing the cohort by conventional definitions of uraemic cardiomyopathy using 
the Penn formula to calculate LVM with echocardiography; 16.5% had normal left 
ventricular dimensions and function, 81.2% had LVH, 34.9% had left ventricular 
dilatation and 18.7% had left ventricular systolic dysfunction. This compares to CMR 
measures for the entire cohort of patients on dialysis therapy of 54.0% with LVH, 
18.0% LV dilatation and 13.0% systolic dysfunction. 39.0% of patients had normal LV 
dimensions by CMR. For both imaging modalities these patterns were not mutually 
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exclusive and by echocardiography, 50.6% had isolated LVH, with 15.3% of patients 
having combined LVH and LV dilatation and 7.1% of patients having combined LVH, 
dilatation and LVSD. By CMR, 39.0% had isolated LVH, 9.0% had combined LV 
dilatation and LVH, and 6.0% having combined LVH, dilation and LVSD (Figures 4.1-
4.2). LVM was greater in patients on haemodialysis compared to peritoneal dialysis 
(LVMI by CMR 102.9 vs. 78.7g m-2, p<0.001). 
 
4.3.3 Echocardiographic measures of left ventricular geometry 
Using the criteria described in Chapter 2 to describe ventricular remodelling, 45.2% had 
normal ventricular geometry and 54.8% had eccentric remodelling.  Of the patients with 
LVH, 44.9% had concentric LVH and 55.1% had eccentric LVH. There were no 
significant differences in remodelling patterns in between patients on haemodialysis 
compared to peritoneal dialysis (44.2% of haemodialysis patients had normal geometry 
compared to 46.9% of peritoneal dialysis, Chi-squared p=0.813), nor between patients 
with a past history of ischaemic heart disease (41.2% of patients with IHD had normal 
geometry compared to 46.3% with no history of IHD, Chi-squared p=0.706). Patients 
with eccentric remodelling had a significantly greater degree of left ventricular 
dilatation than those with normal or concentrically remodelled ventricles (117.3 vs. 89.7 
ml m-2, p=0.001; Figure 4.3). 
 
4.3.4 Comparison of CMR with echocardiography for calculation of left 
ventricular mass and dimensions 
Results and correlation between the echocardiographic dimensions using the Simpson’s 
bi-plane method and Penn formula for LV mass and CMR studies are shown in Table 
4.2 The correlations between CMR and echocardiographic measures of LV mass and 
LVMI measures using the Penn, ASE, Troy and Teichholz formulae are shown in Table 
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4.3 and Figure 4.4. A Bland-Altman plot (Figures 4.5 and 4.6) comparing the two 
methods indicates that using echocardiographic formula the Penn formula overestimates 
LVM by a mean of 141.9g and the ASE formula overestimates a mean of 89.9g  
compared to CMR. Echocardiography overestimates LVMI by 77.6g m-2 and 49.4g m-2 
with the Penn and ASE formulae respectively compared to CMR. The Teichholz 
formula overestimated LV mass by and LVMI by 15.5g and 9.4g m-2. There was no 
significant difference in over estimation of LV mass when patients were compared by 
pattern of ventricular remodelling (overestimation for eccentric remodelling and 
hypertrophy 140.6 vs. normal geometry and concentric LVH 143.6 g, p=0.87). Using 
the Simpson’s bi-plane method to calculate end diastolic and end systolic volumes, 
echocardiography underestimates end diastolic volume by a mean of 46.9ml and end 
systolic volume by 7.2ml compared to CMR (Figures 4.7 and 4.8). 
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Number 100 
Male (%) 65 (65.0) 
Age (years) 52.3 (11.0) 
Height (m) 168.5 (10.2) 
Weight (kg) 74.7 (16.7) 
SBP (mmHg) 138.8 (26.1) 
DBP (mmHg) 81.7 (18.3) 
Haemodialysis (%) 59 (59) 
10 Renal Disease (%)  
 Diabetes 22 (22.0) 
 APKD 9 (9.0) 
 GN 25 (25.0) 
 CPN 10 (10.0) 
 Renovascular 5 (5.0) 
 Unknown/Other 29 (29.0) 
RRT time (months) 9 (59.3) 
Previous IHD (%) 21 (21.0) 
 
Table 4.1 
Background demographics for patients studied with CMR and echocardiography. 
Results are show as mean with standard deviation in parenthesis or number with 
percentage in parenthesis as appropriate except for RRT time which is displayed as 
median and inter quartile range  
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Figure 4.1 Prevalence of left ventricular abnormalities as detected by CMR 
 
Figure 4.2  
Prevalence of left ventricular abnormalities as detected by echocardiography 
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Figure 4.3  
Proportion of patients with left ventricular dilatation as classed by echocardiographic 
pattern of remodelling 
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Figure 4.4  
Scatter plots of echocardiographic measures versus CMR measures of LV mass for 
various M-mode echocardiographic formulae to calculate LV mass 
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 Echocardiography CMR R p 
EF (%) 58.4 (7.4) 67.6 (10.5) 0.51 <0.001 
EDV (mL) 105.7 (34.9) 142.8 (59.1) 0.86 <0.001 
ESV (mL) 45.0 (20.0) 48.5 (31.4) 0.82 <0.001 
EDV/BSA (mLm-2) 57.8 (17.0) 77.1 (28.9) 0.86 <0.001 
ESV/BSA (mLm-2) 24.6 (10.3) 26.1 (16.1) 0.82 <0.001 
Mass (g) 315.2 (130.1) 173.1 (65.2) 0.84 <0.001 
Mass/BSA (g m-2) 171.5 (63.7) 93.2 (30.8) 0.81 <0.001 
 
Table 4.2 Comparison of echocardiographic and CMR measures of left ventricular 
dimensions. Values displayed are mean with standard deviation in parentheses. Correlation 
between variables (R) is by Spearman co-efficient  
 
Method Mean LV mass (g) R p Mean LVMI (g m-2) R p 
ASE 263.6 (104.1) 0.84 <0.001 143.5 (50.8) 0.81 <0.001 
Penn 315.2 (130.1) 0.84 <0.001 171.5 (63.7) 0.81 <0.001 
Troy 332.0 (131.4) 0.84 <0.001 180.7 (64.1) 0.81 <0.001 
Teichholz 190.1 (58.2) 0.82 <0.001 104.0 (28.7) 0.76 <0.001 
 
Table 4.3  
Comparison of M-mode methods of calculating left ventricular mass. Values displayed 
are mean with standard deviation in parentheses. Correlation is by Spearman co-
efficient (R) compared to CMR measures of LV mass 
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Figure 4.5 
 
Figures 4.5 and 4.6. Bland-Altman plots of Echocardiographic LV mass minus CMR 
LV mass against mean of echocardiographic and CMR LV mass for the Penn (Figure 
4.5) and Teichholz formulae (Figure 4.6)  
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Figure 4.7 Scatter plots of echocardiographic measures versus CMR measures of 
LV volume for end diastolic and end systolic volume. End diastolic and end systolic 
volume are calculated by Simpson’s bi-plane method 
 
Figures 4.8   
Bland-Altman plot of CMR LV mass minus Echocardiographic LV mass minus against 
mean of echocardiographic and CMR LV for end diastolic volume 
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4.3.5 Derivation of revised echocardiographic formula for use in ESRD patients 
The highest correlation between CMR and echocardiographic MV mass is using the 
cubed based formulae (Penn, ASE, Troy). As the best fit for a relationship between 
cubed based formulae is linear (Figure 4.4), a linear fit equation can be derived to 
estimate LV mass calculated from CMR, using M-mode echocardiographic recordings 
continuing with cubic assumptions of ventricular geometry. Derivation is shown from 
Figure 4.9 and subsequently the final formula is plotted against CMR LV mass in 
Figure 4.10. 
 
Therefore: CMR LVM (Y) = A + B x X 
 
If the LV is assumed to be cubic then : 
X = (LVID + PWT + IVST)3 – (LVID)3 
 
Then deriving from linear fitting of this graph:  A = 31.3 B = 0.45 
 
A potentially re-derived cubed formula for use in ESRD would therefore be: 
 
CMR LV Mass = 31.3 + 0.45 {(LVID + PWT + IVST)3 – (LVID)3} 
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Figure 4.9  
LV mass by CMR plotted against the LV dimensions cubed to calculate volume of LV 
myocardial tissue with 95% confidence intervals shown 
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Figure 4.10 
Calculated LV Mass using formula LVM= 31.3 + 0.45 {(LVID + PWT + IVST)3 – 
(LVID)3} derived above plotted against  CMR LV mass with 95% confidence intervals 
shown  
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4.4 RESULTS OF ELECTROCARDIOGRAPHIC STUDIES  
 
4.4.1 Patient demographics 
Electrocardiogram (ECG) combined with CMR data were available on 139 patients 
(61.9%) male), of whom 30 (21.5%) were not yet established on long term dialysis 
therapy (28 advanced renal failure not yet started dialysis, 2 failing renal transplant), 61 
(43.9%) on haemodialysis and 48 (34.5%) on peritoneal dialysis. 92.1% of patients had 
a previous history of hypertension and 16.5% had a past history of ischaemic heart 
disease. 
 
4.4.2 Prevalence of left ventricular hypertrophy by CMR  
The mean CMR LVMI for the cohort was 91.6 g m-2 (S.D. 29.4). LVMI was 
significantly higher in males than females (101.3 g m-2 vs. 76.3 g m-2, p<0.001). Based 
on published normal ranges of LV mass, significantly higher numbers of males had 
LVH as defined by CMR compared to females 64.0% of males and 45.3% (Chi-squared 
p=0.031). Significantly higher numbers of patients on haemodialysis (72.1%) had LVH 
compared to those on peritoneal dialysis (41.7%) or those yet to start dialysis therapy 
(50.0%), p=0.003. 
 
4.4.3 Prevalence of left ventricular hypertrophy by ECG 
Using the Cornell criteria for LVH 20.1% of patients had LVH, with 23.7% by 
Sokolow-Lyon criteria and 15.8% by Cornell product. To examine need for revised 
partitions values for LVH in ESRD patients, the cohort were divided by the presence of 
LVH on CMR (Table 4.4) with gender specific QRS voltages and QRS voltage-duration 
products according to LVH status calculated. Patients with CMR LVH had greater 
Sokolow-Lyon voltage, Sokolow-Lyon product, Cornell and Cornell product than those 
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without LVH (p<0.001 for all criteria). As voltage criteria for LVH are gender specific, 
criteria were compared between males and females, with significantly greater Sokolow-
Lyon product in males with LVH than females with LVH (p=0.022). In patients without 
LVH males had significantly greater Cornell product (p=0.046), Sokolow voltage 
(p=0.023) and Sokolow-Lyon product (p=0.013) than females.  
 
4.4.4 Optimisation of ECG criteria for left ventricular hypertrophy  
The sensitivity and specificity of the four criteria were tested using established partition 
values: Sokolow-Lyon ≥35 mV; Cornell gender specific, male ≥28 mV, female ≥20 mV 
and Cornell product ≥2440 mV ms. There is no current Sokolow-Lyon product value 
defined as a cut point for diagnosing LVH and Sokolow-Lyon product ≥2940 mV ms 
was used. This was also tested in males and females to determine revised gender 
specific partition values for the various criteria. Using currently defined criteria for 
Sokolow-Lyon product had the highest overall sensitivity (37.9%). Sokolow-Lyon 
voltage and Sokolow-Lyon product were more sensitive in males while Cornell voltage 
and Cornell product were more sensitive in females (Table 4.5). Receiver operator 
characteristic (ROC) curves (Figures 4.11-4.12) were constructed to test sensitivity and 
specificity of the four criteria and derive new ECG partition values for the diagnosis of 
LVH compared to CMR. Area under a ROC curve was similar for all criteria in the 
whole cohort. When compared by gender, area under the ROC curve was greater in 
females for all criteria, with the maximum area under the curve of 0.828 for Cornell 
voltage in female subjects (Table 4.6). To optimise clinical applicability of partition 
values, the respective sensitivities of the four criteria were calculated at a specificity of 
95% (Table 4.7). 
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LVH on CMR No LVH on CMR 
ECG criteria Male Female Male Female 
Cornell (mV) 18.8 (8.1) 21.5 (8.1) 15.3 (6.5) 12.45 (5.1) 
Cornell product (mV.ms) 1974 (828) 1828 (854) 1403.2 (644)* 1097.5(500) 
Sokolow (mV) 32.0 (13.6) 26.4 (8.3) 23.7 (6.9)* 19.4 (7.4) 
Sokolow product (mV ms) 3089* (1386) 2382 (777) 2164.90(684)* 1698.4 (719) 
 
Table 4.4 
Mean values for QRS voltages and QRS voltage-duration products displayed by gender 
and CMR LVH status. Standard deviations are in parenthesis. * - p<0.05, male 
compared to female 
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 Sensitivity  Specificity 
All patients   
Cornell voltage 30.3 % 93.3 % 
Cornell product 24.1 % 95.0 % 
Sokolow-Lyon voltage 36.9 % 93.3 % 
Sokolow Lyon product 37.9 % 90.0 % 
 Sensitivity Specificity 
 
% (95% CI) 
Positive predictive value Negative predictive value 
Male     
Cornell voltage 16.4 (7.8- 28.8) 93.5 (78.5- 99.0) 81.8 38.6 
Cornell product 20.0 (10.4- 33.0) 93.5 (78.5- 99.0) 84.6 39.7 
Sokolow-Lyon voltage 34.5 (22.2- 48.6) 93.5 (78.5- 99.0) 90.5 44.6 
Sokolow Lyon product 43.6 (30.3- 57.7) 83.9 (66.3- 94.5) 82.8 45.6 
Female     
Cornell voltage 50.0 (29.1- 70.9) 93.1 (77.2- 99.0) 85.7 69.2 
Cornell product 33.3 (15.7- 55.3) 96.6 (82.2- 99.4) 88.9 63.6 
Sokolow-Lyon voltage 20.8 (7.2- 42.2) 100.0 (87.9- 100.0) 100.0 60.4 
Sokolow Lyon product 20.8 (7.2- 42.2) 96.6 (82.2- 99.4) 83.4 59.5 
Table 4.5 Sensitivities and specificities of the established ECG criteria for LVH compared to CMR with gender specific sensitivities 
and specificities 
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Figure 4.11 Receiver operator characteristic curves for Cornell voltage and Cornell 
product for diagnosis of LVH by CMR 
 
  
 
 
Figure 4.12 Receiver operator characteristic curves for Sokolow-Lyon voltage and 
Sokolow-Lyon product for diagnosis of LVH by CMR 
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 Area under ROC curve Sensitivity Specificity 
 (95% CI) 
p Best cut point 
% (95% CI) 
Positive predictive 
value 
Negative predictive 
value 
All patients        
Cornell Voltage 0.714 (0.631- 0.787) < 0.0001 14 74.7 ( 63.6- 83.8) 63.3 (49.9- 75.4) 72.8 65.5 
Cornell product 0.722 (0.639- 0.794) < 0.0001 1224 75.9 ( 65.0- 84.9) 63.3 (49.9- 75.4) 73.1 66.7 
Sokolow-Lyon voltage 0.715 (0.632- 0.788) < 0.0001 28 50.6 ( 39.1- 62.1) 85.0 (73.4- 92.9) 81.6 56.7 
Sokolow Lyon product 0.734 (0.653- 0.805) < 0.0001 2184 69.6 ( 58.2- 79.5) 75.0 ( 62.1- 85.3) 78.5 65.2 
Male        
Cornell Voltage 0.631 (0.520- 0.732) 0.0318 14 70.9 (57.1- 82.4) 51.6 (33.1- 69.8) 72.3 49.9 
Cornell product 0.645 (0.534- 0.745) 0.0160 1350 69.1 (55.2- 80.8) 58.1 (39.1- 75.4) 74.5 51.4 
Sokolow-Lyon voltage 0.696 (0.588- 0.791) 0.0005 26 61.8 (47.7- 74.6) 71.0 (52.0- 85.7) 79.1 51.1 
Sokolow Lyon product 0.703 (0.595- 0.797) 0.0003 2184 70.9 (57.1- 82.4) 64.5 (45.4- 80.8) 78.0 55.5 
Female        
Cornell Voltage 0.828 (0.700- 0.918) < 0.0001 14 83.3 (62.6- 95.2) 75.9 (56.5- 89.7) 74.1 84.6 
Cornell product 0.826 (0.697- 0.916) < 0.0001 1152 87.5 (67.6- 97.2) 69.0 (49.2- 84.7) 70.0 86.9 
Sokolow-Lyon voltage 0.731 (0.591- 0.843) 0.0011 28 45.8 (25.6- 67.2) 93.1 (77.2- 99.0) 84.6 67.5 
Sokolow Lyon product 0.756 (0.618-  0.863) 0.0002 2160 66.7 (44.7- 84.3) 86.2 (68.3- 96.0) 80.0 75.7 
Table 4.6 Area under receiver operator curves for ECG diagnostic criteria for LVH, with best cut point, sensitivities, specificities, 
positive and negative predictive values defined for the cohort and subdivided by gender 
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 Sensitivity % Male Sensitivity % Female Sensitivity % Male partition value Female partition value 
Cornell voltage 22.8 14.5 37.5 >29 >25 
Cornell product 25.3 18.2 41.7 > 2668 >2132 
Sokolow-Lyon voltage 31.6 34.5 25.0 > 36 > 30 
Sokolow-Lyon product 29.1 30.9 25.0 > 3588 > 2760 
 
Table 4.7 Sensitivities of the four ECG criteria and the male/female partition values at 95% specificity
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4.5   DISCUSSION 
 
4.5.1  Results of echocardiographic studies 
As discussed previously, left ventricular disorders, namely LVH, LV dilatation and LVSD, 
so called ‘uraemic cardiomyopathy’, have survival implications for patients with ESRD. 
Previous studies in both ESRD and other populations have suggested that echocardiography 
overestimates LV mass compared to CMR. However in ESRD this finding was based on a 
small pilot study, using a 1.0 Tesla scanner and a fast low angle shot (FLASH) imaging 
sequence(189). The current study was performed using a 1.5 Tesla scanner using a 
trueFISP sequence, allowing better contrast between the ventricular myocardium and blood 
pool. Echocardiography is well established, portable and widely available and therefore 
will likely remain a vital clinical tool but has drawbacks, including operator dependence 
and difficulty in obtaining satisfactory acoustic windows. The major limitation of 
echocardiography is the geometric assumptions required to calculate LV mass and function. 
As ventricular dimensions are measured in the minor axis and then volumes obtained by 
cubing these values, any error in these initial errors is cubed. Moreover, these techniques 
assume the left ventricle to be cubic and while these methods have been validated in normal 
hearts, patients with ESRD have a high prevalence of LV abnormalities, particularly 
eccentric remodelling(213). As LVH in ESRD is due to a combination of pressure and 
volume overload, both concentric and eccentric remodelling ensues. The high prevalence of 
eccentric remodelling in this study (54.8%) essentially invalidates these formulae to 
calculate LV mass in this population.   
 
Previous studies have suggested that in incident ESRD patients, the echocardiographic 
prevalence of LVH is 50-80%, with left ventricular dilatation in 20-40% and LVSD present 
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in 16% of patients(75). Echocardiographic prevalence of LV disorders from the current 
study is similar to these historical data. However, the CMR data suggests that this may 
represent an overestimation of the prevalence of these disorders, due to inherent 
inaccuracies in the use of echocardiography in the ESRD patient population. Overall, by 
CMR, 39.0% of patients had normal left ventricular dimensions and whilst LVH was the 
most common abnormality, the prevalence was lower than by echocardiographic studies at 
54%. The majority of these cases had isolated LVH, rather than a combination of LVH with 
LV dilatation and LVSD. This suggests that as LV chamber dimension is dependent on 
hydration status which varies during the interdialytic period in patients on haemodialysis 
(or is chronically overloaded in patients on peritoneal dialysis), any error in calculation of 
LV mass due to changes in chamber dimension is greatly magnified, when 
echocardiography is used. Some changes in LV mass do occur though the dialysis cycle 
due to changes in the water content of the interstitial tissues of the heart in volume 
overload, but these have been shown by CMR to be of the order of 10g(166).  
 
4.5.2  Echocardiographic studies used to derive measures of left ventricular mass 
The first calculations used to estimate LV mass from M-mode echocardiography were 
described in 1972 by Troy et al, based on the assumption that the LV is cubic(209). 
Subsequent attempts have been made to refine these: 
• The Penn convention equation was derived in later from a modified regression 
equation, based on echocardiographic studies, validated from subsequent post 
mortem studies in 34 patients. Although this study was pivotal, the patient group 
was somewhat heterogeneous, with ten patients with normal hearts, two had 
congestive cardiac failure, previous myocardial infarction was present in twelve 
patients and a variety of underlying conditions, both cardiac and non cardiac, were 
168 
 
the cause of death. The time between echocardiography and death was variable 
ranging from 1-120 days(205) 
• A new adjusted formulae (the ASE convention) was derived and validated by the 
same group of authors on a further 52 individuals. This refined formula is widely 
used, but as the authors acknowledge LV shape was relatively normal in almost 
all patients in this study and therefore the authors recommend that their formulae 
must be restricted to patients without gross distortion of LV chamber shape(206) 
• The Teichholz formula was developed at approximately the same time as the 
cubed formulae and has been shown to be effective in correcting systematic errors 
in LV volumes calculated by the cube function but has not been adopted widely 
for use in clinical studies, perhaps due to its complexity(208) 
 
4.5.3  CMR as a gold standard for calculation of left ventricular dimensions 
These studies to both compare and improve echocardiography and electrocardiography 
methods is dependent on the fundamental premise that CMR does truly represent a ‘gold 
standard’ for measurement of LV dimensions, i.e. a reproducible, accurate method, 
independent of geometric assumptions and ideally validated with post mortem specimens.  
 
A number of studies have shown CMR to be reproducible with low inter- and intra-
observer variability, both in normal volunteers as well as in patients with left ventricular 
hypertrophy, heart failure(194), and dilated cardiomyopathy(214). Post mortem validation 
comparing in vivo CMR images with post mortem specimens has not been performed, 
although animal studies and ex vivo imaging studies in humans show close agreement 
between CMR measured ventricular mass and true LV mass(215;216).  
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4.5.4  Feasibility of deriving novel regression formula for calculation of left 
ventricular mass in end stage renal disease 
Derivation of a revised echocardiographic formula for estimation of LV mass in ESRD is 
an attractive concept, and the formula derived displayed good correlation with CMR LV 
mass. However this formula requires prospective validation in a separate cohort of ESRD 
patients. Other potential limitations of this formula exist. Critically, it is still derived from 
the cube method. This is subject to the same assumptions and limitations regarding 
ventricular geometry as other cube formula. As these measures were developed, 
conventionally the papillary muscles are included in drawing endocardial borders to 
perform CMR analysis of LV mass(169). With echocardiography, the papillary muscles are 
avoided for M-mode measurements and excluded from the endocardial border for bi-plane 
measurements. This would appear to be a crucial issue but perhaps as both methods have 
evolved essentially separately and been validated against post mortem specimens, animal 
models and latex models, this issue is underplayed in the literature. 
 
Despite there being a high prevalence of eccentric remodelling in this study, the pattern of 
ventricular remodelling did not influence the degree of overestimation of LV mass (and 
associated underestimation of end diastolic volume) by echocardiography. The finding that 
end diastolic volume was under-estimated while LV mass was overestimated are consistent, 
but different methods were used (M-mode and Simpson’s bi-plane) to calculate these 
parameters.  These combined findings suggest that fundamentally the disparities between 
CMR and echocardiographic measures are due to difficulty in accurately defining 
endocardial borders and subsequent errors being magnified by calculations to calculate 
dimensions. These errors are accentuated in the ESRD population due to high prevalence of 
both hypertrophied and dilated ventricles.  
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4.5.5  Studies comparing echocardiographic and CMR measures of left ventricular 
mass in other populations 
A number of studies have compared CMR with M-mode echocardiographic measures of 
LV mass. The correlation between CMR and echocardiography and the degree of any 
systematic discrepancy between the methods have to an extent been dependent on the 
population studied.  
• In a study of 212 healthy army recruits echocardiography (ASE formula) 
consistently underestimated LV mass compared to CMR by a mean of 14.3g(217) 
• Echocardiography (Penn formula) overestimated LV mass in 39 patients with LVH 
due to aortic stenosis scheduled for aortic valve replacement by a mean of 37g(218) 
• In one study of hypertensive patients using echocardiography and CMR, 
echocardiography overestimated LV mass by 41g(219) whilst in another small 
study (n=20) of patients with LVH echocardiography overestimated LV mass by 
27.6g(220) 
 
Overall these studies, in keeping with the current study and others in ESRD, suggest that in 
patient groups with a high prevalence of LVH (and therefore distorted LV geometry) 
echocardiography tends to overestimate LV mass, but the opposite is true when large 
population with normal hearts are studied.  
 
4.5.6  Alternative echocardiographic techniques to assess left ventricular mass 
compared to CMR 
Although less widely used to estimate LV mass than the M-mode method, two-dimensional 
(2D) echocardiography is thought to be more accurate and reproducible than M-mode 
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methods. However one study using these methods in patients with hypertension suggests 
that this technique still suffers from intra-observer variability as well as wide limits of 
agreement compared to CMR(221). Using intravenous contrast combined with harmonic 
Doppler imaging has been shown to improve the accuracy of LV mass measurements with 
echocardiography but using this method the convenience of echocardiography as a clinical 
tool is diminished(222). Finally three-dimensional echocardiography measures of LV mass 
appear to show close correlation with CMR measures, although few comparative studies 
exist to date(223). Three-dimensional echocardiography is currently constrained by limited 
availability compared to conventional echocardiography. 
 
4.5.7  Reduction in numbers required to power studies using CMR compared to 
echocardiography 
As CMR is highly reproducible, it offers the potential advantage of reducing the number of 
patients required in clinical trials to show the benefit of a therapeutic intervention on 
cardiac dimensions. Using the data generated from these studies a clinical trial aimed at 
regression of LV mass index of 10g m-2 with 80% power would require 76 patients at 5% 
significance if performed with CMR but 328 patients with echocardiography(224).  
 
4.5.8  Discussion of ECG studies 
Using current ECG criteria, in this population with a high prevalence of LVH, all the 
current criteria in use have a high sensitivity for diagnosing LVH compared to when used 
in the general population (Table 4.5). However, the performance of the various criteria 
varied by gender with the Cornell voltage and Cornell product being superior in females, 
with the Sokolow-Lyon voltage and product being more sensitive indicators of LVH in the 
males. This anomaly in performance when compared by gender is similar to previous 
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studies of ECG versus CMR for diagnosis of LVH in the general population. Similarly, 
when area under a ROC curve was used to compare the criteria (Table 4.6), it is apparent 
that, whilst overall performances of the criteria are similar, the Cornell criteria provide 
considerably superior diagnostic measures in females. Although use of the QT interval to 
calculate Cornell and Sokolow-Lyon product would be expected to further improve 
sensitivity and specificity, in reality this was not the case, perhaps due to differing 
sensitivities of these criteria in this patient group due to baseline prevalence of LV 
disorders, but also as QT dispersion in this population is highly variable. 
 
4.5.9  Feasibility of redefinition of partition values for left ventricular hypertrophy in 
end stage renal disease 
Due the high prevalence of LVH in ESRD, the diagnostic utility of the ECG for diagnosing 
LVH is much higher in the general population and therefore this study confirms it is a 
useful screening test in this group of patients, particularly in light of its low cost and ready 
availability. Other authors have used CMR to optimise partition values in patients with 
hypertension and LVH(225). The high prevalence of LVH theoretically permits further 
increases in the sensitivity of the ECG for diagnosis of LVH by lowering the partition 
values. Although, as expected specificity is lost, it may be that the ECG could be used as a 
screening tool using this method to identify patients for clinical trials. Whilst gender was 
taken into account in analyses to identify optimise partition values for diagnosis of LVH, 
there appears to be very little difference in gender specific optimised cut points (Table 4.7). 
If however values are selected to maintain 95% specificity, it can be seen that female 
partition values for all four criteria are lower than male. Even at 95% sensitivity, the 
diagnostic utility of the ECG for diagnosing LVH is higher than in the non ESRD 
population. 
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4.5.10 Limitations of ECG for diagnosis of LVH in ESRD 
The majority of the patients in this study had a history of hypertension in common with the 
broader ESRD population. Although patients with previous myocardial infarction were 
included, this study did not take into account the influence of previous infarction and 
subsequent myocardial remodelling on the ECG. The chief influence on LV mass is likely 
to be blood pressure but valvular heart disease (particularly due to calcific aortic stenosis) is 
a significant promoter of LVH(226). No attempt to delineate between valvular and 
hypertensive LVH was made and it may be that these features are associated with different 
remodelling processes and direct diagnostic use in ESRD patients with purely valvular 
remodelling is not appropriate.  Similarly, although LVH has prognostic implications, both 
for patients with ESRD as well as the general population(227), the presence of secondary 
repolarisation abnormalities or ‘LVH with strain’ has much greater influence on subsequent 
cardiac outcome in patients with ESRD(207). Whilst long term study of this cohort of 
patients can identify if this effect persists in this group, it is difficult to derive a simple 
algorithm or cut point for diagnosis of LVH that takes into account the presence of these 
repolarisation abnormalities. Finally, as QT dispersion in this group of patients is variable 
and dependent on time point in the dialysis cycle(228), these revised partition values can 
only be applied at the same point that these patients were studied. As a heterogeneous 
group (haemodialysis, peritoneal dialysis and advanced chronic renal failure) this may not 
be appropriate.  
 
4.5.11 ECG as inclusion point for studies 
The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study used ECG 
criteria for LVH to identify patients at higher cardiovascular risk who were subsequently 
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randomised to therapy with atenolol or losartan based antihypertensive therapy(12). As well 
as demonstrating a reduction in cardiovascular morbidity with losartan, this study was also 
able to demonstrate electrocardiographic regression of LVH with both interventions but to a 
greater extent with losartan. Use of the ECG as an inclusion or end point for studies is 
attractive due to its low cost and availability, but is unlikely to be a successful strategy in 
ESRD, due to the large numbers of patients required to use this strategy. Moreover it 
remains unclear to what extent LVH can genuinely be regressed in this population, as 
opposed to artefactual improvements in LV mass primarily due to better volume control, 
such as that seen post renal transplantation, leading to reduced overestimation of LV mass 
with echocardiography. 
 
4.5.12 Conclusions on ECG studies 
Using current criteria for ECG diagnosis of LVH, it is possible to identify patients with 
elevated LV mass index. Therefore, when calibrated against the gold standard of CMR, 
ECG remains a useful tool in identifying patients with LVH. Further refinement of these 
partition values is possible, but has to be interpreted in the context of reduced specificity.  
Using CMR to optimise more readily available investigations such as ECG and 
echocardiography may represent one way of utilising an expensive and highly specialised 
cardiovascular investigation.  
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Chapter 5 
 
 
A study of the determinants of uraemic cardiomyopathy 
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5.1  INTRODUCTION 
As discussed in the introduction, previous reports suggest that the presence of uraemic 
cardiomyopathy is associated with poor long term outcome in patients with ESRD. LVH, 
LV dilatation and LVSD cumulatively confer a worse prognosis. Risk factors previously 
associated with the presence of LVH include hypertension(229), anaemia(124;230), 
hyperparathyroidism(231) and arterial stiffness(232) whilst the presence of ischaemic heart 
disease is the predominant risk factor for LVSD(233).  Studies performed in chapter 3 
confirm that the presence of conventional cardiovascular risk factors such as diabetes, 
cigarette smoking and a past history of ischaemic heart disease are strongly associated with 
CMR findings in keeping with previous myocardial infarction and therefore likely to 
correlate with the presence of LVSD. All previous studies describing the determinants of 
uraemic cardiomyopathy have been performed using echocardiography.  
 
It is not clear if the same factors are responsible for the evolution of LVH (or other forms of 
uraemic cardiomyopathy), when defined by the more accurate method of CMR. For 
example, anaemia has previously been associated with LVH, but it is possible that anaemia 
is secondary to haemodilution in ESRD in fluid overloaded patients and in turn this leads to 
hypertension(113). By using a volume independent measure of LV mass, the following 
studies will attempt to assess how much of these relationships are artefactual interactions 
between systematic overestimation of LV mass in volume overloaded patients and whether 
these relationships are confirmed with CMR. These studies were performed to assess the 
clinical determinants of LVH assessed both by CMR and echocardiography in ESRD. 
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5.2 METHODS 
 
5.2.1 CMR and echocardiography 
Patients were studied with CMR and echocardiography on the same day (described in detail 
in Section 2.3.2). Only patients with ESRD established on dialysis therapy on with both 
echocardiographic and CMR data were studied. CMR and echocardiograms were analysed 
as previously described. 
 
5.2.2  Dialysis data and blood sampling 
Pre- and post-haemodialysis blood pressures were recorded from the dialysis data recorded 
on the electronic patient record. The mean of readings from the three dialysis sessions 
preceding the CMR scan were used. Haemoglobin, albumin, corrected calcium, phosphate 
and urea reduction ratio were collected from the mean of values from the three months 
preceding the scan. All these results were collected as routine part of monitoring for audit 
and clinical care of patients on haemodialysis. The value for the three months preceding the 
scan was used for parathyroid hormone levels, which are checked less often.  In patients on 
peritoneal dialysis blood pressure readings were the mean of the three clinic blood 
pressures preceding the scan. The blood results as before were averaged for these three 
clinic visits, with weekly urinary, peritoneal and total creatinine clearances assessed from 
the recording during the three months prior to the scan. 
 
5.2.3  Statistical methods 
To assess the determinants of cardiac dimensions correlations were sought between these 
and continuous clinical variables by the various methods were assessed with Pearson and 
Spearman correlation co-efficient as appropriate. Independent determinants of cardiac 
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dimensions were assessed using a linear regression model. All analyses were performed 
using the SPSS 13.0 statistical software package (SPSS Inc., Chicago, IL., USA) 
 
5.3  RESULTS  
 
5.3.1  Patient demographics 
Only patients established on dialysis therapy were studied. The cohort consisted of 148 
patients of whom 93 (62.8%) were male. 88 (59.5%) patients were on haemodialysis with 
60 (40.5%) on peritoneal dialysis. Baseline clinical and laboratory data for haemodialysis 
and peritoneal dialysis patients are shown in Table 5.1. Cardiac dimensions are in Table 5.1 
are as measured by CMR. Tests of significance are t-test or Mann-Whitney-U as 
appropriate.  
 
5.3.2  Determinants of left ventricular mass in ESRD using CMR 
Overall cardiac dimensions (LVM, end diastolic and end systolic volume) were 
significantly elevated in HD patients compared to those on PD (Table 5.1). Significant 
correlations were displayed between haemoglobin (Pearson’s R= -0.23, p=0.006), 
parathyroid hormone (Spearman’s R= 0.24, p=0.006) and serum phosphate levels 
(Spearman’s R= 0.17, p=0.044) and LVMI. In patients on haemodialysis both pre-dialysis 
(Pearson’s R- systolic blood pressure= 0.66, p<0.001, diastolic blood pressure= 0.59, 
p<0.001) and post-dialysis blood pressure (Pearson’s R- systolic blood pressure= 0.76, 
p<0.001, diastolic blood pressure= 0.60, p<0.001) correlated strongly with LVMI. 
Similarly in PD patients LVMI was significantly correlated with clinic blood pressure 
(Pearson’s R- systolic blood pressure= 0.55, p<0.001, diastolic blood pressure= 0.32, 
p=0.023). The overall correlation between blood pressure and LVMI is show in Figure 5.1. 
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Although in HD patients there was a significant negative correlation between dialysis 
adequacy as measured by urea reduction ratio and LVMI (Pearson’s R= -0.33, p=0.004), no 
significant relationship existed between dialysis adequacy measured by total weekly 
creatinine clearance and LVMI in patients on PD. 
 
Table 5.2 shows the results of multivariate linear regression analysis on the determinants of 
LVMI in patients. In these analyses, post-dialysis blood pressure measures were used in 
HD patients with clinic blood pressures used in PD patients. Due to their close 
interdependence systolic and diastolic blood pressure were entered separately into the 
model. The table shown uses systolic blood pressure. The major, significant determinants 
of LVMI were systolic or diastolic blood pressure and cholesterol.  
 
The analysis was repeated using the same multivariate linear regression model for only HD 
patients to assess the impact of HD adequacy on LVMI. From this analysis urea reduction 
ratio was not an independent determinant of LVMI. 
 
5.3.3  Determinants of left ventricular mass in ESRD using echocardiography 
Echocardiographic data were available in 88 patients. Again LVMI (181.9 vs. 148.7 g m-2, 
p=0.013), end diastolic volume (Simpson’s biplane end diastolic volume- 111.4 vs. 92.3 
ml, p=0.017) and end systolic volume (48.8 vs. 37.5 ml, p=0.014) were significantly greater 
in patients on haemo- compared to peritoneal dialysis. Significant correlations were 
demonstrated between LVMI and duration of renal replacement therapy (Spearman’s R= 
0.27, p=0.010), blood pressure (post-dialysis blood pressure measures in HD patients 
combined with clinic blood pressures in PD patients - Pearson’s R- systolic blood pressure= 
0.53, p=0.001, diastolic blood pressure= 0.39, p=0.001), parathyroid hormone levels 
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(Spearman’s R= 0.33, p=0.002) and haemoglobin (Pearson’s R= -0.24, p=0.029).  
Additionally aortic valve gradient, not easily measured by CMR, displayed a significant 
correlation with LVMI (Spearman’s R= 0.40, p<0.001). Echocardiographic aortic jet 
velocity and aortic valve pressure gradient were assessed in 93 patients. Severe aortic 
stenosis was not present in the patients studied although 5 (5.4%) patients had moderate 
aortic stenosis (aortic jet velocity 3.0-4.0 m s-1).  
 
As before, multivariate linear regression analysis was performed to assess the determinants 
of LVMI in these patients as measured by echocardiography. Only nine variables were 
entered in the model as fewer patients were available to analyse. The following variables 
were not predictive in initial exploration of the data and were not entered in the model- age, 
gender, diabetes, C - reactive protein and smoking history.  Blood pressure variables were 
treated as previously. The major, significant determinants of LVMI were systolic or 
diastolic blood pressure, duration of renal replacement therapy, cholesterol, phosphate, 
aortic valve gradient and serum corrected calcium. 
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 Haemodialysis Peritoneal dialysis p value 
Number 88 (59.5) 60 (40.5)  
Male 62 (70.5) 31 (51.7) 0.02 
Age (years) 52.5 (11.0) 53.0 (10.5) 0.757 
Height (m) 170.1 (10.5) 166.2 (9.3) 0.026 
Weight (kg) 75.2 (17.5) 73.4 (14.1) 0.522 
RRT time (months) 12.5 (93.0) 5.0 (11.0) <0.001 
10 Renal Disease      
 Diabetes 15 (17.0) 23 (38.3) 
 APKD 12 (13.6) 5 (8.3) 
 GN 21 (23.9) 10 (16.7) 
 CPN 11 (12.5) 4 (6.7) 
 Renovascular 3 (3.4) 4 (6.7) 
 Unknown/Other 26 (29.5) 23 (38.3) 
0.06 
Pre-d SBP (mmHg) 149.9 (24.9) -   
Pre-d DBP (mmHg) 82.6 (13.1) -   
Post-d SBP (mmHg) 136.0 (25.7) -   
Post-d DBP (mmHg) 75.9 (14.2) -   
Clinic SBP (mmHg) -  139.7 (22.5)  
Clinic DBP (mmHg) -  82.3 (11.5)  
Haemoglobin (g dL-1) 11.7 (1.8) 11.5 (1.6) 0.375 
Albumin (g L-1) 40.0 (4.2) 37.9 (4.6) 0.005 
Corrected Calcium (mmol L-1) 2.4 (0.2) 2.4 (0.2) 0.929 
Phosphate (mmol L-1) 1.8 (0.5) 1.7 (0.4) 0.734 
Ca-P product 4.1 (1.3) 4.2 (1.0) 0.852 
PTH (pmol L-1) 20.0 (34.0) 17.15 (39)  
URR (%) 70.7 (8.2) -   
CrCl (L/week/1.73m2) -  86.6 (25.8) 0.871 
LV mass (g) 184.2 (65.5) 153.5 (49.7) 0.003 
LV mass/BSA(g m-2) 99.3 (31.7) 84.3 (25.8) 0.003 
Ejection fraction (%) 65.8 (11.9) 66.9 (12.2) 0.590 
ESV(ml) 57.8 (40.4) 42.6 (26.2) 0.011 
ESV/BSA (ml m-2) 31.2 (21.3) 22.9 (13.0) 0.009 
EDV (ml) 157.6 (62.7) 123.9 (43.7) <0.001 
EDV/BSA(ml m-2) 85.1 (31.3) 67.5 (21.2) <0.001 
Table 5.1 Baseline characteristics of patients. Data are number or mean with percentage or standard deviation 
in parentheses expect for RRT time and PTH where median and interquartile range are shown 
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Figure 5.1 
Scatter plot of systolic and diastolic blood pressures plotted against LVMI assessed by 
CMR. Post-dialysis blood pressure measures were used in HD patients with clinic blood 
pressures used in PD patients 
LVMI-SBP R=0.60, p<0.001 
LVMI-DBP R=0.39, p<0.001 
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Standardised 
coefficient (β) 
Significance (p) 95% CI for β 
LVMI (CMR)     
R2= 0.62     
(Constant) 89.0 0.175 (-40.68, 218.72) 
SBP 0.54 <0.001 (0.40, 0.92) 
DBP 0.40 0.001 (0.23, 1.40) 
Cholesterol -0.30 0.008 (-13.37, -2.11) 
Diabetes -2.00 0.080 (-28.25, 1.63) 
Haemoglobin -0.18 0.129 (-7.18, 0.93)  
Albumin 0.12 0.278 (-0.67, 2.29) 
PTH 0.06 0.600 (-0.15, 0.26) 
Calcium -0.07 0.518 (-45.18, 22.99) 
Phosphate 0.06 0.593 (-9.18, 15.94) 
RRT time 0.16 0.158 (-0.03, 0.15) 
CRP -0.07 0.546 (-0.51, 0.27) 
 
Table 5.2  
Determinants of LVMI as measured by CMR in a multivariate linear regression model 
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Standardised 
coefficient (β) 
Significance (p) 95% CI for β 
LVMI (echo)     
R2= 0.63     
(Constant) -24.64 0. 813 (-232.34, 183.07) 
RRT time 0.31 <0.001 (0.18, 0.45) 
SBP 1.54 <0.001 (1.06, 2.02) 
DBP 1.93 <0.001 (0.97, 2.88) 
Cholesterol -14.25 0.002 (-23.03, -5.46) 
Phosphate 27.25 0.010 (6.89, 47.61) 
Calcium  -64.71 0.026 (-121.22, -8.20) 
Aortic gradient 1.19 0.045 (0.03, 2.35) 
Albumin 2.40 0.050 (-0.002, 4.807) 
PTH 0.18 0.293 (-0.157, .51) 
Haemoglobin 2.40 0.493 (-4.56 9.34) 
 
Table 5.3  
Determinants of LVMI as measured by echocardiography in a multivariate linear regression 
model 
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5.4     DISCUSSION 
 
5.4.1  Overall determinants of left ventricular mass 
Multiple factors were associated with raised LVMI in this cohort of patients. When CMR 
was used as the method of measuring LVMI elevated blood pressure, hyperphosphataemia, 
hyperparathyroidism and anaemia were all associated with greater LVMI. Improved 
dialysis adequacy was associated with lower LVMI in haemodialysis patients but not in 
peritoneal dialysis patients. Haemodialysis patients had greater LVMI compared to those on 
peritoneal dialysis. Other groups have observed this and a commonly cited mechanism for 
this is the presence of an arterio-venous fistula for dialysis access leading to increased 
cardiac output(112). Additionally work from our group has observed that for a given rise in 
cardiac output (e.g. due to the arterio-venous fistula) patients with ESRD have an 
augmented blood pressure response which in turn promotes LVH(113). In any case, 
patients on haemodialysis are exposed to greater systolic blood pressures particularly pre-
dialysis as shown in Table 5.1, in turn promoting LVH.   
 
Factors which correlated with echocardiographic measures of LVH included blood 
pressure, time on renal replacement therapy, hyperparathyroidism, anaemia and peak aortic 
valve pressure gradient. When subjected to multivariate analysis the chief determinant of 
elevated LVMI measured by either CMR or echocardiography was blood pressure, chiefly 
systolic blood pressure. One other variable independently associated with higher LVMI 
measured by either method was hypocholesterolaemia. Male gender was the only other 
independent predictor of increased LVMI measured by CMR, but by echocardiography 
time on renal replacement therapy, hyperphosphataemia, hypocalcaemia and peak aortic 
valve pressure gradient were additional independent predictors of raised LVMI. 
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5.4.2  Blood pressure as a determinant of LVH in ESRD 
Overall in this study hypertension was the major determinant of LVH and represents a 
potential target for treatment to reduce LVH. The nature of this study does not however 
demonstrate the natural history of evolution of LVH in earlier CKD and by the time the 
patient has established ESRD, intervention may be less likely to succeed. Previous work 
form our group has demonstrated that LVMI is elevated even in early CKD, when serum 
creatinine is normal(78). This study only analyses blood pressure trends over the preceding 
three months and whilst this may represent a continuing insult to the uraemic heart, may not 
reflect the long history of exposure to hypertension prior to commencing dialysis. Similarly 
extracellular fluid volume, the chief determinant of changes in blood pressure was not 
assessed in this study. Clinical assessment is notoriously inaccurate for precise 
measurement of extracellular fluid volume, and bioimpedance is required to assess this 
exactly(234). Many other groups have reported the association between hypertension and 
LVH(235;236). There is some debate as to the optimum time to measure blood pressure 
particularly in haemodialysis patients where blood pressure is dependent on timing with 
respect to the dialysis cycle(237). In a similar sized cohort of patients Fagugli et al used 
bioimpedance analysis to demonstrate a close correlation between extracellular water 
volume, blood pressure and LVMI(235).  
 
A number of studies have suggested that 24 hour ambulatory blood pressure monitoring 
(ABPM) is superior for diagnosis and monitoring of hypertension in dialysis patients. 
Cannella et al have demonstrated using ABPM that many haemodialysis patients with 
borderline treated hypertension have significantly higher systolic and diastolic blood 
pressures over a 24 hour period than the pressures measured in the dialysis centre(238). 
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Again blood pressure correlated strongly with LVMI in this study. Similarly, Agarwal et al 
found systolic blood pressure 24 hour ABPM to be a much stronger predictor of LVMI than 
any dialysis centre reading.(237) 
 
Multiple sources of inaccuracy exist in measurement of blood pressure in dialysis patients.  
Appropriate measurement of blood pressure should be after 5 minutes in quiet room 
without talking or active listening. This is difficult to achieve in the dialysis unit. Other 
non-uraemia specific sources of inaccuracy include the white coat effect, cuff size, and 
obesity or vascular disease making obtaining the brachial pulse difficult. Haemodialysis 
specific inaccuracies may be due to difficulty measuring brachial blood pressure in an arm 
with previous haemodialysis access surgery. Immediately post dialysis there is a rapid 
reduction in extracellular fluid volume leading to hypotension. However, the reduction in 
serum potassium leads to vasoconstriction in skeletal muscle and subsequent hypertension. 
Therefore, for accuracy post-dialysis blood pressure should normally be measured at least 
20 minutes post dialysis, but this is frequently inconvenient for patients. 24 hour ABPM is 
likely to demonstrate the true blood pressure more accurately but is time consuming, 
expensive and additionally as dialysis patients frequently have high systolic blood pressures 
and a wide pulse pressure, the high cuff pressures required for measurement lead to 
discomfort(239). 
 
5.4.3  Comparison of determinants of left ventricular mass as assessed by CMR 
compared to echocardiography 
Variables that were predictors for LVH by echocardiography, but not by CMR, included 
duration of renal replacement therapy, hyperphosphataemia, hypocalcaemia and aortic 
valve gradient. As discussed previously, severity of aortic stenosis is not readily assessed 
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within the context of an uncomplicated CMR protocol and CMR sequences to measure this 
were not performed in this study. Perhaps unexpectedly duration of renal replacement 
therapy was not predictive of LVH by CMR. As patients have been on dialysis for longer, 
they become more chronically volume overloaded leading to LV chamber dilatation and 
ventricular remodelling may ensue. It may be that inaccuracies in measurement of LVM 
with echocardiography are augmented in patients with a long history of renal replacement 
therapy. As CMR measurements are less volume dependent and volume dependent 
inaccuracy is minimised.  It is difficult to explain why hyperphosphataemia and 
hypocalcaemia are associated with greater LVM as measured by echocardiography but not 
CMR. 
 
5.4.4  Hyperparathyroidism, hyperphosphataemia and vascular calcification as 
determinants of LVH 
In this study serum PTH and phosphate correlated with LVMI.  Both of these factors are 
likely to increase LVMI by a direct effect on the myocardium and indirect vascular effect. 
Animal models of uraemia have demonstrated both PTH and phosphate to have a 
permissive effect on development of myocardial fibrosis therefore demonstrating a close 
interaction between these circulating factors and development of LVH(240). These animal 
studies are confirmed by a number of clinical cohort studies(73;241). Moreover 
hyperphosphataemia and hyperparathyroidism are key drivers in development of arterial 
calcification in patients in ESRD. Arterial calcification increases cardiac after load hence 
further promoting LVH(232). One dilemma is that patients with the longest history of 
receiving renal replacement therapy are those who have more complications of ESRD such 
as secondary hyperparathyroidism making it difficult to assess the interdependence of the 
relationships between duration of ESRD and the various complications of ESRD such as 
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LVH and secondary hyperparathyroidism. Analysis of the determinants of LVH in patients 
with ESRD from the Dialysis Morbidity and Mortality Study Wave 2, a study of 2,584 new 
ESRD patients commencing dialysis therapy demonstrated that PTH was an independent 
risk factor for LVH(77). 
A number of studies have demonstrated that increased arterial calcification, measured either 
by pulse wave velocity or by electron beam CT scanning has been associated with LVH in 
ESRD patients: 
• One study in children with stages 2-4 CKD and ESRD has demonstrated that these 
alterations in arterial calcification and LVM occur early in CKD and are dependent on 
hyperphosphataemia(241) 
• One study has reported improvements in LVM in a case series of 12 dialysis patients 
following parathyroidectomy(242) 
• Finally, in patients with primary hyperparathyroidism and normal renal function 
cardiomyopathy and cardiac calcification has been reported presumably due to a 
direct effect of parathyroid hormone on the myocardium(243) 
 
5.4.5  Other potential determinants of LVH in ESRD 
Hypocholesterolaemia appears in this study to be directly linked to the presence of LVH. 
Although a direct mechanistic link between low serum cholesterol and increased LVMI is 
unlikely this can be interpreted in two ways. First, patients with LVH are at higher 
cardiovascular risk and the clinician responsible for the patient’s care may have elected to 
treat these patients with statins leading to a reduction in serum cholesterol. Second, 
although not demonstrated in this study, other authors have demonstrated a weak 
correlation between hypoalbuminaemia and increased LVM(244). The same study reported 
a close independent correlation between C - reactive protein and LVM. It is therefore 
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plausible that low serum cholesterol represents either malnutrition (represented by 
hypoalbuminaemia) or inflammation (high C - reactive protein) and in conjunction with 
LVH may represent the presence of the malnutrition-atherosclerosis-inflammation 
syndrome, thereby explaining why low cholesterol offers little cardiovascular protection in 
ESRD. 
 
Although in this current study, patients on haemodialysis had greater LVMI than those on 
peritoneal dialysis, other authors have reported the reverse(245). The explanation given by 
the authors was that patients on peritoneal dialysis are more volume expanded. However, in 
that study pre-dialysis blood pressure and blood pressure in the peritoneal dialysis patients 
were similar and therefore it is possible that peritoneal dialysis patients in this study were 
exposed in total to a greater blood pressure load(245).  
 
5.4.6  Aortic stenosis as a risk for LVH in ESRD 
Aortic valve peak pressure gradient at echocardiography was identified as an independent 
determinant of LVMI. In the general population aortic stenosis classically causes pressure 
induced concentric remodelling, followed by the development of ventricular hypertrophy. 
The presence of aortic valvular calcification has been previously shown to be associated 
with higher LVMI. The severity of aortic stenosis, measured either by peak flow velocity or 
pressure gradient has been demonstrated to correlate with LVMI(226). Therefore 
prevention of valvular calcification may be a therapeutic target for reduction of LVH. Once 
established, aortic stenosis has been demonstrated to progress rapidly in patients with 
ESRD, thereby increasing the necessity for early valve replacement(246). 
 
 
191 
 
5.4.7  Anaemia as a risk factor for LVH in ESRD- fact or fiction? 
In this study, as well as others from our group, anaemia correlated with greater LVMI, 
whether measured with echocardiography or CMR. When subjected to multivariate 
analysis, however this was not an independent predictor of LVMI. In the anephric patient 
anaemia, volume status, blood pressure and haemodilution are closely related and it is 
difficult to tease out whether the relationship between low haemoglobin and increased 
LVMI is a direct effect or indirectly due the action of hypervolaemia on both haemodilution 
and increased blood pressure. A number of studies have demonstrated either a correlation 
between the presence of anaemia and the presence of LVH or showing anaemia to be a risk 
factor for progression of LVH. Most of these progression studies are in patients established 
on dialysis therapy: 
• In a study of 48 dialysis patients, prior to availability of recombinant erythropoietin 
for treatment of renal anaemia, an increase in LVMI increased significantly in parallel 
with the decrease in haemoglobin(247) 
• In 175 patients initiated on dialysis therapy, followed up with echocardiograms at an 
18 month interval, anaemia and systolic blood pressure were independent risk factors 
for LVH(75) 
• In 246 dialysis patients with echocardiography performed at a 12 month interval, even 
after adjusting for baseline LVMI, haemoglobin level and systolic blood pressure 
remain independently important predictors of left ventricular growth (124) 
• By contrast, in the era of established treatment with erythropoietin from the Dialysis 
Morbidity and Mortality Study Wave 2, a studying of 2,584 new ESRD patients 
commencing dialysis therapy, anaemia was not identified as an independent risk 
factor for LVH at commencement of renal replacement therapy(77) 
192 
 
However despite the correlation between the presence of anaemia and LVH and the 
comparable comparison between persisting low haemoglobin levels and increasing LVMI, 
evidence from randomised controlled trials using various forms of erythropoietin does not 
support a treatment strategy of full correction of anaemia in patients with either early 
chronic kidney disease or ESRD: 
• Roger et al showed that treatment with erythropoietin alpha to maintain haemoglobin 
at 12-13g/dL did not affect progression of LVH compared to maintaining 
haemoglobin at 11-12g/dL (female) or 11-13g/dL (male) in patients with stage 3-4 
chronic kidney disease(127) 
• Besarbab et al demonstrated in randomised controlled trial of 1233 haemodialysis 
patients with clinical evidence of congestive heart failure or ischaemic heart disease, 
the use of increasing doses of erythropoietin to achieve and maintain a haematocrit of 
42 percent, was associated with excess mortality compared to maintain a haematocrit 
of 30 percent(126) 
• More recently, in the Correction of Haemoglobin and Outcomes in Renal 
Insufficiency (CHOIR) trial, the use of a target haemoglobin level of 13.5 g/dL (as 
compared with 11.3 g/dL) was associated with increased risk of cardiac events and no 
incremental improvement in the quality of life in patients with GFR 15-
50ml/min(128), whilst the Cardiovascular Risk Reduction by Early Anaemia 
Treatment with Epoetin Beta (CREATE) study showed no significant difference in 
LVM in patients randomised to a haemoglobin of 10.5-11.5 g /dL compared to a 
normal haemoglobin of 13.0-15.0 g/dL in patients with GFR of 15-35.0 ml/min(125) 
 
Therefore whilst there is no doubt that historically anaemia and LVH have been 
interrelated, it is now unclear in the era of treatment of with erythropoietin, what the 
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optimum target haemoglobin should be, either to prevent LVH or improve quality of life, 
whilst minimising risks from non-physiological overcorrection.   
 
5.4.8  Reinventing the wheel -treatment strategies to reduce LVH in ESRD 
Based on this work, focus should once again be redirected at treating blood pressure, 
chiefly systolic blood pressure, to prevent development and progression of LVH. 
Regression of LVH is likely to be more difficult once the patient has established ESRD and 
focus should be directed at aggressive antihypertensive treatment earlier in the course of 
chronic kidney disease, as part of standard management of patients with progressive renal 
disease and hypertension.   
 
Once established on dialysis therapy the options for treatment of hypertension primarily are 
maintenance of euvolaemia (‘dry weight’), antihypertensive medication or a combination of 
these strategies. A number of studies have addressed these issues using changes in 
echocardiographic LVMI as an end point. One confounding factor is that any intervention 
that reduces extracellular fluid will reduce ventricular dilatation and consequently the 
degree of artefactual overestimation of LVMI. Therefore while this strategy is likely to be 
beneficial due to its effect on blood pressure, the positive outcome reported on LVMI may 
partly be due to optimisation on intra-ventricular fluid volume. A number of examples of 
such studies illustrate this point: 
• One uncontrolled Turkish study of 19 haemodialysis has demonstrated excellent 
blood pressure control with rigorous salt control and fluid restriction. LVMI reduced 
by a mean of 43g m-2 over a 6 month period. Although this is an excellent outcome 
for these patients, this reduction in LVMI is so dramatic that it is more likely that 
some of this improvement is artefactual(248)  
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• A number have studies have demonstrated improvements in LVMI following 
conversion to nocturnal haemodialysis, allowing slower ultrafiltration over a greater 
dialysis period. Chan et al showed that nocturnal haemodialysis allowed reduction in 
the need for antihypertensive therapy, improved blood pressure and a reduction in 
LVMI over a follow up period of 1 year in 28 patients switched to nocturnal 
haemodialysis compared to their counterparts on conventional haemodialysis(20)  
• Changing patients from thrice weekly to short daily on-line haemodiafiltration as 
dialysis modality has been demonstrated to significantly reduce LVMI in one small 
study (eight patients). Interestingly this study used CMR to measure LVMI and found 
similar magnitudes of reduction as the echocardiographic studies quoted above. This 
intriguing finding needs explored in larger controlled studies. Whether this dialysis 
modality confers additional benefits via actions on uraemic toxins is unknown(249) 
• Similar findings have been reported in peritoneal patients on both blood pressure and 
LVMI in an open-label randomised controlled trial using icodextrin compared to 
conventional glucose peritoneal dialysis for the night time dwell. Again it is likely 
that the main beneficial effect on LVMI was mediated via improved volume status 
and blood pressure(250) 
 
Limited trial data exist on the use of pharmacological agents to reduce blood pressure or 
LVMI in ESRD. Two small studies have demonstrated a benefit of using angiotensin 
receptor blockers in haemodialysis patients either as monotherapy. In an non-blinded three 
treatment arm study of 33 patients, Suzuki et al reported increased regression of LVMI 
with combined losartan and enalapril either agent alone independent of blood 
pressure(251), whilst losartan was shown to have a beneficial effect as monotherapy on 
LVMI compared to amlodipine or enalapril in a similar study(252). 
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Out with treating blood pressure and revisiting the dilemma of treatment targets in renal 
anaemia, alternative strategies to treat LVMI may revolve around addressing calcium 
phosphate balance and secondary hyperparathyroidism. Sevelamer hydrochloride has 
already been shown to produce less coronary artery calcification (as measured by electron 
beam CT scanning) compared to calcium containing phosphate binders(143). Reduction of 
arterial (and potentially valvular) calcification may reduce cardiac after load and minimise 
LVH. This end point has not been studied using this agent. Similarly vitamin D analogues 
such as calcitriol have been demonstrated in small studies to reduce progression of 
LVH(253). The calcimimetic agent, cinacalcet, currently used for treatment of secondary 
and tertiary hyperparathyroidism may yet prove to have beneficial outcomes on either 
arterial calcification or LVH. Whilst CMR is not able to directly demonstrate calcium 
deposition, techniques developed for assessing arterial stiffness may prove useful end 
points for such studies and may yet provide surrogate equivalent measures of vascular 
function, at the same time as providing definitive LV assessment. 
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Chapter 6 
 
 
Survival of patients undergoing cardiovascular screening for renal transplantation 
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6.1 INTRODUCTION 
Cardiovascular disease (CVD) is the leading cause of death after renal transplantation as 
well as the leading cause of death of patients on the renal transplant waiting list(254). 
Various guidelines have been developed to assess peri-operative risk in the general 
population(255) as well as for renal transplant assessment(192;256).  Further studies using 
a variety of clinical scoring criteria or screening tests have been performed in an attempt to 
identify patients at increased risk of early post transplant death(257). Many of the 
guidelines used in the general population use conventional cardiovascular risk factors to 
classify those patients at increased peri-operative risk. However some of these risk factors, 
such as diabetes, hypertension, ECG abnormalities (or even renal dysfunction itself) are 
either ubiquitous or have a much higher prevalence in the ESRD population. Other risk 
factors such as hypercholesterolaemia have different relationship with outcome in the 
ESRD population. No study to date has used CMR to generate long term follow up data in 
the ESRD/renal transplant candidate population, including those patient undergoing 
assessment who are not transplant listed, and there are still relatively few outcome studies 
for any conditions using CMR.   
 
Identifying patients at high risk is beneficial for a number of reasons. Firstly, some patients 
will be at such high peri-operative risk or have such a short anticipated survival that renal 
transplantation is unlikely to offer any improvement in the quality or longevity of life for 
that patient. As cadaveric organs are in short supply, it is unlikely to be an appropriate use 
of a valuable resource to allocate kidneys to such patients. Other patients may be at 
increased risk of dying, but their risk may potentially be lowered, either by medical therapy 
or surgical intervention. In these cases where evidence may not exist for intervention these 
patients may be identified as suitable for clinical trials of interventions to reduce risk. Some 
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patients who are at lower cardiovascular risk may not benefit from screening, although in 
these cases results may be reassuring and provide a baseline assessment as patients 
frequently face an uncertain wait for a cadaveric kidney. For this reason, the screening tests 
should ideally be non invasive and carry a minimal risk of harm. At the time of study, CMR 
was ideally placed to offer such a test. 
 
The aims of these studies were to assess the utility of CMR in identifying the renal 
transplant candidate at high risk of premature death. Specific hypotheses to be addressed 
included:  
• Does the presence of uraemic cardiomyopathy, as defined by cardiac dimensions at 
CMR predict outcome? 
• Would the presence of LGE on CMR scanning predict poorer patient prognosis? 
• Can CMR provide additional information above standard clinical information to 
inform likely patient outcomes? 
 
6.2 METHODS 
 
6.2.1 Patient demographics 
Patients were recruited from the renal transplant assessment clinic at the Western Infirmary 
as described in Chapter 2. To achieve greater statistical power a larger cohort was created 
by addition of patients assessed for transplantation during the period February 2002 – 
March 2006, including patients studied as part of a previous British Heart Foundation 
Fellowship to Dr Nicola Johnston, as well as the current studies.  
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6.2.2 Cardiovascular assessment 
All patients studied underwent CMR to assess cardiac dimensions and function as 
described previously. Contrast-enhanced CMR was performed in the majority of patients 
scanned with reasons for not administering Gd-DTPA-DMA as before (precipitating 
decline in renal function, patient choice, scan duration and poor venous access).  A 
proportion of patients underwent other tests including clinical history and examination, 
electrocardiography, exercise tolerance testing and angiography as clinically appropriate. 
Methods described in Chapter 2 were used for these tests. All tests were performed within 
the Department of Cardiology at the Western Infirmary, Glasgow. 
 
6.2.3 Coronary angiography 
A subset of patients underwent coronary angiography as part of assessment for renal 
transplant listing. Criteria used to select patients for angiography were as described in 
Chapter 3.2.3 with angiography performed within three months (before or after) of CMR. 
Decision to perform angiography was by an independent cardiologist blinded to the results 
of these studies. Angiograms were classified for severity of coronary artery disease as 
previously described. 
 
6.2.4 Follow up 
Follow up data was collected from date of the CMR scan to 9th November 2006 using 
electronic patient records from the Western Infirmary, Glasgow and Glasgow Royal 
Infirmary Renal Units. With this cohort, death was the only end point used. All patient 
deaths were included in the patient survival analysis. From these data the influence of 
various parameters on patient survival were determined.  
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6.2.5 Statistical methods 
Measures of cardiac function were compared between patients who died during the follow 
up period, with t-test and Chi-squared/Fisher’s exact test used to compare groups. 
Unadjusted survival analysis was performed using the Kaplan–Meier method. Statistical 
significance was determined by the log-rank test. The data were then analysed by Cox 
survival analysis to assess the influence of multiple variables on outcome. Variables 
identified as possibly influential on outcome by univariate analysis were then entered into a 
forward stepwise regression model. All analyses were performed using the SPSS 13.0 
statistical software package (SPSS Inc., Chicago, IL., USA). 
 
6.3 RESULTS 
 
6.3.1 Patient demographics and survival 
Baseline patient demographics are shown in Table 6.1. A total of 300 patients were studied 
(84 with advanced renal failure not on dialysis therapy, two patients with failing renal 
transplants 157 patients on haemodialysis and 57 on peritoneal dialysis). The median 
follow period was 32.5 months. There were 60 patient deaths during the follow up period. 
Survivors were significantly younger than those who died during the follow up period. A 
significantly higher proportion of patients with a past history of diabetes mellitus, 
ischaemic heart disease (Figure 6.1), cerebrovascular disease and peripheral vascular 
disease died. Gender, dialysis modality at the time of scanning, duration of renal 
replacement therapy, smoking history and blood pressure at the time of scanning were not 
associated with patient mortality. 
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6.3.2 Laboratory data and patient outcome 
Certain laboratory parameters were associated with better patient outcome (Table 6.2). 
Patients who died during the follow up period were more likely to be anaemic than 
survivors and additionally were more likely to be malnourished with lower serum albumin. 
Evidence of greater systemic inflammation indicated by higher C- reactive protein was non-
significantly higher in patients who died during the follow up period. There were no 
differences in corrected calcium, phosphate, calcium phosphate product or cholesterol 
levels between patients alive and dead at the end of the follow up period. 
 
6.3.3 Transplant list status, renal transplant listing and outcome 
78 (26.0%) patients were not transplant listed following independent assessment. 222 
patients (74.0%) were transplant listed. 80 (26.7%) patients went on to receive a renal 
transplant of which five diabetic patients received combined cadaveric kidney-pancreas 
transplants.  Patients who were not transplant listed were significantly likely to be older, 
more likely to be diabetic or have a history of peripheral vascular disease. There were a non 
significantly lower proportion of patients with ischaemic heart disease in the transplant 
listed group. The outcome of the patients divided by transplant outcome is shown in Figure 
6.2. There were only seven post transplant deaths during the follow up period with a 1 year 
post transplant patient survival of 95.3%. As the post transplant numbers are relatively 
small with a short post transplant follow up data were not censored at the point of 
transplantation and post transplant outcomes were not studied in detail.  
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 Alive Dead p value 
Number 240  (80.0) 60  (80.0)  
Male 154  (64.2) 37  (61.7) 0.719 
Age (years) 50.3 (10.8) 56.5 (9.6) <0.001 
SBP (mmHg) 136.2 (24.5) 140.1 (24.0) 0.283 
DBP (mmHg) 81.3 (12.8) 80.1 (12.0) 0.525 
10 Renal Disease    
 Diabetes 49 (20.4) 17 (28.3) 
 APKD 30 (12.5) 6 (10.0) 
 GN 47 (19.6) 8 (13.3) 
 CPN 25 (10.4) 2 (3.3) 
 Renovascular 12 (5.0) 4 (6.7) 
 Unknown/Other 77 (32.1) 23 (38.3) 
0.294 
RRT time (months) 12.0 (39.0) 20.0 (41.0) 0.139 
Smoker    
 Never 126 (52.5) 27 (45.0) 
 Current 62 (25.8) 21 (35.0) 
 Ex 52 (21.7) 12 (20.0) 
0.359 
Diabetes 52 (21.7) 21 (35.0) 0.031 
Previous IHD 36 (15.0) 20 (33.3) 0.001 
TIA/CVA 13 (5.4) 9 (15.0) 0.011 
PVD 10 (4.2) 7 (11.7) 0.025 
Table 6.1  
Baseline demographic data for patients alive and dead at the end of the follow up period. Data are 
number with percentage in parentheses or mean with standard deviation in parentheses except for 
RRT time where median and intra-quartile are shown. Tests of significance are t-test and Chi-
square except for renal replacement therapy time where Mann-Whitney is used 
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 Alive Dead p value 
Haemoglobin 11.6 (1.8) 11.0 (1.4) 0.017 
Albumin 39.7 (4.5) 36.0 (5.1) 0.001 
Corrected calcium 2.36 (0.2) 2.38 (0.2) 0.654 
Phosphate 1.75 (0.5) 1.75 (0.6) 0.988 
Ca-P product 4.1 (1.1) 4.3 (1.5) 0.402 
PTH 20.0 (31.3) 20.0 (37.5) 0.876 
Cholesterol 5.4 (1.8) 5.1 (1.4) 0.262 
CRP 7.0 (11.0) 16.0 (34.0) 0.074 
 
Table 6.2 
Laboratory parameters for patients alive and dead at the end of the follow up period. Data 
are mean with standard deviation in parentheses except for parathyroid hormone and C - 
reactive protein where median and intra-quartile are shown. Tests of significance are t-test 
except for parathyroid hormone and C - reactive protein where Mann-Whitney is used 
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Not transplant 
listed 
Transplant 
listed but not 
transplanted 
Transplanted p value 
Number 78 (26.0) 142 (47.3) 80 (26.7)  
Male 49 (62.8) 84 (59.2) 58 (72.5) 0.137 
Age (years) 54.3 (11.3) 52.3 (10.0) 47.5 (11.1) <0.001 
10 Renal Disease      
 Diabetes 24 (30.8) 26 (18.3) 16 (20.0) 
 APKD 5 (6.4) 24 (16.9) 7 (8.8) 
 GN 13 (16.7) 26 (18.3) 16 (20.0) 
 CPN 6 (7.7) 14 (9.9) 7 (8.8) 
 Renovascular 4 (5.1) 7 (4.9) 5 (6.3) 
 Unknown/Other 26 (33.3) 45 (31.7) 29 (36.3) 
0.412 
RRT time (months) 12.0 (40.0) 10.0 (43.0) 24.0 (39.0) 0.739 
Diabetes 30 (38.5) 26 (18.3) 17 (21.3) 0.003 
Smoker      
 Never 38 (48.7) 81 (57.0) 34 (42.5) 
 Current 25 (32.1) 33 (23.2) 25 (31.3) 
 Ex 15 (19.2) 28 (19.7) 21 (26.3) 
0.250 
Previous IHD 20 (25.6) 25 (17.6) 11 (13.8) 0.144 
TIA/CVA 10 (12.8) 8 (5.6) 4 (5.0) 0.095 
PVD 12 (15.4) 3 (2.1) 2 (2.5)  
Table 6.3 Baseline demographic data for patients subdivided by the transplant status at the 
end of the follow up period. Data are number with percentage in parentheses or mean with standard 
deviation in parentheses except for RRT time where median and intra-quartile are shown. Tests of 
significance are Chi-square except for age and renal replacement therapy time where one way 
analysis of variance is used 
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Figure 6.1 (above) and 6.2 (below) Kaplan-Meier survival curves of patients stratified by 
the presence of ischaemic heart disease and transplant status respectively 
  
p=0.001 
p<0.001 
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6.3.4 Uraemic cardiomyopathy as assessed by CMR and outcome 
In the entire cohort of patients there were no significant differences in cardiac dimensions 
or ejection fraction between patients who died and survivors (Table 6.4). There was 
however a trend towards poorer survival in patients with systolic dysfunction compared to 
those with isolated LVH (Figure 6.3). In those patients undergoing contrast enhanced 
CMR, a significantly greater number of patients who died displayed evidence of 
myocardial fibrosis indicated by LGE, in particular subendocardial LGE demonstrating 
previous myocardial infarction (Figure 6.4).  
 
6.3.5 Resting and exercise electrocardiogram and outcome 
263 patients had a resting 12-lead ECG taken at the time of assessment available for 
analysis. Of these 143 (54.4%) were normal.  82 (31.2%) showed LVH by Sokolow-Lyon 
criteria. A total of 79 (30.0%) showing ischaemic changes (either ST abnormalities or the 
presence of Q-waves) of which 39 (14.8%) showed LVH with additional ischaemic 
changes (‘LVH plus strain’). Patients who died during the follow up period demonstrated a 
significantly greater prevalence of presence of ischaemic changes on the ECG (Figure 6.5). 
The presences of LVH or LVH plus strain in isolation were not associated with poorer 
survival (Table 6.5).  
 
212 (70.7%) patients were able to attempt a Bruce protocol exercise tolerance test (Table 
6.5). Survival was significantly poorer in those patients unable to exercise. Of those 
patients who could exercise, the presence of electrocardiographic changes at exercise 
testing was not predictive of long term outcome. However, exercise time was a predictor of 
outcome, with lower median exercise times for patients who died during follow up and with 
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those patients unable to exercise for 6 minutes (as an arbitrary but clinically pragmatic cut 
point) having a greater mortality (Figure 6.6).  
 
6.3.6 Coronary angiography and outcome 
96 (32.0%) patients underwent coronary angiography as selected by an independent 
cardiologist. Overall survival in patients who underwent angiography was no different 
compared to those who did not have this investigation performed (p=0.633). A greater 
burden of coronary artery disease at angiography was associated with poorer outcome, with 
those patients with a total atheromatous plaque burden greater than 74 (equating to one 
coronary artery stenosis >74% or an accumulation of lesser plaque disease) having 
significantly poorer survival (Figure 6.7). 
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 Alive Dead p value 
 240 (80.0) 60 (20.0)  
LV ejection fraction (%) 66.5 (11.7) 65.0 (13.5) 0.378 
LV mass (g) 175.1 (64.9) 184.3 (64.4) 0.328 
End diastolic volume (ml) 141.2 (58.8) 142.0 (62.7) 0.930 
End systolic volume (ml) 50.4 (37.9) 54.4 (44.7) 0.479 
LV mass/BSA (g m-2) 94.7 (31.8) 100.0 (31.2) 0.259 
End diastolic volume/BSA (ml m-2) 75.7 (29.4) 77.1 (32.7) 0.765 
End systolic volume/BSA(ml m-2) 27.3 (20.6) 29.0 (23.6) 0.605 
LGE given 168 (82.8) 35 (17.2) 0.804 
LGE positive 45 (26.8) 16 (45.7) 0.026 
Subendocardial LGE 23 (13.7) 11 (31.4) 0.008 
Diffuse LGE 21 (12.5) 5 (14.3) 0.540 
 
Table 6.4  
Left ventricular dimensions in patients who died and those who were still alive at the end of 
the follow up period. Data are expressed as mean with standard deviation in parentheses for 
cardiac dimensions and number with percentage in for LGE results. Tests of significance 
are t-test and Chi-square/Fisher’s exact test as appropriate 
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Figure 6.3 (above) and 6.4 (below) Kaplan-Meier survival curves of patients stratified by 
the presence of left ventricular abnormalities and presence and subtype of LGE respectively
    
p=0.216 
p=0.024 
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6.3.7 Independent predictors of survival in all patients 
In the Cox multivariate model based on factors identified during the earlier analyses; age, 
previous ischaemic heart disease, receiving a renal transplant and ability to attempt an 
exercise tolerance test were identified as independent predictors of mortality (Table 6.6). 
As there may be an inherent degree of bias in patient selection to receive a renal transplant 
(e.g. patients on the transplant list were younger than those not listed), the analysis was 
performed again leaving this factor out of the model. The results were no different with 
age, previous ischaemic heart disease, and ability to attempt an exercise tolerance test 
identified as independent predictors of mortality in this model. When a similar model was 
used in patients who underwent contrast enhanced CMR, the presence of LGE was not a 
predictor of patient survival independent of other variables (Table 6.7). When only patients 
studied with contrast enhanced CMR age were analysed, age, diabetes, and ability to 
attempt an exercise tolerance test were independent predictors of mortality. 
 
6.3.8 Independent predictors of patients listed for renal transplantation 
As identifying patients at high risk of mortality on the renal transplant waiting list or early 
post renal transplantation may optimise both patient selection and post transplant outcomes, 
a similar Cox multivariate model was performed on the cohort of patients on the renal 
transplant list (Table 6.8).  In these patients predictors of mortality were age, history of 
ischaemic heart disease and female gender. When a similar model was used in patients on 
the transplant list who underwent contrast enhanced CMR, the presence of LGE was not a 
predictor of patient survival independent of other variables. 
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 Alive Dead p value 
Normal ECG 120 (56.6) 23 (45.1) 0.139 
LVH 66 (31.1) 16 (31.4) 0.973 
LVH plus strain 30 (14.2) 9 (17.6) 0.528 
ST changes 50 (23.6) 19 (37.3) 0.046 
Q waves 16 (7.5) 7 (13.7) 0.161 
Any ischaemic changes 57 (26.9) 22 (43.1) 0.023 
Performed exercise tolerance test 178 (74.2) 31 (51.7) 0.001 
ECG changes 30 (16.6) 7 (22.6) 0.416 
Median exercise time (minutes) 7.0 (3.25) 5.0 (4.0) <0.001 
 
Table 6.5  
Electrocardiographic data for patients who died and those who were still alive at the end of 
the follow up period.  Data are number with percentage in parentheses except for exercise 
time where median and intra-quartile are shown. Tests of significance are Chi-square 
except for exercise time where Mann-Whitney-U is used 
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Figure 6.5 (above) and 6.6 (below) 
Kaplan-Meier survival curves of patients stratified by the presence of an ischaemic ECG 
and ability to perform an exercise tolerance test 
 
p=0.014 
p<0.001 
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Figure 6.7 
Kaplan-Meier survival curves of patients stratified by coronary angiography status 
p=0.011 
  
  
214 
 
 
 
Table 6.6 
Results of the Cox regression survival analysis for all patients 
 Patient survival 
 Univariate analysis Multivariate analysis 
Variable HR (95.0% CI ) p HR (95.0% CI) p 
Age 1.064 (1.025, 1.104) 0.001 1.063 (1.025, 1.102) 0.001 
IHD 2.786 (1.333, 5.824) 0.006 2.828 (1.488, 5.374) 0.002 
Transplanted 0.339 (0.145, 0.790) 0.012 0.361 (0.157, 0.830) 0.016 
Able to attempt ETT 0.550 (0.278, 1.087) 0.085 0.510 (0.273, 0.954) 0.035 
Haemoglobin 0.882 (0.751, 1.035) 0.123     
Diabetes 1.800 (0.834, 3.882) 0.134     
SBP 0.989 (0.975, 1.004) 0.158     
Gender (ref female)  0.629 (0.308, 1.282) 0.201     
Ischaemic ECG 1.566 (0.769, 3.189) 0.217     
RRT time (months) 0.995 (0.987, 1.004) 0.263     
LVMI 1.006 (0.994, 1.017) 0.354     
Ejection fraction 1.012 (0.987, 1.037) 0.365     
Ever smoked 1.321 (0.667, 2.616) 0.425     
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Table 6.7 
Results of the Cox regression survival analysis for patients who underwent contrast 
enhanced CMR 
 Patient survival 
 Univariate analysis Multivariate analysis 
Variable HR (95.0% CI ) p HR (95.0% CI) p 
Diabetes 3.386 (1.162 9.866 0.025 2.777 (1.095, 7.044) 0.032 
Age 1.051 (0.993, 1.112) 0.083 1.057 (1.004, 1.113) 0.036 
Ischaemic ECG 2.095 (0.784, 5.594) 0.140 2.486 (1.063, 5.814) 0.036 
SBP 0.982 (0.961, 1.004) 0.108     
Transplanted 0.406 (0.117, 1.403) 0.154     
Gender (ref female) 0.447 (0.147, 1.361) 0.156     
Able to attempt ETT 0.534 (0.199, 1.435) 0.214     
Ever smoked 1.741 (0.680, 4.460) 0.248     
Presence of LGE 1.744 (0.554, 5.497) 0.342     
Ejection fraction 1.024 (0.971, 1.080) 0.373     
IHD 1.870 (0.428, 8.168) 0.405     
RRT time 0.997 (0.987, 1.007) 0.509     
LVMI 1.007 (0.985, 1.029) 0.541     
Haemoglobin 0.981 (0.779, 1.237) 0.874     
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Table 6.8 
Results of the Cox regression survival analysis for patients on the renal transplant list 
 Patient survival 
 Univariate analysis Multivariate analysis 
Variable HR (95.0% CI ) p HR         (95.0% CI) p 
Age 1.114 (1.055, 1.177) 0.000 1.111 (1.056, 1.168) <0.001 
IHD 5.597 (1.953, 16.036) 0.001 6.154 (2.616, 14.476) <0.001 
Gender (ref female) 0.273 (0.102, 0.729) 0.010 0.301 (0.131, 0.692) 0.005 
Transplanted 0.314 (0.107, 0.922) 0.035     
Haemoglobin 0.836 (0.668, 1.046) 0.117     
Diabetes 2.605 (0.751, 9.030) 0.131     
Able to attempt ETT 0.513 (0.204, 1.286) 0.154     
Ejection fraction 0.975 (0.934, 1.018) 0.245     
Ever smoked 1.659 (0.667, 4.127) 0.277     
Ischaemic ECG 1.426 (0.470, 4.321) 0.531     
RRT time 0.998 (0.985, 1.010) 0.701     
LVMI 0.997 (0.978, 1.018) 0.804     
SBP 0.998 (0.976, 1.021) 0.869     
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6.4 DISCUSSION 
 
6.4.1 Predictors of survival in a cohort of patients screened for renal transplantation 
In this cohort of all patients undergoing cardiovascular screening as part of assessment for 
renal transplantation, the independent predictors of patient survival were younger age, 
absence of ischaemic heart disease, receipt of a renal transplant and ability to attempt an 
exercise tolerance test. Similarly in patients on the transplant list, age, ischaemic heart 
disease and female gender were predictors of mortality. The original hypothesis that factors 
consistent with uraemic cardiomyopathy would be associated with adverse outcome was 
not confirmed as patients who died had neither significantly greater LVMI nor lower 
LVEF. However, with contrast enhanced CMR, the presence of LGE, in particular 
subendocardial LGE, indicating myocardial fibrosis, was associated with adverse outcome. 
Cardiovascular risk factors either associated with, or indicating the presence of ischaemic 
heart disease, such as ischaemic changes on the ECG or diabetes were also associated with 
mortality.  
 
Although the presence of LGE at contrast enhanced CMR conferred a worse prognosis, this 
finding was not independent of other variables. It is not clear if the lack of independent 
prognostic information provided by CMR is due to lack of statistical power, with fewer 
patients studied with this method or due to the close association between the findings at 
contrast enhanced CMR and cardiovascular risk factors leading to a lack of any 
independent association. Nonetheless, the follow up data support the notion that CMR may 
identify those patients at greater risk of premature death. Other studies have looked at the 
prognostic value of LGE in different patient groups at high cardiovascular risk: 
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• In a CMR study of 101 patients with idiopathic dilated cardiomyopathy the 
presence of midwall myocardial fibrosis indicated by LGE was demonstrated by 
multivariate analysis to be the sole significant predictor of death or 
hospitalisation(190) 
• A study of 195 patients with classical ischaemic heart disease but with not 
documented previous myocardial infarction the presence of LGE provided further 
prognostic value for major adverse cardiac events and cardiac mortality beyond 
common clinical, angiographic, and functional predictors(258) 
 
Both these studies have shown that in other patient groups at high risk of cardiovascular 
disease LGE identifies patients at elevated risk of major adverse cardiac events, 
hospitalisation or death. As patients with ESRD are at least as high risk as these patient 
groups it seems plausible that contrast enhanced CMR may provide further useful 
information of long term outcome in patients which may yet inform either transplant 
workup, or the decision to proceed to invasive investigations.   
 
6.4.2 The resting and exercise ECG and outcome in potential renal transplant 
candidates 
Although many of these findings demonstrating the relationship with cardiovascular risk 
factors and outcome in patients screened for renal transplantation have been reported 
previously(207;259); the finding that objective assessment of functional capacity with the  
Bruce protocol exercise tolerance test predicts outcome is novel. This simple, widely 
available test has been used to risk stratify patients with suspected or confirmed ischaemic 
heart disease for many years. Conventional logic suggests that this test is unlikely to be 
useful in cohorts of patients with renal failure due the high prevalence of ECG 
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abnormalities and the lower functional capacity due to issues such as fluid status, 
arthropathy associated with renal bone disease and peripheral vascular disease. As a tool for 
indicating which patients have underlying severe coronary artery disease, the exercise ECG 
is unlikely to be a useful tool and perhaps paradoxically the resting ECG has been 
demonstrated to a better predictor of the presence of coronary artery disease(49). However, 
this study has shown that the exercise test is an excellent test to assess functional capacity, 
irrespective of the presence of ECG changes. Furthermore the American College of 
Cardiology/American Heart Association (ACC/AHA) guidelines for perioperative 
cardiovascular evaluation for noncardiac surgery suggest that functional assessment in 
metabolic equivalent (MET) levels should form part of evaluation for surgery(255). Stage 1 
of the exercise test is equivalent to 4.8 MET and therefore is a reassuring finding prior to 
non/semi-urgent surgery such as renal transplantation. 
 
6.4.3 Guidelines for screening for cardiovascular disease in potential renal 
transplant recipients 
Various guidelines for screening for cardiovascular disease in potential renal transplant 
recipients have been generated under the auspices of organisations such as the American 
Society of Transplantation and the European Renal Association(192;256). Interestingly, at 
the time of writing the previous draft guidelines from the British Transplant Society have 
been withdrawn for revision and the draft Australian guidelines (Caring for Australians 
with Renal Impairment) have been withdrawn and not replaced. Further British guidelines 
may appear from the Renal Association at some point. It is recognised that cardiovascular 
disease is the leading cause of death after renal transplantation. However in Western 
populations cardiovascular disease is often the leading cause of death in the general 
population as well as in the dialysis population. Therefore, the focus should be on reducing 
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the risk of post transplant cardiovascular disease, and in particular perioperative and early 
post transplant death. Hence the reasons for screening potential renal transplant recipients 
for cardiovascular disease are threefold. First, identifying transplant candidates with 
ischaemic heart disease allows patients and clinicians to better understand the risk of 
transplantation. Second, it would be hoped that pre-transplant revascularisation that may 
reduce the risk of transplantation.  Finally intensive risk factor modification may lead to 
better patient and graft outcomes(37). 
 
The most detailed guidelines from the American Society of Transplantation suggest the 
following strategy. First, assess ischaemic heart disease risk factors: a prior history of IHD, 
men ≥45 or women ≥55 years, (IHD in a first degree relative, current cigarette smoking, 
diabetes, hypertension, hypercholesterolaemic and left ventricular hypertrophy). Next 
aggressive risk factor modification should be pursued. Patients at high risk, diabetic 
nephropathy, prior history of IHD, or ≥2 risk factors, should have a cardiac stress test and 
those with a positive cardiac stress test should undergo coronary angiography for possible 
revascularisation prior to transplantation(192). The current European Renal Association 
guidelines are less detailed but suggest that as cardiovascular disease is the main cause of 
mortality after transplantation careful evaluation is mandatory to detect and treat 
symptomatic coronary disease, valve disease, cardiomyopathy and pericardial disease(256). 
The ACC/AHA guidelines for perioperative cardiovascular evaluation for noncardiac 
surgery are broadly similar suggesting that the risk of the surgical procedure, risk factor 
assessment, functional capacity and non invasive testing should guide patient selection for 
coronary angiography(255).   
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The dilemma exists in patients with ESRD that the evidence for cardiovascular risk factor 
reduction with statins or with blood pressure management is not present. Many of the 
cardiac risk factors have accumulated over a long period of renal insufficiency and are 
potentially irreversible (such as LVH, family history and diabetes). Most of these 
recommendations for assessment are based on observational studies either with 
radionuclide myocardial perfusion imaging or stress echocardiography rather than on any 
specific intervention.  
 
Reviewing the studies of perfusion imaging, a meta analysis by Rabbat et al of the 12 
studies using myocardial perfusion scanning in potential renal transplant recipients 
concluded that both reversible and fixed perfusion defects were associated with a 
significantly increased risk of cardiac death and myocardial infarction(260). As there was 
no difference between fixed and reversible defects, it is difficult to know whether these 
studies identify patients who would have benefited from coronary revascularisation. 
However, a negative scan is reassuring. Similarly, in a comparative study between 
myocardial scintigraphy (SPECT), dobutamine stress echocardiography, and coronary 
angiography in 126 renal transplant candidates showed a sensitivity and negative predictive 
value of <75% for the presence of coronary disease suggesting that whilst these scans may 
well carry prognostic information they are of limited value at guiding the need for coronary 
angiography(261). 
 
6.4.4 Coronary angiography, ischaemic heart disease and renal transplantation 
In the current study, survival was not significantly different between those patients 
undergoing angiography and those who did not. However patients with a greater burden of 
coronary atheroma, fared significantly worse over the follow up period. The implication is 
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that irrespective of the original indication for performing angiography, the degree of 
coronary atherosclerosis predicts outcome. In this cohort of 96 patients undergoing 
angiography, very few went on to have coronary revascularisation (eight undergoing 
percutaneous intervention and two undergoing coronary artery bypass grafting).The reasons 
for this are unclear but may reflect perceived high procedure risk, absence of symptoms 
leading to reluctance to perform revascularisation, or the technical challenge of performing 
revascularisation in ESRD where the vessels are typically heavily calcified. With such a 
small cohort it is not possible to analyse any impact coronary revascularisation has on 
survival. 
 
There are few studies to inform the decision to revascularise asymptomatic patients prior to 
major surgery. One large study, the Coronary Artery Revascularisation Prophylaxis 
(CARP) trial, assessed the long-term benefit of preoperative coronary-artery 
revascularisation among 510 patients with stable coronary artery disease scheduled for 
elective vascular surgery (aneurysm repair or peripheral vascular surgery(262). At 30 days 
after the vascular operation, a postoperative myocardial infarction, defined by elevated 
troponin levels, occurred in 12 percent of the revascularisation group and 14 percent of the 
no-revascularisation group (p=0.37) indicating no significant difference between the 
groups, suggesting that in patients on optimal medical management, a strategy of coronary-
artery revascularisation before elective vascular surgery among patients with stable cardiac 
symptoms cannot be recommended. These patients did not have significant renal 
impairment with only one patient in each group requiring post operative dialysis therapy.  
 
In patients with ESRD assessed for transplantation undergoing coronary revascularisation, 
only one study exists of 26 asymptomatic diabetic patients who were found to have 
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stenoses of greater than 75%(263). Patients randomised to revascularisation (either 
percutaneous intervention or bypass grafting) prior to transplantation had fewer post 
transplant cardiovascular disease events than patients managed with medical therapy. 
However this study could be criticised as patients in the medical treatment arm received 
short acting nifedipine, which has been suggested to cause an increase in ischaemic heart 
disease events, where current optimal medical management would include a beta-blocker. 
The small sample size makes it possible that the observed differences were due to chance 
and additionally as this study was only performed in diabetics it is not clear whether the 
findings can be extrapolated to non diabetic patients.  
 
A more practical strategy may be to use perioperative beta blockade which has been shown 
in retrospective analysis of larger United States patient databases to be associated with 
lower risk of perioperative death in patients at high (but not low) cardiac risk(264). This 
strategy has not been trialled in ESRD, but would appear to be a more pragmatic approach 
than undertaking a programme of coronary revascularisation, particularly where the 
evidence from the general population does not support such a course of action. 
 
6.4.5 Renal transplantation and survival compared to dialysis as treatment for end 
stage renal disease 
Until fairly recently it was difficult to be certain whether renal transplantation offered a 
survival advantage compared to long term dialysis therapy. Inevitably selection bias exists 
between patients on the transplant list who tend to be younger, fitter and have less co 
morbidity, and those patients who are not transplant listed.   Wolfe et al studied outcome in 
228,552 patients on dialysis using data from the United States Renal Data System 1991-
1996. Only 46,164 patients were on the transplant list, of whom, 23,275 received a first 
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cadaveric renal transplant(265). Patients on the transplant list were younger and healthier 
than those who were not, but long-term mortality rate was 48 to 82 percent lower among 
transplant recipients than patients on the waiting list with relatively larger benefits among 
patients who were 20 to 39 years old, white patients, and younger patients with diabetes. 
Similar benefits were shown in a much smaller cohort of patients comparing wait listed 
patients to transplanted patients in Ontario, Canada(266). However it still remains unclear 
whether patients at greatly increased cardiovascular risk, at much higher perioperative 
mortality would still benefit from renal transplantation, which becomes a greater dilemma 
when one considers that the demand for cadaveric kidneys greatly outstrips supply.  
 
Oniscu et al studied patients listed for transplantation in Scotland and have suggested that 
even in elderly patients (>60 years old) transplantation offers significant survival advantage 
as a treatment for ESRD than dialysis(267). Again in this study, patients who were 
transplanted had significantly less co morbidity. In another United States Renal Data 
System analysis, Meier-Kriesche et al observed that rates of cardiovascular disease peaked 
in the first three months post operatively and thereafter continued to fall, whilst in wait 
listed patients the risk of cardiovascular events continued to rise inexorably, and hence the 
authors proposed that transplantation halts the progression of cardiovascular disease in 
ESRD(268). An attractive but implausible interpretation of this study would be to suggest 
that patients at the very highest risk of cardiovascular disease should be offered cadaveric 
kidneys as a priority, as long as they are prepared to accept the increased perioperative risk 
of death. One dilemma in patients with greater risk of cardiovascular disease is that they 
may require further cardiac investigations, which dependent on healthcare resources, may 
be time consuming. This may result on further time spent on the renal transplant waiting 
list (or delay access to the waiting list). The long term consequences of this may result in 
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poorer graft outcome post transplantation as it is well documented that increased waiting 
time on dialysis is a powerful predictor of poorer graft survival(269). 
 
6.4.5 Limitations of the current study of outcome in patients undergoing 
cardiovascular screening for renal transplantation 
As a single centre study, this analysis is too small to truly assess the impact of 
transplantation on patient survival. The very low revascularisation rate has made it 
impossible to contribute further to debate on impact of this intervention in potential renal 
transplant recipients. Furthermore, as not all patients had the same investigations, including 
angiography, it may be difficult to draw any more conclusions of the impact of these test 
results on outcome. The reason for this was primarily that it was felt to be unethical to 
submit all patients to invasive investigations as part of a study and so invasive 
investigations and interventions were only performed by a clinician blinded to the notion 
that long term patient outcomes were being studied. Finally as an end point, death was used 
in survival analysis rather than major adverse cardiac events such as hospitalisation, 
myocardial infarction (fatal and non-fatal), cardiac failure and cardiac death. The reason for 
this was that as patients were frequently followed up at another hospital, the investigator 
was unable to be certain regarding the cause of hospitalisation or diagnosis of a major 
adverse cardiac event. Defining myocardial infarction or cardiac failure are difficult in 
ESRD due to the high prevalence of ECG abnormalities, frequent rises in biomarkers of 
myocardial necrosis such as troponin in the absence of coronary artery occlusion and 
development of pulmonary oedema due to hypervolaemia rather that primary cardiac 
dysfunction.  
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6.4.6 Conclusions and further studies required in the role of cardiovascular 
assessment for renal transplantation 
There is a high mortality amongst patients screened as potential renal transplant recipients 
with 20% of patients dying over a median follow up period of 32.5 months. Patients who 
received a renal transplant had a better survival than those who did not, with the major 
predictors of death being the presence of, or risk factors for ischaemic heart disease. CMR 
with contrast indicated patients at greater risk of death, but not independent of other 
variables. Based on the results of these data, an appropriate strategy would be to attempt to 
reduce the risk of ischaemic heart disease a long time prior to the development of ESRD 
and the need for renal transplantation. Further study of reduction of perioperative risk in 
patients undergoing renal transplantation is required, examining whether coronary 
revascularisation has any benefits in this cohort of patients as well as investigation of 
optimal medical therapy for the potential renal transplant recipient.  
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Chapter 7 
 
 
A study of the diagnostic utility of brain natriuretic peptide in end stage renal disease 
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7.1  INTRODUCTION 
Brain natriuretic peptide (BNP) is a hormone synthesised and secreted primarily by the 
ventricles of the heart(270). Natriuretic peptides, specifically brain natriuretic peptide 
(BNP) are released from the heart in response to chamber distension and thus are increased 
in the presence of volume expansion and cardiac overload. Their physiological role is to 
cause vasodilatation and promote natriuresis to maintain volume homeostasis(271). 
Increasingly serum levels of BNP are used to both diagnose and manage cardiovascular 
disorders(272). However, the diagnostic role of serum BNP levels in patients with 
advanced renal dysfunction remains to be defined. Patients with ESRD have a high 
prevalence of left ventricular disorders, specifically LVH, which may reduce the diagnostic 
utility of BNP. In addition, ventricular stretch may be determined by intravascular volume 
status rather than by cardiac dysfunction.    
 
Nonetheless, since the prognosis of patients with end stage renal failure and co-existing 
heart failure is so poor, the availability of a further marker of cardiac “distress” may in 
future become a useful diagnostic tool and in due course may become a primary goal for 
titration and tailoring of therapy. Whilst population studies demonstrate that BNP is a 
useful test for targeted screening for LVSD in the general population(272), in the ESRD 
population echocardiographic studies have suggested that BNP correlates with LV 
dimensions, but appears to be more closely related to LV mass than cardiac 
dysfunction(273). Similarly, BNP may be a predictor of long term survival in these 
patients(274), but there are limited ‘real world’ studies of patients with ESRD and 
superimposed ischaemic heart disease and/or congestive heart failure.  
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The following studies were performed in order to determine the diagnostic accuracy of 
serum BNP in patients with ESRD for both the presence of LVH and LVSD. Additionally 
the relationship between serum BNP and long term survival was examined. 
 
7.2 METHODS 
 
7.2.1 CMR technique and analysis 
All patients were studied with the CMR technique described in detail in Chapter 2 (2.3.2).  
 
7.2.2 Measurement of serum brain natriuretic peptide levels 
Prior to CMR scanning 30ml of venous blood was drawn. 5ml of blood was added to a 
potassium-EDTA tube and centrifuged for 10 minutes at 3000 revolutions per minute prior 
to freezing at -200C. Samples were analysed in batches in the neuroendocrine laboratory 
(Dr Ian Morton, University of Glasgow). Serum BNP was measured using by a one step 
radioimmunoassay (ShionoRIA, Shinogi, Japan).   
 
7.2.3 Statistical methods 
Differences between groups of patients were analysed by Chi-squared or Fisher’s exact test 
(as appropriate) for categorical data and paired t-test and Mann–Whitney–U testing for 
parametric or nonparametric data. One way analysis of variance (ANOVA) was used for 
comparisons between more than two groups. As BNP demonstrated a skewed distribution 
log-transformation was performed. Correlations between cardiac dimensions, volume of 
myocardial fibrosis and BNP were assessed with Pearson and Spearman correlation co-
efficient as appropriate. Receiver operator characteristic (ROC) curves were plotted to 
assess diagnostic utility of serum BNP. BNP levels between patients who died or had a 
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vascular event during the follow up period were divided into tertiles and subjected to an 
unadjusted survival analysis by the Kaplan–Meier method. All analyses were performed 
using the SPSS 13.0 statistical software package (SPSS Inc., Chicago, IL., USA), except 
ROC curves which were performed with the MedCalc software package (MedCalc 8.1, 
MedCalc Software, Belgium).  
 
7.3 RESULTS 
 
7.3.1 Dialysis modality and serum BNP levels 
Blood sampling and CMR scanning was performed on 114 patients (60 haemodialysis, 37 
peritoneal dialysis and 17 pre-dialysis patients).  Serum log10BNP was significantly lower 
in pre-dialysis patients than in patients on haemodialysis (log10BNP in pre-dialysis patients 
1.70 vs. 2.28 in HD patients, p=0.004) but not peritoneal dialysis (1.70 vs. 1.77 in CAPD 
patients, p=0.717). Although the elevation in BNP levels in HD may reflect differences in 
LV dimensions (mean LVMI- HD 101.3g m-2, PD 80.4 g m-2, pre-dialysis 80.1 g m-2, 
p=0.005), to minimise any potential effect of renal excretory function on serum BNP levels, 
only results for patients established on renal replacement therapy were analysed. 
 
7.3.2 Baseline demographics and serum BNP levels 
Baseline demographics, LV dimensions and BNP levels are shown in Table 7.1. 
Significantly more male patients studied were on haemodialysis compared to peritoneal 
dialysis. Correspondingly patients on HD were significantly taller. A significantly greater 
proportion of patients with diabetes were on PD. Patients on PD had been receiving renal 
replacement therapy for a shorter duration. LV dimensions were significantly larger in 
patients on HD (LVMI 101.3 vs. 80.4 g m-2, p=0.001; end diastolic volume/BSA 85.0 vs. 
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66.6 p=0.003). Serum BNP and log10BNP levels were greater in patients on HD (mean 
log10BNP was 2.28 in HD patients vs. 1.77 in PD patients, p<0.001). 
 
7.3.3  Relationship between left ventricular dimensions and serum BNP levels 
Serum log10 BNP positively correlated with LVMI, end diastolic volume/BSA and end 
systolic volume/BSA.  Serum BNP negatively correlated with LVEF. Similar degrees of 
correlation were demonstrated in both patients receiving haemodialysis and peritoneal 
dialysis (Table 7.2). 
 
7.3.4 Serum BNP levels in patients with left ventricular hypertrophy and/or left 
ventricular systolic dysfunction 
Patients with LVH had significantly higher BNP levels than those without LVH (patients 
with LVH mean Log10BNP was 2.32 vs. 1.75 in patients without LVH, p<0.001) as did 
patients with LVSD (mean Log10BNP was 2.67 in patients with LVSD vs. 1.99 in patients 
without LVSD, p=0.001; Figure 7.1). The utility of BNP levels as a diagnostic test for LVH 
or LVSD was tested using area under receiver operator characteristic (ROC) curves. The 
area under the curve (AUC) for the diagnosis of LVH for the whole cohort population using 
BNP was 0.74 and 0.78 for a diagnosis of LVSD (Figure 7.2). Table 7.3 gives the 
sensitivity, specificity, and positive and negative predictive values for a BNP 
concentrations determined by optimum cut-point of the ROC for diagnoses of LVH and 
LVSD in the whole cohort, as well as patients subdivided by dialysis modality. The 
sensitivity of BNP as a test for LVH was 50.0% and specificity was 85.4% and for LVSD 
the sensitivity and specificity were 69.2% and 83.3% respectively. 
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7.3.5 Relationship between BNP and presence of late gadolinium enhancement 
From this cohort, 92 patients underwent contrast enhanced CMR with intravenous Gd-
DTPA-BMA underwent as described in Chapter 2. 30 (32.6%) patients had evidence of 
myocardial fibrosis indicated by LGE, of which 18 (19.6%) had subendocardial LGE 
representing old myocardial infarction and 12 (13.0%) had diffuse LGE. Patients with 
evidence of myocardial fibrosis indicated by LGE had higher serum BNP levels than LGE 
negative patients (LGE positive mean log10BNP 2.38 vs. 1.94 in LGE negative patients, 
p=0.003). Comparing subtypes of LGE, patients with subendocardial LGE had significantly 
higher BNP levels than LGE negative patients (subendocardial LGE log10BNP mean 2.54 
vs. 1.94 in LGE negative patients, p<0.001). There were no significant differences in BNP 
between patients with the two subtypes of LGE (subendocardial LGE mean log10BNP 2.54 
vs. 2.14 in diffuse LGE patients, p=0.158), nor were there significant differences between 
patients with diffuse LGE and LGE negative patients (Figure 7.3). 
 
Overall there was a significant correlation between serum BNP levels and the mass of 
myocardial fibrotic tissue indicated by LGE (R=0.38, p=0.041). Patients with 
subendocardial LGE demonstrated a significant correlation between serum BNP and mass 
of tissue indicated by LGE (R=0.50, p=0.034) shown in Figure 7.4, whilst in patients with 
diffuse LGE there was not a significant correlation between BNP and mass of myocardial 
fibrotic tissue (R=0.15, p=0.640). 
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 Haemodialysis Peritoneal Dialysis p value 
Number (%) 60  37   
Age 51.4 (11.3) 53.7 (11.0) 0.322 
Male (%) 46 (76.7) 19 (51.4) 0.010 
Height (m) 170.9 (9.4) 166.2 (9.7 0.024 
Weight (kg) 75.1 (16.9) 74.3 (13.8 0.817 
RRT time (months) 26.4 (84.4) 6.2 (11.1) <0.001 
Past history of IHD (%) 11 (18.3) 7 (18.9) 0.942 
Diabetes (%) 9 (15.0) (16) (43.2) 0.002 
Smoker (%)      
 Never 32 (53.3) 17 (45.9)  
 Current 18 (30.0) 13 (35.1) 0.226 
  Ex 10 (16.7) 7 (15.8)  
SBP (mmHg) 136.9 (27.3) 140.6 (22.8) 0.511 
DBP (mmHg) 81.8 (14.9) 82.5 (12.0) 0.814 
Ejection fraction (%) 66.6 (9.5) 66.5 (13.0) 0.978 
LV mass index (g m-2) 101.3 (32.5) 80.4 (20.6) 0.001 
End diastolic volume/BSA (ml m-2) 85.0 (31.0) 66.6 (20.6) 0.003 
End systolic volume/BSA (ml m-2) 29.6 (18.4) 22.7 (13.1) 0.052 
BNP 191.0 (750) 54.0 (91) <0.001 
Log10 BNP 2.28 (0.70) 1.77 (0.53) <0.001 
Table 7.1  
Background demographics for dialysis patients. Results are show as mean with standard 
deviation in parenthesis or number with percentage in parenthesis as appropriate except for 
RRT time and BNP which are displayed as median and inter quartile range. Tests of 
significance are t-test and Chi-squared between groups, except for RRT time and BNP 
where Mann-Whitney-U was used 
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 All patients Haemodialysis Peritoneal dialysis 
 
Spearman’s R p Spearman’s R p Spearman’s R p 
Ejection fraction -0.33 0.001 -0.33 0.011 -0.45 0.005 
LV mass 0.51 <0.001 0.47 <0.001 0.40 0.015 
End diastolic volume 0.51 <0.001 0.47 <0.001 0.40 0.013 
End systolic volume 0.52 <0.001 0.48 <0.001 0.54 0.001 
LV mass index 0.61 <0.001 0.58 <0.001 0.48 0.004 
End diastolic volume/BSA 0.58 <0.001 0.56 <0.001 0.43 0.011 
End systolic volume/BSA 0.56 <0.001 0.52 <0.001 0.58 <0.001 
 
Table 7.2 
Correlation co-efficients between ventricular dimensions and serum BNP 
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Figure 7.1 Box plots for Log10BNP in patients with and without LVH defined by CMR 
evidence (above) and LVSD (below) 
p<0.001
p=0.001
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Figure 7.2 Receiver operator characteristic curves BNP for the diagnosis of LVH 
(above) and LVSD (below)  
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 Best cut-off AUC for ROC curve p Sensitivity Specificity PPV NPV 
 pmol/L (95% CI)  % (95% CI)   
All patients        
LVH 196 0.74  (0.64-0.83) <0.001 50.0 (36.3-63.7) 85.4 (70.8-94.4) 82.4 55.6 
LVSD 397 0.78  (0.68-0.86) <0.001 69.2 (38.6-90.7) 83.3 (73.6-90.6) 39.1 94.6 
Haemodialysis        
LVH 196 0.73  (0.60-0.84) <0.001 61.5 (44.6-76.6) 76.2 (52.8-91.7) 82.8 51.6 
LVSD 1082 0.82  (0.70-0.91) 0.002 71.4 (29.3-95.5) 90.6 (79.3-96.8) 50.0 96.0 
Peritoneal dialysis        
LVH 54 0.71  (0.54-0.85) 0.017 70.6 (44.1-89.6) 75.0 (50.9-91.2) 70.6 75.0 
LVSD 114 0.87  (0.72-0.96) <0.001 83.3 (36.1-97.2) 87.1 (70.1-96.3) 55.6 96.4 
 
Table 7.3 
Areas under receiver-operator-characteristic curves for the use of BNP for the diagnosis of LVH and LVSD in the whole cohort, 
patients receiving haemodialysis and patients receiving peritoneal dialysis. Percent and 95% confidence intervals are shown for 
the threshold of best cut-point values. The best cut-point values are defined as those which maximise both sensitivity and 
specificity 
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Figure 7.3 
Box plots for Log10BNP in patients defined by subtype of LGE demonstrated by CMR  
p<0.001
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Figure 7.4  
Log transformed serum BNP level plotted against mass of subendocardial myocardial 
fibrosis indicated by LGE  
 
R=0.50 
p=0.034 
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7.3.6 Prognostic value of brain natriuretic peptide 
During the follow up period eleven patients died. The median follow up period was 838 
days (inter quartile range 385). There were no significant differences in BNP between 
survivors and patients who died during the follow up period (survivors mean log10BNP 
2.09 vs. 1.98 patients who died, p=0.626). The influences of the measures of BNP on 
survival are shown as Kaplan-Meier survival curves in Figures 7.5.  
 
During the follow up period there were an additional seven non-fatal cardiovascular 
events (five patients had a myocardial infarction; one patient underwent coronary 
revascularisation and one patient had a cerebrovascular event). Again there were no 
significant differences in serum BNP between than survivors who remained event-free 
and patients who had a non-fatal cardiovascular event (event-free patients mean 
log10BNP 2.06 vs. 2.46 in patients who had a cardiovascular event, p=0.074). 
 
Combining death with non-fatal cardiovascular events as a combined cardiovascular end 
point (total of 18 events), there were no significant differences in serum BNP between 
than survivors who remained event-free and patients who had a non-fatal cardiovascular 
event (mean log10BNP 2.06 vs. 2.17 in patients who died, p=0.562).  
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Figure 7.5 
Kaplan-Meier survival curves for all cause mortality with patients stratified by serum 
BNP tertile 
 
 
 
 
 
 
p=0.180 
242 
 
7.4 DISCUSSION 
 
7.4.1 Serum BNP in cardiovascular disorders in the general population and 
ESRD 
BNP was originally isolated from porcine brain, and is produced in small amounts by 
the glomerular epithelial cells(275). The past decade has seen a developing role for the 
use of natriuretic peptides (both BNP and atrial natriuretic peptide- ANP) to screen for 
left ventricular dysfunction in the general population(272;276). Additionally, it is likely 
that using serum BNP levels will become a routine tool to assess response to therapeutic 
interventions in patients with chronic heart failure (CHF)(277). To date the situation is 
less clear in patients with ESRD. The prognostic implications of left ventricular 
disorders in patients with ESRD are well established with LVH, left ventricular 
dilatation and LVSD being associated with worse survival(76;77). There is a pressing 
need for new diagnostic and prognostic tools to identify patients with ESRD at 
increased risk of premature cardiovascular events, specifically those with structural and 
functional abnormalities of the left ventricle, to facilitate appropriate and timely 
therapeutic intervention. However, in dialysis patients there is difficulty in defining 
ventricular chambers volumes which are dependant on hydration status and vary in the 
intra-dialytic period. Furthermore, the levels of circulating natriuretic peptides depend 
on renal function, due to renal metabolism and excretion(278). Thus natriuretic peptide 
levels may be increased by volume overload due to intravascular volume and reduced 
renal clearance in the absence of any cardiac dysfunction(279). The high incidence of 
ventricular disorders in the dialysis, compared to the general population, may further 
alter the diagnostic potential of BNP as a screening test. 
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7.4.2 Basic pathophysiology of mechanisms of production, action and excretion of 
brain natriuretic peptide 
BNP is a 32 amino acid polypeptide (molecular weight 3.5 kDa), with a plasma half life 
of approximately 22 minutes in healthy individuals(280). It is secreted mainly by 
cardiac ventricles and, to a small extent, by renal glomerular cells. Cardiac secretion is 
in response to ventricular volume expansion, pressure overload and increased wall 
tension. Thus, plasma BNP levels reflect the level of left ventricular overload and, in 
patients with CHF, BNP levels correlate with LV filling pressures, NYHA class and are 
inversely related to left ventricular ejection fraction, or exercise performance(281). BNP 
is synthesised as high molecular weight preproBNP in the ventricular myocardium, and 
enzymatically cleaved to proBNP in response to myocyte stretching. It is thereafter 
released as hormonally active BNP and inactive N-terminal-proBNP (NT-
proBNP)(282).  
 
Serum levels of both BNP and NT-proBNP are elevated in patients with CHF and tend 
to change in parallel. However, due to differences in molecular size and metabolism 
there is variation between the utility of BNP and NT-proBNP in the diagnosis of 
ventricular dysfunction or hydration status, specifically in patients with renal failure.  
BNP is eliminated from plasma primarily by neutral endopeptidase receptors and 
degraded. Although these enzymes are found in the kidney, glomerular filtration has 
only a minor role in elimination of BNP. NT-proBNP is a larger molecule (molecular 
weight 8.5kDa) and is not cleared significantly by the clearance receptor or neutral 
endopeptidases(283). It has been speculated that clearance of NT-proBNP is principally 
by renal excretion. These confounding factors may explain the direct correlation 
between renal function and serum NT-proBNP levels and therefore the limited utility of 
serum NT-proBNP in patients with CKD(284).  
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The physiological actions of BNP, and other natriuretic peptides, oppose the effects of 
over-activity of the renin angiotensin-aldosterone system, the sympathetic nervous 
system and endothelin-1. In the kidney, BNP inhibits sodium resorption, promoting 
natriuresis and increases glomerular filtration rate. The natriuretic peptides also relax 
vascular smooth muscle, causing both arterial and venous dilation, thereby reducing 
blood pressure and ventricular preload(271).  
 
Even in normal individuals there is considerable inter-individual variability in plasma 
BNP levels. This may contribute to susceptibility to volume overload and hypertension. 
From the Framingham dataset it appears that heritable factors may have a substantial 
role in determining plasma BNP levels, with a region suggestive of genetic linkage on 
chromosome 12p13(285). This finding provides insight into the mechanisms present in 
patients with normal ventricular dimensions and no obvious cause for a raised BNP. 
Moreover, due to its short half-life BNP production is dependent on continuing gene 
expression and translation.  
 
Several studies have investigated the impact of CKD on serum levels and metabolism of 
BNP. This issue is particularly vexed by the increasing prevalence of LVH in patients 
with progressive renal disease(78). Myocyte hypertrophy causes increased serum BNP 
even in the presence of normal renal function(286). As BNP can be found in relatively 
normal to high levels in the urine of patients with CKD, it can be assumed that BNP is 
cleared sufficiently by the endopeptidase system to ensure that it maintains some 
diagnostic utility in the presence of renal impairment(287).  
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7.4.3 Results of study of diagnostic properties of serum brain natriuretic peptide 
in end stage renal disease 
In this cohort of patients BNP correlated more closely with LVMI than any parameter 
indicating LV stretching (LV end diastolic or end systolic volume) or LV function, 
although there were also significant correlations between these factors and serum BNP 
levels. However, using ROC analysis serum BNP appeared to be a worthwhile 
diagnostic tool in the diagnosis of either LVH or LVSD.  In particular BNP had a high 
negative predictive value (94.6%) for excluding the diagnosis of LVSD. Conversely, 
when used as a diagnostic tool for LVH, the reverse was true, with serum BNP having a 
high positive predictive value for LVH but a much lower negative predictive value. 
Either way, when compared to LV dimensions it would appear that BNP may be a 
useful indicator of patients with LV abnormalities requiring further assessment of LV 
function (with either echocardiography or CMR). In patients who underwent contrast 
enhanced CMR, perhaps unsurprisingly; higher BNP levels appeared to indicate patients 
with previous myocardial infarction, in keeping with the findings of Chapter 4 
suggesting that LVSD in uraemia is almost inevitably linked to underlying coronary 
artery disease. In the small number of patients with myocardial infarction, BNP directly 
correlated with the mass of infarcted tissue. Whether this indicates that BNP is 
produced primarily by infarcted tissue or as a secondary response to the presence of 
infarction is unclear from this study. Laboratory studies of cultured cardiac fibroblasts 
suggest that BNP is likely to be produced in response to, and to counteract the 
production of myocardial fibrosis(288). 
 
 BNP was higher in patients on haemodialysis than peritoneal dialysis. Whilst this is 
likely to be related to greater LV mass, some studies have suggested that the presence of 
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an arteriovenous fistula as vascular access for haemodialysis may additionally lead to 
raised natriuretic peptide levels by increasing cardiac output(112). 
 
7.4.4 Diagnostic properties of brain natriuretic peptide in the general population 
One of the most promising uses of serum BNP is in the assessment of left ventricular 
dysfunction. Population based studies have shown that it may be an effective tool for 
screening for asymptomatic left ventricular dysfunction. By identifying patients with 
asymptomatic left ventricular dysfunction it is likely that evolution to clinical heart 
failure will be prevented by instigating evidence based therapy with angiotensin 
converting enzyme (ACE) inhibitors and beta-blockers. Examples of studies using BNP 
to screen or diagnose echocardiographic LVSD or clinical heart failure are listed: 
• In one population based study the presence of a raised BNP concentration 
(greater than 5.2 pmol/L) gave an overall sensitivity of 77% and specificity of 
87% (92% and 72%, respectively, in participants aged 55 years or older) for the 
presence of echocardiographic LVSD. However, this population based study has 
either not reported renal dysfunction in the main analysis and subsequently 
found renal failure to be associated with the presence of a raised serum BNP (or 
NT-BNP) despite normal echocardiographic findings(272;289). 
• In patients with of acute dyspnoea presenting to hospital, the large “Breathing 
Not Properly” study found a raised BNP to be better than any clinical variable at 
predicting a final diagnosis of heart failure One of the most useful points to 
emerge from this study is that in this setting BNP appears to be an extremely 
useful tool for ruling out heart failure with a negative predictive value of 90% 
for a BNP threshold of 28.9 pmol/L with a sensitivity of 90% for a diagnosis of 
heart failure(290). It should be noted that patients with severe renal failure (GFR 
<15ml/min/1.73m2 or dialysis dependent) were excluded from this study 
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• In the BNP for Acute Shortness of Breath Evaluation (BASEL) study, a BNP 
based strategy for the initial assessment and management of patients with 
dyspnea can prevent hospitalisation, the need for intensive care and reduce 
length of hospital stay in patients presenting with acute dyspnoea. Furthermore, 
these improvements ensure that treatment of these patients is carried out in a 
cost effective manner(291) 
 
The obvious difference between these population based studies and the cohort of ESRD 
patients is that the diagnostic cut points for either LVSD or LVH is much greater in 
ESRD than in the general population (196 pmol/L for LVH and 397pmol/L for LVSD). 
This is in keeping with findings of a previous study from our group and is likely to 
reflect both the reduced clearance of BNP in ESRD and the greater prevalence of LVH 
in patients with ESRD. From these and other studies, it is apparent that serum BNP is a 
promising diagnostic tool for the diagnosis of left ventricular dysfunction in the general 
population, either used as a targeted screening measure in asymptomatic patients, as part 
of the diagnostic workup of patients presenting with acute dyspnoea or to monitor 
response to therapy. The current study suggests that BNP may be a useful tool in the 
ESRD population, although our previous findings suggest than the same diagnostic 
utility does not hold true across a spectrum of CKD(292). 
 
7.4.5 Diagnostic properties of BNP in end stage renal disease 
The high prevalence of LVH and LVSD in ESRD (compared to the general population) 
poses an additional problem that may limit the diagnostic screening potential of BNP, 
notwithstanding the additional problems of defining appropriate serum BNP levels in 
ESRD. Nevertheless, there have been some other promising studies that assess the 
diagnostic potential of BNP in dialysis patients: 
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• In an echocardiographic study combining both haemodialysis and peritoneal 
dialysis patients, a close correlation was found between serum BNP and LV 
mass. BNP had a high sensitivity (88%) for the diagnosis of LVH, with a 
positive predictive value of 87%. In the same study BNP was a less impressive 
marker for LVSD with a sensitivity of 94% but a specificity of only 22%(273) 
• It has been reported that BNP levels are lower in PD patients than in HD 
patients(293). Whether this is due to reduced cardiac stress in PD patients, as 
suggested by the authors, or due to a reduction in BNP related to improved 
residual renal function in PD patients is not addressed by this small study 
• Although BNP levels are generally higher in ESRD patients with LVSD, the 
relationship between BNP and LV ejection fraction does not appear to be as 
strong as its correlation with LV mass(273). In studies assessing the relationship 
between BNP and the presence of atherosclerotic coronary disease, it appears 
that HD patients with CAD have higher levels of serum BNP that those with 
normal coronary arteries(294). This supports the notion of a close association 
between LVSD and coronary artery disease in ESRD as demonstrated in Chapter 
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Many of these studies specifically excluded patients with a history of CHF, exposing 
limitations on these investigations into the relationship between serum BNP and 
severity of LVSD as the patients with most severe cardiac dysfunction have been 
excluded. This current study suggests that, while BNP shows potential as a marker of 
LVH and has been proposed to be a further therapeutic target to assess regression of 
LVH, it is unlikely that serum BNP will be able to replace echocardiography (or CMR) 
in the diagnosis of LVSD. Further study is required of a larger number of dialysis 
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patients to define BNP levels consistent with normal LV dimensions, LVH and LVSD 
taking into account hydration status, to improve the diagnostic utility of BNP. 
 
7.4.6 Prognostic role of serum brain natriuretic peptide in end stage renal disease 
Serum BNP was highest in the patients who were at highest cardiac risk, based on CMR 
findings and previous reports on the prognostic implications of uraemic 
cardiomyopathy. In this study however, BNP did not predict patients likely to die or 
have a cardiac event during the follow up period. Possible limitations of this study 
include the small cohort of patients, relatively short follow up period and limited 
number of events. On the basis of this study alone BNP does not provide useful 
prognostic information for the management of patients with ESRD. This finding 
conflicts with other similar studies in this ESRD population. As well as providing 
diagnostic value, a number of studies have shown the prognostic value of serum BNP in 
dialysis patients:  
• The CREED investigators have demonstrated that serum BNP appears to be an 
important predictor of mortality in a group of haemodialysis and peritoneal 
dialysis patients, independent of LV mass and LV function(274). This is an 
important finding given the interdependence of these factors already outlined 
• Other studies of shown that in patients on maintenance HD with no prior history 
of cardiac events, an elevated BNP is significantly associated with an increased 
risk of cardiovascular mortality. These studies however all had a relatively low 
number of events (13-16 events) and it of interest that despite fairly similar 
cohort size and follow up time, their results appear to conflict with the current 
study(295;296) 
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Therefore based on these and the current study it is clear that the role of serum BNP as a 
prognostic marker for patients on renal replacement therapy, needs to be defined in 
larger studies, specifically controlling for the presence of coronary artery disease, itself 
a major determinant of both LVSD and poor cardiovascular outcomes.  
 
7.4.7 Other potential roles for brain natriuretic levels in end stage renal disease 
BNP has been touted as a potential marker to assess hydration status in the dialysis 
patient. As natriuretic peptides are secreted in response to myocardial stretch, and are 
therefore increased in patients with hypervolaemia, and BNP measurement may guide 
assessment of ‘dry weight’ in the haemodialysis patient. From a physiological 
standpoint, atrial natriuretic peptide has been shown to increase in response to volume 
overload, and theoretically would appear to the most promising for assessment of 
volume status. A number of studies have tried to compare the use serum BNP to assess 
hydration status with measurement of extracellular water content by bioimpedance or 
inferior vena caval diameter(297;298).  Results of these studies have also been 
disappointing, with a lack of a correlation between BNP levels and pre- and  post-
dialysis hydration status, although pre-dialysis BNP appeared to a significant predictor 
of pre dialysis over hydration indicated by extra-cellular fluid/total body water ratio 
assessed by bioimpedance(298). Again difficulty exists in interpreting these studies if 
the confounding factor of increased LVM is taken into account.  
 
As BNP has been shown to predict survival in some studies in ESRD a role may 
develop for the use of BNP as a goal of treatment in interventional studies in ESRD. 
This approach has been used in patients with heart failure. One short study, using BNP 
levels to guide titration of ACE inhibitor dosage, showed a more favorable response in 
heart rate and other neurohumoral factors in patients whose therapy was titrated 
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specifically to reduce BNP levels(299). However, this possibility has yet to be tested in 
this population in large trials in either heart failure or the ESRD population. One small 
study has shown a significant reduction in BNP levels in 14 haemodialysis patients with 
LV dilatation in response to metoprolol therapy, with a corresponding improvement in 
ventricular dimensions(300). 
 
7.4.8 Effect of dialysis on serum BNP  
In considering the effect of haemodialysis therapy on serum BNP levels, there are two 
factors to take into account. Firstly, BNP has a half life in non-uraemic patients of 
approximately 22 minutes, and is cleared by endopeptidases. It is likely that 
ultrafiltration (during dialysis treatment) will lead to reduced ventricular stretch and 
reduced serum BNP levels, due to reduced production. Secondly, any clearance by the 
dialysis process itself must be taken into account.  However BNP is a relatively large 
molecule and there is conflicting evidence for this effect. In one study assessing the 
relationship between BNP and hydration status there was no significant difference 
observed in pre- and post-dialysis serum BNP(298). Other studies have shown BNP to 
be reduced by haemodialysis and it appears that dialytic clearance is of importance as in 
both these studies greater clearance of BNP is achieved with a high flux dialyzer. 
Moreover, whilst BNP is reduced by dialysis with both high and low flux dialysis 
membranes NT-BNP appears to only be significantly reduced by a high flux membrane. 
Crucially, in one of these studies dialysate BNP was measured and both BNP and NT-
BNP were found to be partially cleared by dialysis(301). These results are intriguing 
and it is clear that larger studies of this nature are required to assess thoroughly the 
impact of the dialysis process on serum BNP levels.  
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7.4.9 Conclusions 
Serum BNP has emerged as a rapid, convenient diagnostic tool for identifying and 
managing patients with heart failure.  In the ESRD population BNP appears to have a 
role in assessing LVH and complementing echocardiography or CMR in evaluating 
patients with symptoms or clinical signs of LV dysfunction. A raised BNP carries at 
least important diagnostic value and may provide further prognostic information 
(although not in this study). It may yet have a potential role as a target for intervention 
in the attempt to reduce cardiovascular disease in the ESRD population. It is likely that 
the role of BNP-targeted therapy requires better definition in the general population 
patients with heart failure (in which there is evolving evidence) prior to translating this 
to ESRD. A cut-off point in ESRD needs to be defined for which further assessment of 
ventricular function is required in patients with ESRD. Such cut-points have been 
demonstrated in this study and these now require prospective validation. This is 
particularly true in asymptomatic patients who may benefit from additional therapeutic 
interventions to prevent the evolution of either progressive LVH or LVSD which are 
associated with reduced survival.   
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Chapter 8 
 
 
A study of vascular function with cardiovascular magnetic resonance imaging in 
end stage renal disease 
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8.1 INTRODUCTION 
Arterial function is deranged in patients with ESRD. This is due to a combination of 
both accelerated arteriosclerosis and atherosclerosis. Epidemiological studies have 
shown that increased arterial stiffness, most commonly assessed by measurement of 
pulse wave velocity (PWV) or augmentation index, is independently associated with 
cardiovascular morbidity and mortality in these patients(302;303). However, although 
these studies are generally felt to be robust, using applanation tonometry as an indirect 
measure of central arterial function may be prone to limitations. Cardiac MRI permits 
visualisation of large arteries and blood flow. It thereby facilitates direct measurement 
of aortic compliance and aortic pulse wave velocity. Although blood flow and pulse 
wave velocity have been extensively studied with MRI in healthy volunteers, few 
studies have been performed using MRI to assess vascular function in any pathological 
disease state. 
 
CMR potentially offers an integrated method of assessing vascular as well as ventricular 
function during the same examination. Given the strong relationship between vascular 
stiffness and outcome in ESRD, CMR measures of vascular function may identify 
patients at increased cardiovascular risk. As patients with ESRD are at extremely high 
cardiovascular risk with an established link between altered arterial compliance and 
outcome, they represent an ideal patient population to validate this technique for 
translation for use in other patient groups at risk of cardiovascular disease.  
 
The following pilot studies were performed in order to: 
• develop methods for measuring vascular function using CMR 
• validate the relationship between CMR measures of vascular function, namely 
aortic distensibilty, aortic volumetric arterial strain(VAS) and PWV 
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• assess the relationship between CMR measures of vascular function and 
conventional cardiovascular risk factors 
• establish a cohort of patients to determine the long term prognostic implications 
of CMR measures of vascular function 
 
8.2 METHODS 
 
8.2.1 CMR measures of aortic distensibilty and pulse wave velocity 
All patients and volunteers underwent CMR imaging of both the left ventricle and 
thoracic aorta as described in detail in section 2.3.2. Gd-DTPA-BMA was administered 
to all patients bar exceptions as described as exceptions in section 3.4. Contrast was not 
administered to controls. Scan time to perform only the measures of vascular function 
was 12 minutes. 
 
8.2.2 Measurement of aortic distensibilty 
This was performed as described in detail in section 2.4.3. Briefly aortic distensibilty 
was calculated from change in aortic volume and simultaneous brachial blood pressure 
acquired during the scan using the formula: 
 
where (Aortic volume)max and (Aortic volume)min are the maximal and minimal 
calculated aortic volumes obtained during the cardiac cycle.  
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Aortic volumetric arterial strain (VAS), which is non-pressure dependent, was 
calculated from the formula: 
 
8.2.3 CMR measurement of pulse wave velocity 
PWV was measured as described in detail in section 2.4.3. Briefly, velocity was 
calculated from blood flow along the aorta at three points-  the ascending aorta at the 
level of the bifurcation of the pulmonary trunk, the transversely contiguous position of 
the descending aorta and the junction of the thoracic and abdominal aorta at the level of 
the diaphragm.  
 
PWV was calculated from the distance between these points and the time delay between 
propagation of the flow wave from each point using the equation: 
Pulse wave velocity = Distance/Time 
 
Pulse wave velocity was calculated over two distances- ascending aorta-diaphragmatic 
level aorta (PWV 1-3), and ascending aorta-contiguous descending thoracic aorta (PWV 
1-2). This was to account for cases where PWV from ascending aorta-diaphragmatic 
level aorta measurement was not possible due to the tortuous vessel preventing accurate 
aortic length and flow patterns being recorded.    
 
8.2.4 Applanation tonometry measurement of pulse wave velocity 
Healthy volunteers underwent measurement of PWV was using the SphygmoCor 
system (AtCor Medical, West Ryde, Australia) on the same day as CMR scanning by 
Dr Lukas Zimmerli (University of Glasgow). After 15 minutes of rest in the supine 
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position, pulse wave velocity measurements were performed by applanation tonometry. 
Aortic PWV was assessed by the time difference between pulse wave upstrokes, which 
were consecutively measured at the right carotid artery and right femoral artery and 
aligned by ECG-based trigger. 
 
8.2.5 Follow up 
Follow up data was collected from date of the CMR scan to 9th November 2006 using 
electronic patient records from the Western Infirmary, Glasgow and Glasgow Royal 
Infirmary Renal Units. With this cohort, death and cardiovascular events (myocardial 
infarction, cerebrovascular event, coronary revascularisation and amputation for 
peripheral vascular disease) were collected as end points. 
 
8.2.5 Statistical methods 
Correlations between cardiac dimensions, measures of arterial function and continuous 
clinical variables by the various methods were assessed with Pearson and Spearman 
correlation co-efficient as appropriate. Differences between groups were tested by t-test 
and Mann-Whitney-U test. Measures of vascular function were compared between 
patients who died or had a vascular event during the follow up period with these 
measures divided into tertiles or quartiles and subjected to an unadjusted survival 
analysis by the Kaplan–Meier method. Statistical significance was determined by the 
log-rank test. The data were then analysed by Cox survival analysis to assess the 
influence of multiple variables on outcome. Variables identified as possibly influential 
on outcome by univariate analysis were then entered into a forward stepwise regression 
model. All analyses were performed using the SPSS 13.0 statistical software package 
(SPSS Inc., Chicago, IL., USA) except comparison between SphygmoCor and CMR 
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measurement of PWV which was performed using Bland-Altman plots on the MedCalc 
8.1 software package (MedCalc Software, Belgium). 
 
8.3 RESULTS 
 
8.3.1 Patient and control demographics  
Patient demographics at the time of scan are shown in Table 5.1. 147 patients with 
advanced renal failure and 20 controls were studied. The groups of controls and uraemic 
patients had a similar age and sex distribution. A total of 144 patients had aortic VAS 
measurement and 122 patients had measurement of aortic distensibilty available for 
analysis. 22 patients did not have blood pressure readings to calculate distensibilty 
(either due to bilateral arteriovenous fistulae for dialysis making recording impossible, 
sphygmomanometer failure or due to blood pressure being recorded non-synchronously 
with the aortic distensibilty trace). The automated sphygmomanometer was broken for a 
portion of the study reducing the number of successful blood pressure recordings. 
Combined aortic compliance and PWV were available in 19 control subjects and 116 
patients. 28 PWV traces performed with CMR were not of sufficient technical quality 
for analysis either due to tortuous vessels, patient movement or failure of computer 
analysis of the trace.  
 
8.3.2 Measures of vascular function 
Demographic and vascular function data are shown in Table 8.1. No significant 
differences in patient demographics or vascular function were exhibited between 
patients with advanced renal failure not yet on dialysis therapy (24 patients, 16.3% of 
the uraemic group) and those established on renal replacement therapy (123 patients, 
83.7% of the uraemic group) and therefore these patients were combined as a single 
259 
 
‘uraemic’ group. Systolic and diastolic blood pressures were higher in uraemic patients 
than controls as expected.  
 
Cross sectional aortic volume (i.e. cross sectional aortic area multiplied by the slice 
thickness) was significant greater in uraemic patients. Aortic distensibilty and VAS 
were significantly lower in uraemic patients than controls (median distensibilty 2.4 x 10-
3 vs. 4.9 x 10-3 mmHg-1, p<0.001; VAS 0.13 vs. 0.19, p=0.001), whilst PWV 1-3 was 
non-significantly higher compared to controls (median 7.5 vs. 6.7 m s-1, p=0.069). PWV 
1-2 was numerically higher in uraemic patients compared to controls (median 7.1 vs. 
6.4 m s-1, p=0.620).  
 
8.3.3 Comparison between CMR and applanation tonometry for measurement of 
pulse wave velocity 
Combined measurement of PWV by applanation tonometry and CMR was performed in 
14 healthy volunteers.  Mean difference between the two measures was 0.2 m s-1.   The 
comparison between the two methods of measurement of PWV is shown as a Bland 
Altman plot (Figure 8.1). 
 
8.3.4 Haemodynamic relationship between pulse wave velocity, aortic 
distensibilty and volumetric arterial strain 
As both PWV and aortic distensibilty exhibited skewed distributions log transformation 
was performed. Pulse wave velocity displayed a significant negative correlation 
between aortic distensibilty (PWV 1-3 R= -0.48, p<0.001; PWV 1-2 R=  -0.37, 
p<0.001) and VAS (PWV 1-3 R= -0.47, p<0.001; PWV 1-2 0.38, p<0.001) in uraemic 
patients but not controls (aortic distensibilty-PWV 1-3, R= -0.35, p=0.139; VAS-PWV 
1-3, R= -0.38, p= 0.111). Overall Spearman correlation co-efficient for the whole group 
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(combined uraemic and control) for PWV1-3 was R= -0.49, p<0.001 for aortic 
distensibilty and R= -0.48, p<0.001 for aortic VAS (Figure 8.2).  
 
Assessing the relationship between central haemodynamics and aortic vessel 
characteristics, there was a significant correlation between cross sectional aortic volume 
and diastolic blood pressure in both uraemic patients (R = 0.242, p=0.007) and controls 
(R = 0.54, p=0.015), but not between aortic cross sectional area and either systolic 
blood pressure or pulse pressure. PWV correlated directly with both systolic (PWV 1-3 
R= 0.32, p=0.004, PWV 1-2 R= 0.28, p=0.006) and diastolic blood pressure (PWV 1-3 
R= 0.26, p=0.020, PWV 1-2 R= 0.33, p=0.001).  
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 Uraemic Control p value 
Number 147  20   
Age 51.5 (11.2) 49.6 (9.4) 0.469 
Male (%) 93 (63.3) 12 (60) 0.777 
Height (m) 169.6 (9.7) 170.7 (8.8) 0.640 
Weight (kg) 76.0 (16.0) 74.9 (10.3) 0.770 
On dialysis (%) 123 (83.7) -  - 
RRT time (months) 8.0 (55.6) -  - 
Past history of IHD (%) 24 (16.3) -  - 
Diabetes (%) 47 (32.0) -  - 
Smoker (%)      
 Never 85 (57.8) 13 (65.0)  
 Current 39 (26.5) 2 (10.0) 0.220 
  Ex 23 (15.6) 5 (25.0)  
SBP (mmHg) 139.7 (24.6) 116.4 (9.9) <0.001 
DBP (mmHg) 82.6 (13.0) 74.8 (7.4) 0.010 
Cross sectional aortic volume (mL) 5.0 (2.0) 3.5 (0.9) <0.001 
Aortic distensibilty (x 10-3 mmHg-1) 2.4 (2.0) 4.9 (2.9) <0.001 
Aortic volumetric arterial strain 0.13 (0.09) 0.19 (0.11) 0.001 
PWV 1-2 (m s-1) 7.1 (4.5) 6.4 (2.5) 0.620 
PWV 1-3 (m s-1) 7.5 (3.1) 6.7 (2.9) 0.069 
Table 8.1 
Background demographics for uraemic patients and controls. Results are show as mean 
with standard deviation in parenthesis or number with percentage in parenthesis as 
appropriate, except for RRT time and measures of vascular function which are 
displayed as median and inter quartile range. Tests of significance are t-test and Chi-
squared between groups, except for measures of vascular function where Mann-
Whitney-U was used 
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Figure 8.1 
Bland Altman plot comparing CMR and applanation tonometry (SphygmoCor) methods 
for measuring pulse wave velocity in healthy volunteers 
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8.3.5 Clinical correlates of aortic distensibilty and volumetric arterial strain 
Aortic distensibilty demonstrated a significant negative correlation with age in both 
uraemic patients (aortic distensibilty R= -0.44, p<0.001, VAS R= -0.44, p<0.001; 
Figure 8.3) and controls (aortic distensibilty R= -0.55, p=0.013, VAS R= -0.45, 
p=0.047).  
 
In uraemic patients there were no significant correlations between haemoglobin, dialysis 
adequacy (either urea reduction rate in haemodialysis or creatinine clearance in 
peritoneal dialysis), time on renal replacement therapy, any lipid parameter, C - reactive 
protein, calcium, phosphate or calcium phosphate product and aortic distensibilty or 
VAS. There were no significant differences in aortic distensibilty or compliance 
between genders. Aortic distensibilty and VAS were significantly reduced in patients 
with diabetes mellitus (diabetics – median aortic distensibilty 1.8 x 10-3  vs. non-
diabetics 2.8 x 10-3 mmHg-1, p=0.001; VAS 0.11 vs. 0.15, p=0.001), patients with a past 
history of ischaemic heart disease (median aortic distensibilty 1.8 x 10-3  vs. 2.6 x 10-3  
mmHg-1, p=0.028; VAS 0.11 vs. 0.15, p=0.009; Figure 8.4) or peripheral vascular 
disease (median aortic distensibilty 1.2 x 10-3 vs. 1.8 x 10-3 mmHg-1, p=0.005; VAS 
0.14 vs. 0.07, p=0.015).   
 
No significant differences in aortic distensibilty or VAS between patients treated with 
statin therapy, or those requiring antihypertensive therapy. There were no significant 
differences between aortic distensibilty between dialysis modalities nor was there any 
correlation between time on renal replacement therapy and aortic distensibilty or VAS.  
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Figure 8.2 Scatter plot of log transformed pulse wave velocity plotted against 
negative log transformed aortic distensibilty 
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Figure 8.3  Scatter plot of negative log transformed aortic distensibilty plotted 
against age for normal controls and uraemic patients 
R=0.49, p<0.001 
Uraemic R=0.44, p<0.001 
Normal   R=0.55, p<0.05 
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Figure 8.4  
Box and whisper plots of log transformed aortic distensibilty in patients with and 
without a past medical history of diabetes mellitus and ischaemic heart disease 
p=0.001 
p=0.028 
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8.3.6 Relationships between aortic distensibilty and left ventricular dimensions 
and late gadolinium enhancement 
Significant negative correlations were demonstrated between aortic distensibilty and 
LVMI (R= -0.21, p=0.021) and end systolic volume (R= -0.18, p=0.048) but no other 
LV dimension. Aortic VAS correlated with markers of cardiac function - ejection 
fraction (R= 0.23, p=0.006) and stroke volume (0.19, p=0.024). Of the 119 patients who 
had combined vascular function measures with Gd-DTPA-BMA contrast enhanced 
studies, 37 (31.1%) patients had evidence of myocardial fibrosis indicated by LGE as 
described in Chapter 3 of which 20 (14.6%) patients had subendocardial LGE 
representing previous myocardial infarction and 17 (12.4%) had diffuse LGE. Patients 
who were positive for LGE had lower aortic distensibilty and VAS than LGE negative 
patients (median aortic distensibilty 2.0 x 10-3 for LGE positive vs. 2.8 x 10-3 mmHg-1 
for LGE negative patients, p=0.027; VAS 0.11 vs. 0.14, p=0.056). Patients with 
subendocardial LGE representing previous myocardial infarction had significantly 
lower aortic distensibilty and VAS than patients who were LGE negative (median aortic 
distensibilty 1.6 vs. 2.2 x 10-3 mmHg-1 p=0.008; VAS 0.09 vs. 0.14, p=0.006). There 
were no significant differences in aortic distensibilty or VAS between patients with 
diffuse LGE and patients with subendocardial LGE. Additionally there were no 
significant differences between patients with diffuse LGE and LGE negative patients 
(Figure 8.5). 
 
In patients with subendocardial LGE, there was a significant negative correlation 
between aortic distensibilty and the absolute mass of fibrotic myocardial tissue 
represented by subendocardial LGE (R= -0.57, p=0.032). There was additionally a 
negative correlation between percentage of the LV mass occupied by fibrotic 
myocardium and aortic distensibilty (R= -0.54, p=0.047; Figure 8.6).  A significant 
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correlation between aortic distensibilty or VAS and mass of myocardial fibrosis was not 
present in patients with diffuse LGE. 
 
8.3.7 Clinical correlates of pulse wave velocity 
In uraemic patients, but not controls, increased PWV correlated significantly with age 
(PWV 1-3 R= 0.41, p<0.001, PWV 1-2 R= 0.34, p<0.001; Figure 8.7).  In uraemic 
patients there were no significant correlations between haemoglobin, dialysis adequacy 
(either urea reduction rate in haemodialysis or creatinine clearance in peritoneal 
dialysis), time on renal replacement therapy any lipid parameter, C - reactive protein, 
phosphate or calcium phosphate product and PWV. There was however a significant 
negative correlation between serum corrected calcium and PWV (PWV 1-3 R= -0.22, 
p=0.034) and with serum albumin (PWV 1-2 R= -0.25, p=0.007) There were no 
significant differences in PWV between genders.  
 
Although PWV was numerically higher in patients with diabetes, a past history of 
ischaemic heart disease of peripheral vascular disease compared to those patients 
without this conditions none of these differences were statistically significant. There 
were no significant relationships demonstrated between PWV and cardiac mass and 
function or between the presence or extent of myocardial fibrosis demonstrated by LGE. 
 
There were no differences in systolic or diastolic blood pressure at the time of scanning 
between patients not requiring antihypertensive therapy (n=68) and those treated with 
either calcium channel antagonist (n=29) or angiotensin converting enzyme 
inhibitor/angiotensin receptor blocker monotherapy (n=27) or a combination of these 
agents (n=19). However PWV was non-significantly higher in patients treated with 
calcium channel antagonist monotherapy compared to those treated with angiotensin 
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converting enzyme inhibitor/angiotensin receptor blocker monotherapy (calcium 
channel antagonist group - median PWV 1-2 7.1 m s-1 inter quartile range (IQR) 7.3 vs. 
angiotensin converting enzyme inhibitor/angiotensin receptor blocker group - median 
PWV 1-2 7.2 m s-1 IQR 2.9, p=0.067; Figure 8.8). 
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Figure 8.5  
Box and whisper plots of log transformed aortic distensibilty in patients divided by 
pattern of late gadolinium enhancement 
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Figure 8.6 Mass of subendocardial myocardial fibrosis indicated by LGE plotted 
against log transformed aortic distensibilty 
p= 0.006 
R = -0.57, p=0.032 
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Figure 8.7  Scatter plot of log transformed pulse wave velocity plotted against age for 
normal controls and uraemic patients 
ACE/ARB MonoRxACEi + ARB + CAACEi + CACA MonoRXNil
Antihypertensive  regime
1.40
1.20
1.00
0.80
0.60
0.40
Lo
g 
PW
V 
1-
2
 
Figure 8.8 Box and whisper plots of log transformed pulse wave velocity in patients 
divided by antihypertensive therapy. Abbreviations CA – calcium channel antagonist, MonoRx 
– monotherapy, ACEi - angiotensin converting enzyme inhibitor, ARB - angiotensin receptor 
blocker 
R= 0.41, p<0.001 
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8.3.8 Relationship between CMR measures of vascular function on survival and 
combined mortality and cardiovascular events 
Follow up data combined with vascular function measurements were available for 144 
patients. The median follow up period was 719 days (IQR 375 days). Over the follow 
up period there were 20 deaths, giving an overall mean death rate in this cohort of 76.2 
per 1000 patient years. Patients who died had significantly lower aortic distensibilty 
than those who where alive at the end of the follow up period. There were no significant 
differences in VAS or PWV between survivors and patients who died.  Analysing the 
effect of blood pressure at the time of the scan on survival demonstrated that patients 
who died had significantly higher systolic and pulse pressure than survivors, but there 
were no significant differences in diastolic blood pressure (Table 8.2). The influences of 
the measures of vascular function on survival are shown as Kaplan-Meier survival 
curves in Figures 8.9 and 8.10.  
 
During the follow up period there were an additional 12 non-fatal cardiovascular events 
(five patients had a myocardial infarction; four patients underwent coronary 
revascularisation, two patients undergoing amputation for peripheral vascular disease 
and one patient had a cerebrovascular event). These patients had significantly lower 
aortic distensibilty and VAS than survivors who remained event free. Pulse pressure in 
these patients was higher. There were no significant difference in blood pressure 
between than survivors who remained event free and patients who had a non-fatal 
cardiovascular event. 
 
Combining death with non fatal cardiovascular events as a combined cardiovascular end 
point, overall patients who reached this combined end point had significantly lower 
aortic distensibilty (median 1.7 x 10-3 vs. 2.7 x 10-3 mmHg-1, p<0.001) and VAS (0.12 
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vs. 0.14, p=0.006) and higher systolic blood pressure (mean 152.9 vs. 136.5 mmHg, 
p=0.001) and pulse pressure (mean 67.0 vs. 54.5 mmHg, p=0.001) than those who did 
not. The influences of the measures of vascular function on cardiovascular vents are 
shown as Kaplan-Meier survival curves in Figures 8.11 and 8.12. There were no 
significant differences in either diastolic blood pressure (mean 85.9 vs. 82.0 mmHg, p= 
0.154) or pulse wave velocity (median PWV 1-2 6.5 vs. 7.1 m s-1 p=0.387; median 
PWV 1-3 7.4 vs. 7.5 m s-1, p= 0.711) between those who reached the combined end 
point and those who did.   
 
8.3.9 Multivariate analysis of relationship between CMR measures of vascular 
function and survival 
In a Cox forward stepwise regression model assessing patient survival; diabetes, 
systolic blood pressure and aortic distensibilty were identified as significant 
independent predictors of patient survival. In a similar analysis assessing the combined 
cardiovascular end point of death or a vascular event; diabetes, aortic distensibilty and 
aortic VAS were significant predictors of events. Due to their close interdependence, 
blood pressure variables and aortic distensibilty were entered individually into the each 
model to determine their influence. Similarly either aortic distensibilty or VAS were 
entered individually to the model but not together.  
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 Alive Dead p value 
Number 124 (86.1) 20 (13.9)  
Age 51.5 (11.3) 51.9 (11.1) 0.876 
Male (%) 80 (64.5) 10 (50.0) 0.213 
On dialysis (%) 102 (82.3) 18 (18.0) 0.363 
RRT time (months) 3.9 (45.6) 18.4 (83.4) 0.018 
Past history of IHD (%) 19 (15.3) 5 (25.0) 0.281 
Diabetes (%) 34 (27.4) 12 (60.0) 0.004 
Smoker (%)      
 Never 73 (58.9) 10 (50.0)  
 Current 30 (24.2) 8 (40.0) 0.304 
  Ex 21 (16.9) 2 (10.0)  
SBP (mmHg) 137.3 (23.6) 156.3 (21.4) 0.001 
DBP (mmHg) 82.1 (12.9) 87.4 (11.7) 0.092 
PP (mmHg) 55.20 (17.1) 69.0 (17.1) 0.001 
Cross sectional aortic volume (mL) 5.0 (1.9) 5.1 (2.3) 0.634 
Aortic distensibilty (x 10-3 mmHg-1) 2.4 (2.0) 2.1 (2.1) 0.009 
Aortic volumetric arterial strain 0.12 (0.09) 0.15 (0.10) 0.176 
PWV 1-2 (m s-1) 7.1 (4.1) 6.5 (5.8) 0.807 
PWV 1-3 (m s-1) 7.6 (2.9) 7.3 (2.3) 0.330 
Table 8.2  
Demographic data for patients were alive and dead at the end of the follow up period for 
uraemic patients and controls. Results are show as mean with standard deviation in 
parenthesis or number with percentage in parenthesis as appropriate except for RRT 
time and measures of vascular function which are displayed as median and inter quartile 
range. Tests of significance are t-test and Chi-squared between groups, except for 
measures of vascular function where Mann-Whitney-U was used 
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Figures 8.9 and 8.10 Kaplan-Meier survival curves for all cause mortality with patients 
stratified by systolic blood pressure tertile and aortic distensibilty tertile  
p=0.186 
 
 
p=0.011 
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Figures 8.11 and 8.12  
Kaplan-Meier survival curves for survival to either CV end point or death with patients 
stratified by aortic VAS quartile and pulse wave velocity tertile 
 
 
 
 
p=0.005 
p=0.834 
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Table 8.3 
Cox survival analysis for patient survival. Because of their close correlation SBP aortic 
distensibilty and aortic VAS were entered separately into the model. Results for other 
variables are shown with systolic blood pressure in the model 
 Patient survival 
 Univariate analysis Multivariate analysis 
Variable HR         (95.0% CI ) p HR         (95.0% CI) p 
Diabetes 3.031 (1.036, 8.866) 0.043 4.214 (1.631, 10.886) 0.003 
SBP (mmHg) 1.015 (0.992, 1.038) 0.197 1.022 (1.000, 1.044) 0.049 
Log aortic distensibilty 0.072 (0.008, 0.694) 0.023 0.135 (0.019, 0.948) 0.044 
Log aortic VAS 0.107 (0.007, 1.732) 0.116     
Duration RRT (days) 1.000 (1.000, 1.000) 0.421     
Age (years) 1.015 (0.969, 1.063) 0.526     
Gender (ref male) 0.833 (0.312, 2.226) 0.716     
Haemoglobin (g/dL) 0.910 (0.670, 1.236) 0.547     
Albumin (g/L) 0.942 (0.839, 1.058) 0.311     
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Table 8.4 
Cox survival analysis for patient survival to either death or cardiovascular event. 
Because of their close correlation SBP aortic distensibilty and aortic VAS were entered 
separately into the model. Results for other variables are shown with systolic blood 
pressure in the model 
 Combined CV event and death survival 
 Univariate analysis Multivariate analysis 
Variable HR         (95.0% CI ) p HR         (95.0% CI) p 
Diabetes 2.989 (1.276 7.004) 0.012 2.409 (1.087 5.337) 0.030 
Log aortic distensibilty 0.052 (0.009 0.319) 0.001 0.066 (0.013 0.347) 0.001 
Log aortic VAS 0.021 (0.002 0.206) 0.001 0.026 (0.004 0.175) <0.001 
Duration RRT (days) 1.000 (1.000 1.000) 0.560     
SBP (mmHg) 1.014 (0.995 1.032) 0.142     
Age (years) 1.023 (0.984 1.062) 0.248     
Gender (ref male) 0.827 (0.368 1.860) 0.646     
Haemoglobin (g/dL) 0.958 (0.748 1.225) 0.731     
Albumin (g/L) 0.984 (0.896 1.080) 0.728     
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8.4 DISCUSSION 
 
8.4.1 Basic physiology of aortic function 
 The aorta as a large artery has two discrete functions. Firstly, as a conduit, it delivers 
blood and hence oxygen to the tissues. This role is expressed by mean blood pressure 
and blood flow. Disruption to this role, primarily by atherosclerosis, potentially results 
in distal ischaemia. Additionally, large arteries have a buffering function, to dampen 
pressure oscillations from intermittent cardiac pumping (the ‘Windkessel’ effect), 
therefore transforming the pulsatile blood flow into a steady stream as required by 
peripheral organs and tissue. Alterations in shear stress or tensile stress within the 
arterial wall lead to arterial remodelling, with blood pressure being the principal 
determinant of these stresses. The characteristics of arterial remodelling are dependant 
on the nature of the haemodynamic stimuli applied to the vessel. Chronic increase in 
arterial blood flow will result in subsequent increase in the vessel lumen whilst increase 
in tensile stress will lead to thickening of the arterial walls, in keeping with the law of 
Laplace, which states that transmural stress directly proportional to the transmural 
pressure and radius and inversely proportional to the arterial wall thickness(304).  
Atherosclerosis may further affect arterial remodelling due to alterations in blood flow 
patterns and shear stresses in the vessel wall as well as by direct endothelial injury. 
However this is likely to be of lesser importance in the thoracic aorta, as atherosclerosis 
occurs preferentially in the medium sized conduit vessels.     
 
8.4.2 Alterations of aortic function in ESRD 
The prime action of atherosclerosis is to disrupt the conduit function of the artery. 
Although patients with ESRD have many risk factors to promote the development of 
atherosclerosis (diabetes, hypertension, age, dyslipidaemia and smoking) and 
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endothelial function is clearly deranged in uraemia(305), it still remains unclear whether 
the nature of the interactions between the vascular endothelium and atherogenic plaque 
are different to the general population. In any case, these studies focus on the thoracic 
aorta, and whilst aortic plaque may be found in this region, as basal blood flow is 
unchanged until the lumen diameter is reduced by 50%, altered conduit function 
unlikely to be of prime importance as a pathological mechanism in the aorta(304).  
 
In ESRD the large arteries classically undergo remodelling characterised by dilatation 
and hypertrophy of the arterial intima-media. This remodelling is associated with 
stiffening and the dampening role of the vessel is affected(306). The consequence of 
this is primarily an increase in systolic and reduction in diastolic blood pressure 
resulting in higher pulse pressure. This is due to two mechanisms. Firstly a higher 
pressure wave is generated by the direct effect of the LV pumping blood into the stiff 
arterial tree. Additionally as vessel stiffness increases this is associated with a rise in the 
PWV over any given arterial segment, in keeping with the Moens-Korteweg equation.  
Thereafter this pressure wave (forward travelling) is reflected at any point of 
discontinuity in the arterial tree, generated an echo wave travelling backward toward the 
ascending aorta. The resultant sum of these incident and pressure waves is the measured 
pulse pressure wave and is dependant on their amplitude and timing.  In young healthy 
individuals this reflected wave occurs during diastole and is the associated increase in 
early diastolic pressure augments coronary perfusion. However in conditions where the 
dampening function of the arterial tree is reduced such as aging or uraemia, this 
beneficial mechanism is disturbed. As PWV increases the reflected waves occur earlier, 
and are more likely to occur during systole than diastole, ‘closer’ in phase with the 
incident wave(307). This therefore leads to an increase in aortic and LV pressure during 
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systole.  This increases cardiac work and the LV after load whilst additionally reducing 
coronary perfusion(308).  
 
Haemodynamic factors which promote arterial remodelling present in ESRD patients, 
although not specific to uraemia, include age and blood pressure. Factors specific to 
uraemia include hypervolaemia due to water and sodium retention, arteriovenous 
shunts, chronic volume and flow overload secondary to anaemia(306).  Arterial medial 
calcification is pronounced in patients in ESRD and is a key mediator of increased 
arterial stiffness(309). This occurs due to changes in the phenotype of vascular smooth 
muscle cells. Factors which may affect this in ESRD include altered calcium and 
phosphate metabolism, chronic inflammation and associated low levels of fetuin-A or 
osteprotegerin (inhibitors of arterial calcification), genetic factors or the presence 
unknown uraemic toxins up regulating expression of genes known to promote 
calcification in vascular smooth muscle cells(142;147;310;311). 
 
8.4.3 Relationship between aortic distensibilty, volumetric arterial strain and 
pulse wave velocity 
As different methods of measuring arterial stiffness aortic distensibilty, VAS and PWV 
were demonstrated to be significantly correlated with each other. Using CMR to 
measure aortic distensibilty or VAS visualises changes in the aortic cross sectional 
volume throughout the cardiac cycle. Therefore these measures are true representations 
of vascular function. This study therefore confirms that PWV (an indirect measure of 
arterial stiffness) and either aortic distensibilty or VAS (direct measures) are directly 
related. To an extent this represents validation of the technique for measurement of 
PWV.  
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8.4.4 Results of studies of aortic distensibilty 
These data represent the first report of using CMR to assess vascular function in 
uraemic patients. The uraemic patients had significantly increased aortic stiffness 
compared to age matched normal subjects, represented by reduced aortic distensibilty 
and VAS with associated vessel dilatation. In keeping with the relationship between 
increased arterial stiffening and advancing age, there was a significant relationship 
between reduced aortic distensibilty and VAS and increasing age, both in uraemic 
patients and in healthy controls. 
 
In the uraemic patients, aortic distensibilty and VAS were demonstrated to be reduced 
in patients at highest cardiovascular risk, i.e. those with diabetes and/or a past medical 
history of ischaemic heart disease or peripheral vascular disease. No other factors such 
as drug therapy, adequacy of dialysis, duration of renal replacement therapy, dialysis 
modality or any laboratory parameter appeared to be significantly associated with aortic 
distensibilty or VAS. Therefore overall increased aortic stiffness, as indicated by 
reduced aortic distensibilty or VAS, was demonstrated to be present in uraemic patients 
with the presence of classical cardiovascular risk factors. 
 
The relationship between these markers of aortic function and LV dimensions show a 
weak but significant relationship between increased aortic stiffness and increasing 
LVMI and end systolic volume, suggesting that reduced aortic distensibilty may 
promote LV afterload and hence cardiac hypertrophy. Aortic VAS, which is 
independent of blood pressure, correlated with markers of cardiac systolic function, 
namely ejection function and stroke volume, suggesting that in the failing heart where 
systolic blood pressure is lower, increased arterial stiffness remains deleterious to 
ventricular performance.  
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Finally in the small group of patients with subendocardial LGE indicating previous 
myocardial infarction, the relationship between volume of infarcted tissue and aortic 
distensibilty offers a direct demonstration of the interaction between increased arterial 
stiffness and reduced diastolic coronary artery perfusion(308) leading to increased area 
of infarction. This may be one explanation long term outcome post myocardial 
infarction is poor in patients with ESRD. 
 
8.4.5 Limitations of studies with aortic distensibilty and aortic volumetric 
arterial strain 
Calculation of aortic distensibilty is based on cross-sectional volume of the vessel wall 
and pulse pressure. For practical reasons, direct aortic blood pressure measurement has 
been substituted by non-invasive indirect brachial blood pressure measurement. 
Therefore it is difficult to dissociate any clinical effect associated with changes in aortic 
distensibilty from that due directly to pulse pressure, which is well described as an 
independent predictor of outcome in ESRD. Nonetheless, as it is otherwise impossible 
to truly assess aortic stiffness, without documentation of pressure within the vessel 
lumen, the approach used in this study has been used widely in other patient 
groups(312-314). For this reason the aortic VAS, the fractional increase in aortic 
volume during the cardiac cycle was also used. This does not depend on blood pressure 
variables and in this study appeared to display fairly similar relationships with clinical 
variables and outcome. There is however limited literature to support its use. 
Additionally, whilst this is the largest study to date using aortic distensibilty in any 
patient group, the number of patients in any subgroup, such as diabetes or with previous 
ischaemic heart disease was small, therefore limiting conclusions that can be drawn 
from this study.  
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Although it is highly likely that arterial calcification is the intricately involved as a 
pathomechanism for reduced aortic compliance, CMR is unable to display calcific 
lesions due to their absence of water (and hence proton) content. This compares 
relatively unfavourably with multi-slice computed tomography (CT), which has 
emerged as a tool for assessing cardiac calcification(144). However, multi-slice CT is 
not able to accurately distinguish between intimal and medial calcification and requires 
ionising radiation. Therefore, serial CT scans to test a therapeutic intervention is an 
unattractive option compared to using cardiac MRI as a surrogate measure of 
calcification.  
 
8.4.6 Results of studies of pulse wave velocity 
This represents one of the largest studies of pulse wave velocity with CMR in any 
pathological disease state. Previous, smaller studies have demonstrated the feasibility of 
measuring PWV in healthy volunteers using CMR(312;315;316). In this study, PWV 
was numerically higher in uraemic patients compared to age matched controls in 
keeping with findings of previous studies using alternative methods to measure pulse 
wave velocity(315). Additionally, PWV rose significantly with advancing age in both 
uraemic and control patients. In keeping with the findings for aortic distensibilty and 
VAS, PWV tended to be higher in patients at highest cardiovascular risk (patients with 
diabetes, ischaemic heart disease or peripheral vascular disease), although with PWV 
none of these differences reached statistical significance.  Like aortic distensibilty, 
generally there were no associations between PWV and dialysis modality, adequacy, 
time on renal replacement therapy or biochemical or haematological data. It is difficult 
to interpret a negative correlation between serum corrected calcium and PWV as other 
studies have shown the converse to be true. However a negative relationship between 
PWV and albumin may be due to low serum albumin levels reflecting over hydration 
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leading to vessel dilatation, or may indicate patients with the malnutrition-
inflammation-atherosclerosis complex.  
 
The differences in PWV between patients on various classes of antihypertensive 
therapy, alludes to potential differences between actions of antihypertensive agents on 
central haemodynamics but due to the limited numbers in each group, firm conclusions 
cannot be drawn. One study however has observed beneficial influences on long term 
survival in similar patient groups with ACE inhibitors compared to other agents(317), 
which may reflect beneficial haemodynamic effects. No prospective randomised 
controlled trials exist in this population to confirm this observation. 
 
8.4.7 Limitations of study of PWV with CMR 
Certain limitations of using CMR to measure PWV were highlighted by this study. 
Developing the technique required extensive collaboration to develop the Cardiowarp 
analysis software to measure aortic lengths and and interpret flow curves generated with 
CMR imaging of blood flow in the aorta. Although the results for PWV are broadly 
similar to the findings of other studies of healthy volunteers using either CMR or 
applanation tonometry to measure PWV, PWV in the uraemic patients appears lower 
than found in other studies(303). This was a cohort of uraemic patients being assessed 
for renal transplantation and may be healthier than other cohorts studied in the literature. 
Unfortunately direct comparison of CMR derived PWV with applanation tonometry 
was not possible in the uraemic patients.  
 
Potential sources of error in measurement of PWV include the assessment of aortic 
length. A number of studies were discarded due to unfolding of the aorta taking it out of 
the plane of imaging and therefore not suitable for analysis. Of the scans analysed, 
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although the aorta was entirely visualised in the sagittal plane of imaging, tortuousity of 
the vessel in and out of the sagittal plane used for image acquisition may not have been 
detected. This potentially may have lead to underestimation of aortic length and hence 
PWV.  
 
By assessing flow at three points along the aorta, the technique assumes that all scans 
are acquired at the same time points relative to the cardiac cycle. Although in the 
majority of scans this appears to be the case, this represents a further source of error. 
Additionally the aorta itself is regionally heterogeneous and in terms of its composition 
and hence its viscoelastic properties. Finally, the flow sensitive phase contrast CMR 
images were acquired at a temporal resolution of approximately 15ms. This compares 
poorly to the temporal resolution of Doppler probes typically used for applanation 
tonometry of 10 MHz. 
 
8.4.8 Prognostic implications of CMR studies of vascular function 
Independent predictors of mortality during the follow up period were diabetes, aortic 
distensibilty and systolic blood pressure. Due to their close interdependence, systolic 
blood pressure and aortic distensibilty could not be independently assessed. However 
when a combined end point of  death, non-fatal myocardial infarction, cardiac 
revascularisation, amputation for peripheral vascular disease and cerebrovascular event 
was used, only diabetes and aortic distensibilty or VAS were independent predictors of 
events. Age was not a predictor of outcome in this group of patients. Therefore aortic 
distensibilty or VAS predict outcome whatever age the patient, rather than merely being 
reflective of older uraemic patients having stiffer vessels as demonstrated earlier. In 
keeping with other studies, time on renal replacement therapy was significantly longer 
in those patients who died during the follow up period(303), but this factor was not 
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independently associated with outcome. Therefore in this patient group, aortic 
distensibilty was a predictor of mortality and/or vascular events whatever the age of the 
patient and even if the CMR was performed long after the patient had started renal 
replacement therapy.  
 
8.4.9 CMR measures of vascular function as surrogate markers of cardiovascular 
risk 
As a potentially novel marker of increased cardiovascular risk, no data exist on the 
natural history of progression of aortic distensibilty in uraemic patients, or whether it 
can be improved by therapeutic intervention. The assumption is that reduced aortic 
distensibilty is reflective of arterial calcification. As arterial calcification has been 
demonstrated by electron beam CT to progress in patients on dialysis therapy and be 
related to oral intake of calcium (primarily as calcium containing phosphate 
binders)(143), one strategy to improve aortic distensibilty may be to use non-calcium 
containing phosphate binders such as sevelamer hydrochloride or lanthanum chloride to 
reduce to calcium load whilst controlling serum phosphate. Analogues of inhibitors of 
arterial calcification are in the early stages of development and may be of clinical 
benefit. CMR measures of vascular function, in particular aortic distensibilty, represent 
potentially useful surrogate markers of cardiovascular risk for future trials of such 
interventions.        
 
8.4.10 Assessment of vascular function using CMR 
A variety of studies have attempted to address the role of aortic distensibilty as a marker 
of either cardiovascular risk or relating aortic distensibilty to cardiac performance. Like 
the current study, it appears that CMR measures of arterial function represent attractive 
surrogate markers for intervention for other groups at high risk of cardiovascular 
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disease. Currently data relating CMR measures of arterial function on long term 
outcome are scant and similarly there a few studies to suggest that arterial function 
assessed by this method can be modulated: 
• In otherwise healthy young individuals, obese subjects have been shown by 
CMR to have increased aortic cross sectional area and decreased aortic 
elasticity(318) 
• In patients with either systolic or diastolic heart failure, aortic distensibilty was 
reduced compared to controls and correlated with exercise capacity as assessed 
by peak volume of oxygen consumption at cardiopulmonary exercise 
testing(313) 
• A small study of 33 hypertensive patients demonstrated that aortic distensibilty 
increased in patients following treatment with either nicardipine or alacepril but 
not trichlormethiazide over a 12 week treatment period. This effect appeared to 
be independent of changes in pulse pressure, which did not significantly differ 
between the three groups(319) 
• In Marfan syndrome, where the leading cause of death is aortic dissection, both 
aortic distensibilty and aortic diameter have been shown to be independent 
predictors of progressive aortic dilatation(320). A further CMR study has shown 
that beta-blocker therapy significantly improves aortic distensibilty in these 
patients(321) 
• An interesting pilot study has demonstrated that arterial endothelial function can 
be studied using CMR to by assessing cross sectional flow mediated dilation of 
the brachial artery(316) 
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8.4.11 Other studies using CMR to assess pulse wave velocity 
A small number of studies have used CMR to assess PWV, either validating the 
technique against established methods or comparing the results to clinical characteristics 
of the subjects studied. Generally, studies assessing validation of CMR measures of 
vascular function have focused on measurements in normal volunteers: 
• Rogers et al compared applanation tonometry and CMR measured PWV in 
healthy volunteers across a wide age range. Similar to the current study they 
found that PWV measured with both tonometry and CMR increased with 
age(315) 
• One study in healthy volunteers validated aortic PWV using complex 
mathematical derivation of PWV by alternative methods. This study assumes 
that in young adults, by the time of maximum blood flow, flow direction is 
unidirectional (no reflected waves) and uses fluid dynamic theory to estimate 
PWV from maximum blood flow rates and changes in aortic cross sectional 
area. Although an attractive concept it is unclear how this translates to older 
patients (all subjects were 21-30 years old) as aortic stiffening occurs. The 
scanning protocol used was similar to the current study(312)  
• One CMR study of healthy volunteers demonstrated a close correlation between 
aortic compliance and PWV in the thoracic aorta, and again show significant 
correlations between aortic stiffness and age by both methods (322)  
• PWV assessed by CMR has been show to correlate with age but no other clinical 
parameters in patients with juvenile idiopathic arthritis(314) 
 
8.4.12 Arterial stiffness in uraemia - clinical implications and long term survival  
A large number of studies have been performed assessing both the determinants of 
increased arterial stiffness, measured with alternative methods, and its relation to long 
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term survival in patients with ESRD, using either elastic incremental modulus, PWV or 
augmentation index as markers of arterial stiffness: 
• Factors consistently associated with increased arterial stiffness include age, 
diabetes, and systolic blood pressure (or pulse pressure)(323-325) 
• A number of studies have identified other factors associated with increased 
arterial stiffness including serum calcium or the presence of inflammation 
indicated by C-reactive protein(325)  
• Using electron beam CT, Covic et al have shown that PWV measured with the 
SphygmoCor apparatus correlates with the degree of coronary artery 
calcification, even when corrected for confounding variables such as age and 
duration of renal replacement therapy(193) 
• A number of survival studies from the group of London et al demonstrate that 
PWV is an independent predictor of both all cause and cardiovascular mortality 
in patients on haemodialysis(302;303;326). Interestingly in one of these studies 
in a cohort of 180 dialysis patients followed up for 52 months brachial blood 
pressure was a less impressive predictor of outcome compared to central 
measures of aortic PWV(326) 
 
8.4.13 Conclusions 
This study has demonstrated that vascular function can be measured using CMR in 
uraemic patients. Increase in aortic stiffness, indicated by reduced aortic distensibilty, 
reduced VAS and increased PWV are all associated with risk factors for cardiovascular 
disease including diabetes, previous ischaemic heart disease, peripheral vascular disease 
and advancing age. Although PWV measured by CMR was not associated with long 
term outcome, both aortic distensibilty and VAS were independent predictors of 
combined vascular events and mortality. Aortic distensibilty predicted all cause 
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mortality. It is likely that these derangements in aortic function are due to arterial 
calcification although this requires correlation with conventional methods of assessing 
calcification such as CT scanning. CMR offers a novel non-invasive tool to assess 
vascular function in these patients. Aortic distensibilty and VAS are potential targets for 
therapeutic intervention to reduce cardiovascular risk in uraemia. 
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Chapter 9 
 
 
A study of dermatological complications of contrast enhanced magnetic resonance 
imaging 
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9.1 INTRODUCTION 
The main goal of the studies contained in Chapter 3 was to assess the relationship 
between myocardial tissue abnormalities, indicated by contrast enhanced CMR and 
uraemic cardiomyopathy defined by CMR. Furthermore, these abnormalities were 
shown to predict long term outcome. Therefore, the next intention was to use this 
information to power a prospective study with the goal of either preventing the 
development of myocardial fibrosis or reducing the progression of myocardial fibrosis 
using findings at contrast enhanced CMR as a study end point.  
 
However in April 2006 a case series emerged from Austria postulating a link between 
gadolinium based MRI contrast agents and the development of nephrogenic systemic 
fibrosis (NSF)(327), previously labelled nephrogenic fibrosing dermopathy, in patients 
with advanced chronic kidney disease. This was subsequently followed by a caution 
issued by the United States Food and Drug Administration, regarding the use of 
gadolinium based MRI contrast agents and the development of NSF.  
 
NSF was first identified in 1997 and presents as a scleromyxoedema-like condition 
affecting patients with advanced kidney disease(328). Approximately 200 cases have 
been reported to the NSF registry(329). The clinical manifestations include thickened, 
oedematous, indurated or discoloured skin affecting the limbs and trunk. The face is 
typically spared. Progression may occur over weeks resulting in joint contractures and 
severe restriction of movement.  Multi-organ involvement has been observed and 
mortality is high with death occurring often from sepsis as a complication of immobility 
or hypoventilation if lung and diaphragm involvement occurs(330). 
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Although clinical cases of NSF had been documented prior to the commencement of 
these studies at the hospitals from which the patients were recruited, no causative link 
between gadolinium and NSF had been proven. Whilst this uncertainty existed, future 
contrast enhanced CMR studies were suspended and a retrospective case-control study 
was performed to assess any link between exposure to gadolinium based MRI contrast 
agents and development of NSF. 
 
9.2 METHODS 
 
9.2.1 Identification of patients and MRI data 
A retrospective analysis was undertaken of all prevalent patients on renal replacement 
therapy within the renal units of Glasgow Royal Infirmary and the Western Infirmary 
Glasgow between 1st January 2000 and 1st July 2006 to identify all cases of NSF. The 
computerised electronic patient record (EPR) was interrogated to using the keywords 
“nephrogenic”, “dermopathy”, “fibrosing”, “scleromyxoedema” to identify all cases 
(“fibrosis” and “systemic” were not used as many more cases were generated of 
unrelated conditions such as pulmonary fibrosis or systemic lupus erythematosus 
without identifying further cases of NSF).  Additionally all consultant nephrologists 
working at these two units were asked to forward details of any patients they had cared 
for with NSF. Patients with NSF therefore formed the group of cases. Each case was 
reviewed thoroughly with respect to the clinical history and histopathological records. 
 
As controls all patients undergoing dialysis therapy for established renal failure (defined 
as dialysis dependent for >90 days) at the Western Infirmary, Glasgow over the same 
time period were identified via the EPR.  A search was performed of the radiology 
computer system for all records of magnetic resonance imaging with the number of 
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gadolinium-containing scans and cumulative gadolinium contrast dosage and type 
recorded for each patient. Doses were recorded in the radiology database. Where this 
was unavailable the MRI logbook was checked. Gadolinium exposure was calculated 
over the six and a half-year period for all non-NSF patients and for the period 1st 
January 2000 until the first presentation of disease for all patients in the NSF group. 
Patients who had functioning renal grafts throughout the study period and thus did not 
receive dialysis were excluded during the time they were not on dialysis therapy. 
 
9.2.2 Statistical Methods 
Non-parametric testing (Mann-Whitney-U test) was used to assess differences between 
median doses of gadolinium contrast and total number of gadolinium-enhanced MRI 
between NSF and non-NSF groups. Statistical analysis was performed by SPSS version 
13.0 (SPSS Inc, IL, USA). 
 
9.3 RESULTS 
 
9.3.1 Demographics of patients undergoing renal replacement therapy at the 
Western Infirmary, Glasgow 2000-2006  
A total of 814 patients were identified who had received renal replacement therapy for 
ESRD at the Western Infirmary during the period 01/01/2000 to 01/07/2006.  The mean 
age at starting RRT was 56.5 years and 471 (7.9%) patients were male.  The cause of 
ESRD was diabetic nephropathy in 124 (15.2%), adult polycystic kidney disease in 51 
(6.3%), glomerulonephritis in 168 (20.6%), chronic pyelonephritis in 95 (11.7%), 
renovascular disease in 98 (12.0%), miscellaneous other known causes of ESRD in 65 
(8.0%) and 213 (26.2%) with an unknown or unclassifiable cause of their renal failure.  
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9.3.2 Cases of nephrogenic systemic fibrosis identified in North Glasgow 
A total of 15 patients were identified with a diagnosis of NSF as evidenced by clinical 
and pathological findings noted within the clinical records.  Four cases were identified 
at the Western Infirmary Glasgow and 11 cases at Glasgow Royal Infirmary. 13 of the 
15 cases were biopsy proven. Compared to the control cohort of patients undergoing 
renal replacement therapy for ESRD at the Western Infirmary, patients with NSF were 
significantly younger at the time of starting renal replacement therapy (median age NSF 
group 51.7 vs. non-NSF group 60.9, p= 0.031). A greater proportion of patients who 
developed NSF were female compared to those who did not (NSF group 66.7% female 
vs. non-NSF group 41.9% female, p=0.054). The demographics of patients with and 
without NSF are shown in Table 9.1. At the end of the study period 6/15 (40.0%) of 
patients with NSF had died.   
 
9.3.3 Contrast enhanced magnetic resonance imaging performed during the 
period 2000-2006  
Over the six and a half-year period, 204 (24.7%) of the total 825 patient cohort (NSF 
cases from both hospitals plus controls from the Western Infirmary dialysis population) 
patients underwent a total of 248 gadolinium-enhanced MRI scans. Six (2.4%) of these 
MRIs used gadobenate-dimeglumine  (Multihance, Bracco S.p.A., Milan, Italy) as the 
contrast agent with median dose volume of 15ml.  228 (91.9%) of these scans were 
performed with gadodiamide (Omniscan, GE Healthcare, Chalfont St Giles, UK) with a 
median dose volume of 32ml.  11 (4.4%) scans used gadopentetate dimeglumine 
(Magnevist, Berlex, Canada) as the contrast agent with median dose volume of 15ml, 
and three (1.2%) scans used gadobutrol (Gadovist, Schering, West Sussex, UK) as the 
contrast agent with median dose volume of 15ml. 
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9.3.4 Relationship between exposure to MRI contrast agents and development of 
NSF 
Of the patients who developed NSF only one patient had not been exposed to MR 
contrast (Table 9.2). All other patients who developed NSF had undergone MR 
scanning with gadodiamide used as the contrast agent. None of these patients had been 
exposed to other MR contrast agents. When compared to the 190 patients who had 
undergone contrast-enhanced MR and not developed NSF, the 14 NSF patients were 
found to have been exposed to a significantly higher median dose of gadodiamide-based 
contrast than their non-NSF counterparts (median 51.5ml v 32ml, p<0.001).  
Additionally the median dose of gadodiamide-based contrast used for their first MRI 
scan was significantly higher in patients who developed NSF (45.0 vs. 32ml, p<0.001). 
There was additionally a significantly greater number of MRI scans performed on 
patients who developed NSF (median of two scans per patient in the NSF group and one 
per patient in the non-NSF patients, p<0.001). The frequency of performance of 
contrast-enhanced MR examinations steadily increased over the study period as shown 
in Figure 9.1 with the cumulative numbers of diagnoses of NSF following a similar 
trend. 
 
9.3.5 Characteristics of patients who developed nephrogenic systemic fibrosis 
The baseline demographics and outcome for the patients who developed NSF is 
displayed in Table 8.2. Other than exposure to MR contrast in all but one patient, there 
were no consistent recurrent clinical features present in all these patients, either in terms 
of underlying renal diagnosis, time on dialysis, concurrent medication or co-morbidity 
(data not shown). The median time period from MRI scan to diagnosis of NSF was 70 
days with an interquartile range of 313.5 days. Although one patient (Patient 5) had a 
time interval of 2395 days between first MRI scan and onset of symptoms of NSF, a 
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second MRI was performed after development of skin changes. As a retrospective study 
it is not clear what, if any, exacerbation was related to the first or second scan. Skin 
biopsy was performed after the second scan in this patient. Six patients died during the 
follow up period, one patient spontaneously regained renal function sufficiently to 
discontinue dialysis (Patient 6) and one patient has undergone cadaveric renal 
transplantation (Patient 12). The patient who has regained renal function has also been 
treated with photophoresis therapy and has experienced improvement but not resolution 
in her skin condition. One patient (Patient 15) has been treated with immunosuppression 
(prednisolone and sirolimus) and at the time of data collection this has been poorly 
tolerated and has not led to any dermatological improvement. 
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Characteristic Non-NSF NSF p 
Number of patients 810  15  - 
Age at start of RRT 60.9 (28.8) 51.7 (20.9) 0.031 
Male (%) 471 (58.1) 5 (33.3) 0.054 
Diagnosis  (%)      
 Diabetes  124 (15.4) 4 (26.7) - 
 APKD 51 (6.3) 1 (6.7) - 
 GN 161 (20.0) 5 (33.3) - 
 CPN 94 (11.7) 3 (20.0) - 
 Renovascular 98 (12.2) 0 (0.0) - 
 Other 63 (7.8) 0 (0.0) - 
 Unknown 213 (26.5) 2 (13.3) - 
Number undergoing MRI 190 (23.5) 14 (93.3) <0.001 
Mortality at end of study period 405 (50.0) 6 (40.0) 0.604 
 
 
Table 9.1. Clinical characteristics of the complete of cohort of patients comparing those 
with and without a diagnosis of NSF. All variables expressed as value (%) expect age 
expressed as median and interquartile range.   
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Figure 9.1 
Graph displaying the cumulative number of contrast enhanced MRI scans performed in 
this cohort of patients – left axis (black) with the cumulative frequency of diagnosis of 
nephrogenic systemic fibrosis displayed - right axis (red) 
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CASE 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 
Sex M F M F M F F M F F M F F F F 
Primary diagnosis U CPN DM GN DM GN U U AP CPN DM CPN GN GN GN 
Skin biopsy Y Y Y Y Y Y Y N Y Y Y Y N Y Y 
Age at diagnosis (years) 63.2 61.0 43.5 54.3 67.1 49.0 63.7 43.7 37.7 20.5 60.4 58.5 59.8 73.2 50.50 
Age starting RRT (years) 61.6 56.6 42.4 22.2 67.0 49.0 56.7 38.9 35.1 17.0 59.9 51.7 59.1 66.2 48.97 
Time on RRT (years) 1.6 4.4 1.1 32.1 0.1 0.0 7.0 4.8 2.6 3.5 0.5 6.8 0.7 7.0 1.53 
RRT modality PD HD HD HD HD HD HD HD HD HD HD HD PD HD PD 
MRI Y Y Y N Y Y Y Y Y Y Y Y Y Y Y 
MRI-NSF time (days) 76 83 477 - 2395 35 2 4 16 52 64 289 99 441 6 
Previous MRI 2 2 1 - 1 1 3 1 1 2 1 1 2 5 0 
MRI post NSF 1 3 0 - 1 1 1 1 0 3 0 0 1 1 0 
HCO3 (mmol/l) 22 24 26 25 18 28 18 36 17 25 23 26 29 21 28 
Treatment - Ph - - Ph - - - - - - - - - Im 
Renal function - - - - - Sp - - - - - Tx - - - 
Outcome S I M M S I M M N/A M M S S N/A D 
Table 9.2 Baseline characteristics of NSF cases. Abbreviations: M - male; F - female; U - unknown; CPN - pyelonephritis; DM - diabetes mellitus; GN - glomerulonephritis; AP - adult 
polycystic kidney disease; Y - yes; N - no; Time on RRT - at diagnosis with NSF; RRT modality - at the time of NSF diagnosis; PD - peritoneal dialysis; HD - haemodialysis; MRI-NSF 
time - time interval between gadolinium-enhanced MRI and NSF onset; Previous MRI - total number of MRI scans prior to NSF diagnosis; MRI post NSF - number of MRI scans 
performed after a diagnosis of NSF; HCO3 - serum bicarbonate level within 30 days of MRI; Ph – photophoresis; Im – immunosuppression; -  no change; Sp - spontaneous improvement; 
Tx - renal transplant; Outcome - of NSF; S - stable; I - improved; M - dead; D  – deteriorating; N/A - not applicable/follow up time too short for comment. 
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9.4 DISCUSSION 
 
9.4.1 Results of this study 
These data support an association between the use of the gadodiamide-based contrast 
agent (Gd-DTPA-BMA, Omniscan) and the development of nephrogenic systemic 
fibrosis. Patients who developed NSF were exposed to higher initial and subsequent 
doses of gadodiamide than those who did not and additionally underwent more contrast 
enhanced MRI scans.  However one patient developed NSF without ever undergoing 
contrast enhanced MRI scanning suggesting that gadodiamide is not the sole cause of 
NSF. Conversely although 6.6% in this cohort of ESRD patients undergoing MRI 
scanning with gadodiamide developed NSF, cases of NSF were over-represented in this 
group by including cases from two hospitals (Western Infirmary, Glasgow and Glasgow 
Royal Infirmary) but only using a control group of a cohort of patients on renal 
replacement therapy from one hospital (Western Infirmary, Glasgow). This approach 
was used to ensure accuracy of the data collected regarding contrast agents used for 
MRI scanning. If the entire dialysis population from each centre was selected then there 
would be a prevalence of 15 cases for a total of 1826 patients on maintenance dialysis. 
Between both centres 425 contrast enhanced MRI scans were performed, giving an 
incidence of NSF of 3.5% in patients with ESRD who have undergone previous MRI 
scanning.  
 
None of the alternative gadolinium based contrast agents were associated with the 
development of NSF suggesting that it may be properties of the chelating molecule or 
an interaction between the gadolinium chelate and the uraemic milieu that leads to 
development of NSF. Based on these findings, caution should be used in future before 
using gadolinium based contrast agents in the ESRD population, both by reducing the 
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dose of contrast used and by focusing on strategies to minimize exposure to the 
gadolinium chelate compound.   
 
9.4.2 Pathogenesis of nephrogenic systemic fibrosis 
Currently the pathogenesis of NSF remains unclear. Approximately 90% of patients 
with the condition are established on dialysis therapy. The condition has been described 
in both patients receiving haemodialysis and peritoneal dialysis and no one underlying 
renal disease, dialysis technique; manufacturer, dialysate or dialysis unit has been 
consistently associated with NSF(331). Hypercoagulable states have been reported in 
NSF including patients experiencing deep vein thrombosis and pulmonary embolus as 
well as thrombosed dialysis access (both femoral grafts and arteriovenous fistula). 
These have not been a universal finding(332). Other associated findings reported in 
patients with NSF have included underlying liver disease, most commonly, hepatitis B- 
or C-induced cirrhosis(333). The significance of any of these associations is unclear but 
suggests that vascular injury or thrombosis may set in motion a process of aberrant 
processes akin to early wound healing, leading to abnormal collagen deposition. 
 
More recently the spindle cells present in the dermis of patients with NSF has been 
demonstrated to be a CD34-postive dendritic fibroblast, giving rise to the concept of a 
‘circulating fibrocyte’ of bone marrow origin migrating from the circulation to the 
dermis and differentiating into cells which histologically resemble dermal 
fibroblasts(334). These circulating cells suggest that NSF is a systemic disorder. The 
trigger for the migration and differentiation of these CD34-postive fibrocytes is not 
clear but thrombosis and/or endothelial injury are possibly responsible. 
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9.4.3 Clinical features of nephrogenic systemic fibrosis 
The cutaneous features of NSF include skin-coloured to erythematosus papules which 
classically coalesce to the characteristic brawny plaque with peau d’orange surface 
changes. The skin becomes marked thickened with a woody texture. The condition 
usually follows a symmetrical distribution involving the limbs and trunk, most typically 
between the ankles and mid-thighs and wrists and upper arms. The face is usually 
spared(332). Patients may complain of pain in the affected areas. Arthritis is not seen 
but joint contractures may develop over a time course of weeks. Loss of function is 
extremely common and patients may become wheelchair bound. 
 
Although the condition was initially thought to be confined to the skin, systemic 
involvement has been described including diaphragmatic and pleural involvement 
indicated by hypoventilation and reduced gas transfer as well as pericardial and 
myocardial disease manifest as cardiomyopathy and arrhythmia(330). The natural 
history of the disease is not yet well understood. Some patients report a gradual 
improvement in mobility and slight softening of the skin over time, either spontaneously 
or in response to therapy. Complete spontaneous healing in a patient with ongoing 
kidney disease has not yet been reported. Some patients with NSF (approximately 5% 
or less) have an exceedingly rapid and fulminant disease course that may result in death.  
 
9.4.4 Histological findings in nephrogenic systemic fibrosis 
As the disease extends into the subcutaneous fascia a deep biopsy specimen is required. 
Characteristic biopsy findings include increased cellularity in the dermis and in the 
subcutaneous septa. This increased cellularity consists of dermal spindle-cell 
proliferation (CD34-postive) with variable mucin deposition and little inflammation; 
occasional multinucleated giant cells, elongated elastic fibres, and dystrophic 
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calcification. An Alcian blue stain is often used to highlight the increased deposition of 
acid mucin in the dermis(335). Histological features of NSF are demonstrated from a 
skin biopsy of one of the patients in this study in Figure 9.2. In keeping with the concept 
of NSF as a deranged process of aberrant wound healing increased expression of 
transforming growth factor β1 has been demonstrated in the affected skin and 
muscle(336).  
 
Differential diagnoses of NSF include scleromyxoedema, eosinophilia–myalgia 
syndrome, eosinophilic fasciitis, systemic sclerosis/morphea, porphyria cutanea tarda, 
fibroblastic rheumatism, Spanish toxic oil syndrome, vinyl chloride exposure and β2-
microglobulin amyloidosis.  
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Figure 9.2  
NSF lesions showing normal epidermis, thick collagen bundles with numerous clefts and 
plump fibroblast-like cells, and Alcian blue staining. Photograph courtesy of Dr Michael 
Edward, University of Glasgow 
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9.4.5 Postulated triggers for the development of nephrogenic systemic fibrosis 
As endothelial or vascular injury has previously been implicated in the pathogenesis of 
NSF a number of case reports have suggested a temporal relationship between vascular 
insults, either operations or thrombotic events, and development of NSF. Approximately 
15% of patients report a surgical procedure (other than renal or hepatic transplantation) 
immediately antecedent to the onset of NSF. If transplantation is included, the 
percentage climbs to 48%. Inclusion of formation of dialysis fistula and central dialysis 
catheter placement increases the total of patients experiencing a vascular intervention 
prior to development of NSF approximately 90%. However this finding must be 
interpreted in the context that vascular interventions are extremely common in patients 
with ESRD, irrespective of their NSF status(332).  
 
An alternative proposal has suggested that erythropoietin therapy may be implicated in 
the pathogenesis of NSF. Patients with NSF have been observed to have been treated 
with higher doses of erythropoietin(337). Whether this suggests a common aetiological 
link between erythropoietin resistance (due for example to chronic inflammation) and 
NSF is not clear. Erythropoietin resistance may indicate bone marrow fibrosis as part of 
the NSF syndrome, although this has not been demonstrated in clinical practise. 
Moreover high-level exposure to erythropoietin may contribute to the disease by 
increasing numbers of circulating haematopoietic stem cells and endothelial progenitors 
(and hence CD34-postive circulating fibrocytes). Erythropoietin has also been shown in 
vivo to trigger an exaggerated fibrin induced wound-healing response that is 
histologically similar to NSF(338). However it will be almost impossible to determine 
the role, if any, of erythropoietin in the development of NSF. 
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9.4.6 Pharmacokinetics of gadolinium based contrast agents in end stage renal 
disease 
Gadodiamide (Gd-DTPA-BMA; Omniscan) is distributed in the extracellular fluid and 
entirely excreted from the body through the kidneys by glomerular filtration, with an 
elimination half-life in normal renal function of 80–100 min. Therefore this compound 
gadolinium is excreted from the body as a complex, i.e. unchanged from the 
administered form. 98% of administered gadodiamide is excreted at 24 hours in normal 
renal function)(339). A number of small studies have been performed to assess the 
pharmacokinetics of gadolinium based contrast agents in end stage renal disease: 
• In patients with severely reduced renal function (glomerular filtration rate 2-
10ml/min, not on dialysis therapy), the elimination half-life of gadodiamide 
injection is prolonged (34.3 hours +/- 22.9). In the same group of studies 65% of 
the gadodiamide injected was eliminated during a haemodialysis session(340) 
• In another study using gadopentetate dimeglumine (Gd-DTPA; Magnevist) the 
average excretory rates of the total administered agent was 78.2%, 95.6%, 
98.7% and 99.5% in the first to fourth hemodialysis sessions, respectively(341) 
• Peritoneal clearance appears to much less efficient for removal of gadodiamide. 
Of the studies available it appears that approximately 69% of the gadodiamide is 
excreted over a 22 day period(340) 
• One concern with gadodiamide compared to the other contrast agents relates to 
the risk of transmetallation. Gadodiamide has excess chelate compared to the 
other agents and is theoretically less stable with a higher risk of transmetallation 
resulting in release of toxic free Gd3+. Transmetallation has not been observed in 
these pharmacokinetic studies in ESRD patients and its role in development of 
NSF is unproven(342) 
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9.4.7 Adverse effects of gadolinium based contrast agents in end stage renal 
disease  
Common side effects following administration gadolinium based contrast agents include 
headache, nausea, taste disturbance and urticaria. Typically with gadodiamide the 
incidence of these side effects is approximately 2% for headache and <1% for all other 
effects. As the excretion is delayed these side effects are likely to be exacerbated in 
renal impairment. Anaphylaxis is a rare occurrence. 
• Reports of nephrotoxicity in patients with advanced renal impairment exist with 
gadolinium based agents. Nonetheless the risk of precipitating dialysis is rare 
and serum creatinine usually returns to baseline. Risk factors for developing 
gadolinium induced nephrotoxicity include a lower glomerular filtration rate at 
baseline and diabetes(343;344) 
• Massive life threatening free iron mobilisation has been reported in an ESRD 
patient with biochemical iron overload following administration of Gd-
DTPA(345) 
• Pseudohypocalcaemia is commonly observed following administration of 
gadolinium based contrast agents due to gadolinium’s interference with the 
colorimetric assays used to measure serum calcium. Serum calcium is normal 
when measured by mass spectrometry. This effect is prolonged in renal 
impairment(346) 
 
9.4.8 Relationship between gadolinium based contrast agents and nephrogenic 
fibrosing dermopathy 
A link between gadolinium based contrast agents, in particular gadodiamide, and NSF 
was first postulated in April 2006 by Grobner(327), with further subsequent reports 
emerging from Denmark(347). To date only gadodiamide has been implicated with 
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NSF. The findings of the current study are entirely in keeping with these observations 
and extend this association by demonstrating a dose dependent relationship and 
indicating a theoretically risk of developing NSF following administration of 
gadodiamide of approximately 3.5%. The first report postulating this link suggested that 
acidosis was a prominent feature at the time of MRI scanning in patients who developed 
NSF. This has not been observed in subsequent studies and was not the case in the 
current study. 
 
Two recent studies using spectroscopy have been able to demonstrate the presence of 
gadolinium particles in the skin of patients with NSF(348;349). However gadolinium 
particles were not present in the skin of all affected patients. Therefore these studies, 
along with this work, strengthen the epidemiological association between gadolinium 
based contrast agents and development of NSF but do not provide causation or a 
mechanism for its pathogenesis. The authors speculate that gadolinium retained in tissue 
is phagocytosed by macrophages and this intracellular gadolinium results in the up 
regulation of profibrotic cytokines and/or growth factors that ultimately eventuate in 
dermal or systemic fibrosis. 
 
9.4.9 Treatment of nephrogenic systemic fibrosis 
No consistently successful treatment for NSF has emerged. Various therapies have been 
tried including oral and topical corticosteroids, thalidomide, ultraviolet therapy, 
plasmapheresis and intravenous immunoglobulins. Isolated reports suggest that some of 
these interventions are beneficial in individual cases(350). Extracorporeal photophoresis 
has been advocated most widely with a number of reports published to suggest 
benefit(333;351). Whether this is due to a direct effect on the circulating fibrocyte is 
speculative. Restoration of renal function, whether by treatment of the underlying renal 
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disease or by renal transplantation is likely to be of benefit as impaired renal function is 
one consistent finding in all patients with NSF. 
 
9.4.9 Conclusions 
This study has confirmed an association between used of gadodiamide as a MRI 
contrast agent and development of NSF.  This relationship appears to be dose related 
and development of NSF occurs following the demonstration of gadodiamide and is 
exacerbated by multiple further exposures. Based on these findings, in combination 
other studies, gadodiamide should no longer be considered safe for use in patients with 
advanced chronic kidney disease or patients with established ESRD. If there is no 
alternative to its use, the lowest diagnostic dose should be used and prompt dialysis 
after the scan to remove the gadodiamide. It is not clear is alternative gadolinium based 
agents are safe or it the preponderance of cases of NSF related to gadodiamide merely 
reflect that this agent accounts for >90% of the scans performed. Use of contrast 
enhanced CMR as a tool for future research in this population has been jeopardised by 
the finding of the association between NSF and gadolinium based contrast agents. 
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Chapter 10 
 
 
General discussion and conclusions 
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10.1 Definition of uraemic cardiomyopathy with cardiac magnetic resonance 
imaging 
The principal aim of this project was to determine whether a cardiomyopathy, specific 
to uraemia could be described in vivo using CMR. The chief method used to investigate 
this was using the contrast agent gadolinium-DTPA-BMA. A further question was to 
unravel the relationship between ischaemic heart disease (or coronary artery disease) 
and uraemic cardiomyopathy. Contrast enhanced CMR allowed the identification of 
myocardial infarction, thereby allowing a clear distinction between the presence of 
cardiomyopathy potentially related to uraemia and that where the major determinant 
was premature coronary artery disease. 
 
The results contained in Chapter 3 demonstrate two distinct pathological processes or 
subtypes of uraemic cardiomyopathy. Firstly, the presence of left ventricular systolic 
dysfunction is closely associated with subendocardial late gadolinium enhancement, in 
keeping with previous myocardial infarction. This is in keeping with the aetiology of 
the majority of cases of left ventricular systolic dysfunction in the general population. 
The one feature specific to uraemia in this setting is that the progression of coronary 
artery atherosclerosis is accelerated in uraemia, leaving patients with ESRD vulnerable 
to future myocardial ischaemia. Second, and specifically to uraemia, diffuse LGE 
representing fibrosis through the left ventricular myocardium was observed in some, but 
not all, patients with left ventricular hypertrophy. There were no precedent reports of 
this finding, but this observation is in keeping with histopathological studies of cardiac 
tissue in uraemia. Since these findings have been published, a number of authors have 
commented on the novelty of this observation using CMR, which appears to 
demonstrate a further strength of this technique(352;353).  
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10.2 Long term implications of uraemic cardiomyopathy and other 
cardiovascular risk factors in uraemia 
Both subtypes of uraemic cardiomyopathy described with contrast enhanced CMR 
appeared to be associated with poorer survival. However using the conventional 
definitions of cardiomyopathy with left ventricular function or dimensions, neither LVH 
nor left ventricular systolic dysfunction were demonstrated to be independently 
associated with poor outcome, although there was a trend towards poorer survival with 
left ventricular systolic dysfunction. This may relate purely to small sample size of the 
cohort of patients. By contrast with other similar studies, all these patients were being 
considered for renal transplantation, and may have by definition been fitter, with less 
severe cardiac abnormalities than studied in other cohorts(75-77). A centre or era effect 
is possible, where patients with left ventricular hypertrophy are less likely to experience 
a premature cardiovascular event in the first decade of the twenty-first century 
compared to the last decade of the twentieth.  In the West of Scotland, with such a high 
rate of coronary artery disease, patients with only left ventricular hypertrophy, without 
coronary artery atherosclerosis, may be relatively protected from cardiovascular events 
compared to the rest of the population, although this seems unlikely. Survivor bias may 
be present in patients who survive to commence dialysis therapy as the majority of 
patients with cardiovascular disease and renal impairment will die of cardiovascular 
disease before requiring dialysis. Ultimately it is less clear, why in this cohort of 
patients, the presence of uraemic cardiomyopathy, detected by cardiac morphology 
appeared to have less of an impact on survival than expected.  
 
The outcome studies contained in Chapter 6, observed that the greater determinants of 
long term outcome were conventional risk factors such as age, diabetes and presence of 
ischaemic heart disease. Clearly the ability to receive a renal transplant, the only 
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definitive treatment to reverse uraemia, improves survival, but there is an inevitable 
selection bias, in choosing relatively fitter patients for transplantation. One practical 
application emerged by studying this cohort of patients. An objective method of 
documenting functional capacity using an exercise tolerance test conveys useful 
prognostic information for long term prognosis. This may help indicate which patients 
at much higher risk, who still require invasive investigations with angiography, and in 
whom further cardioprotective strategies may be contemplated, e.g. beta blockade, anti-
platelet therapy or statins. Unfortunately, an evidence base for many of these 
interventions is still lacking in this patient group. 
 
10.3 Investigation of vascular function in uraemia using cardiac magnetic 
resonance imaging 
At the point of inception of the series of all the studies contained within this project, 
CMR was still a relatively new technique. Although clearly an attractive method for 
studying vascular function, there were very limited data published on the use of CMR 
for assessing vascular function as part of integrated cardiovascular risk assessment in 
any patient population(315;316). As there is a well established link between 
cardiovascular outcome and arterial stiffness, studied with alternative 
methods(302;303), in patients with ESRD; this appeared to be an ideal cohort to 
develop this technique with.  
 
The studies contained within Chapter 8 clearly demonstrate arterial stiffness is distorted 
in ESRD compared to normal individuals, and is further reduced by the presence of 
additional cardiovascular risk factors, superimposed upon uraemia. Interestingly, both 
parameters for measuring aortic stiffness, aortic distensibilty or aortic volumetric 
arterial strain, were independent predictors of cardiovascular events in these patients. 
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This finding requires further exploration. One hypothesis would suggest that long term 
dialysis patients have acquired extremely stiff vessels, which may not be amenable to 
intervention with corrective therapy. Study is required to identify ESRD at highest risk 
of developing reduced arterial stiffness, perhaps using circulating markers of either 
calcification or atherosclerosis, such as fetuin-A, osteprotegerin, homocysteine or 
matrix Gla protein(130;310;311).  
 
10.4 Nephrogenic systemic fibrosis- a devastating new disorder in uraemic 
patients 
The identification of a link between CMR contrast agents, in particular gadolinium-
DTPA-BMA, and nephrogenic systemic fibrosis was an unexpected and catastrophic 
event. Of the patients in this study, as far as can be identified, no patient who developed 
NSF received an isolated MRI scan for research purposes, with patients with NSF 
undergoing multiple scans, particularly for planning vascular access for dialysis or to 
image large vessels to assess peripheral vascular disease. Further reports of the 
association of this condition with gadolinium containing contrast agents have emerged. 
Currently, there are no plans to restart research based MRI scanning in ESRD patients 
using gadolinium based contrast agents until this issue is resolved.  
 
10.5 Limitations of these current studies 
One major goal of this study was to identify the relationship between CMR findings, 
particular LGE and arrhythmia and sudden cardiac death. As part of the initial 
investigation, a 24-hour ambulatory ECG monitor recording was proposed in all 
patients, with the intention of studying minor rhythm abnormalities(78). Unfortunately 
for technical reasons this was not possible, leaving an unexplored gap between CMR 
findings and arrhythmia. Similarly, although details on cardiovascular events, hospital 
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admissions and mortality were collected from the renal electronic patient records, 
causes of death and cardiovascular event data were not collected. Where this data is 
included it is verified information. Potentially this information is available for all 
subjects, but was deemed too costly to collect, following discussions with the 
administrative group of the Scottish Renal Registry, who in turn can access records held 
by the Information Services of the National Health Service for Scotland. 
  
Vascular function studies would have been improved by detailed correlation with 
measures of vascular function using established methods such as the SphygmoCor 
system, particularly in the ESRD cohort. This was not technically feasible due to the 
geographical location of the examination room used for SphygmoCor examination. 
When piloted on a number of ESRD patients, it was reported to require too long a 
session to make to the study day an acceptable duration to retain patient comfort. One 
solution would have been to perform SphygmoCor examination on a separate occasion 
from CMR, but as vascular dimensions are dependent on hydration status, this may have 
lead to inaccuracies in the correlation between the various methods.  
 
10.5 Cardiac magnetic resonance imaging- a novel surrogate end point for 
clinical trials in end stage renal disease? 
As discussed previously, CMR is ideally placed as an end-point for trials assessing left 
ventricular remodelling both in the ESRD and in other populations(354). Methods to 
reduce left ventricular hypertrophy include drug therapy, alterations to the dialysis 
schedule or minimising the haemodynamic instability of dialysis with techniques such 
as haemodiafiltration. Methods such as haemodiafiltration are attractive as they may 
increase clearance of ‘uraemic factors’ responsible for promotion of left ventricular 
growth.  Additionally measures of vascular function could be studied in using CMR, 
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using interventional strategies to reduce arterial stiffness, such as calcium free 
phosphate binders. 
 
10.6 Future work with cardiac magnetic resonance in end stage renal disease 
The initial findings of these studies demonstrating the presence of diffuse LGE as a 
clear marker for uraemic cardiomyopathy along with the suggestion that it may be a 
marker for patients at risk of sudden cardiac death, suggested that a clinical trial aimed 
at either preventing the development or progression of cardiac fibrosis in ESRD would 
be desirable, using the presence and extent of diffuse LGE as an end point. Therapeutic 
agents which have negative effects on myocardial fibrosis, which were proposed, 
include angiotensin receptor blockers(355), or an aldosterone antagonist such as 
spironolactone or eplerenone, which may oppose the direct effect of aldosterone in 
promoting myocardial fibrosis(356).  
 
Similarly from a clinical perspective, the ability to non-invasively detect functionally 
significant coronary artery stenosis using stress perfusion CMR is extremely attractive. 
This technique would be ideal for indicating which patients require coronary 
angiography as part of work up for renal transplantation, as well as helping to plan 
coronary revascularisation in patients with critical coronary stenosis. One recent study 
had demonstrated that CMR was able to distinguish haemodynamically relevant from 
non-relevant coronary lesions, delineated by the use of fractional flow reserve at 
angiography, with a high sensitivity and specificity(357). A prospective trial to assess 
stress perfusion CMR in patients being assessed for renal transplantation was planned, 
comparing findings at CMR with angiography. Unfortunately, with the emergence of 
the link between gadolinium and nephrogenic systemic fibrosis, all plans to perform 
prospective trials using gadolinium contrast were halted.  
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One CMR application which is likely to provide further insight into myocardial 
metabolism in uraemia is phosphorous-31 magnetic resonance spectroscopy (31P-MRS). 
This does not require a contrast agent. By analysing left ventricular high-energy 
phosphates the derived phosphocreatine/adenosine triphosphate ratio can be calculated 
which indicates the energy metabolism and the phosphate potential (energy charge) of 
the myocardium. In a cross sectional pilot study, uraemic patients had higher LV mass, 
lower phosphocreatine/adenosine triphosphate ratio in compared to patients with a 
kidney transplant and healthy controls(204). The prognostic implications of these 
findings are unclear, but this may be an attractive target for intervention, with the goal 
of improving myocardial metabolism.   
 
Identifying vulnerable coronary artery plaque has in patients with coronary artery 
disease has been an area of intense research with CMR. As the coronary arteries are 
difficult to image due to motion artefact, the carotid arteries offer the most easily 
accessible site for non-invasive assessment of atherosclerotic disease. Assessment of 
atherosclerotic plaque anatomy, size and characterisation by MR is based on the signal 
intensities and morphological appearance of the plaque on T1-weighted, proton dense-
weighted and T2-weighted sequence. Current level of resolution on MRI allows the 
assessment of the composition of the carotid atherosclerotic plaque, between fibrous 
tissue, lipid and necrotic core, calcium, haemorrhage, thrombus, and the state of the 
fibrous cap, based on their different signal intensities(358). This technique would be 
applicable to study in patients with ESRD, where it is not clear if rates of cardiovascular 
events are related to the stability of the atherosclerotic plaque, or the subsequent 
haemodynamic effects which follow plaque rupture and thrombosis, occluding a less 
compliant vessel, where compensatory reperfusion may be harder to achieve. CMR can 
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additionally assess plaque progression or regression with time and in response to 
therapy(359).  
 
Finally, there has been a great deal of interest in the use of ultrasmall superparamagnetic 
particles of iron oxide to label macrophages within the vulnerable atherosclerotic 
plaque. Accumulation of these particles in macrophages in predominantly ruptured and 
rupture-prone human atherosclerotic lesions has been demonstrated in the vessels of 
patients undergoing carotid endarterectomy using CMR(360). Whether this technique is 
safe in ESRD patients is unknown. 
 
10.7 Interventions to reduce cardiovascular risk in end stage renal disease 
There remains a pressing need to reduce the risk of future cardiovascular events in 
patients with ESRD. One clear goal which, although is not currently evidence based is 
likely to benefit all patients is the aggressive treatment of cardiovascular risk factors in 
patients with less severe chronic kidney disease, who do not yet (and may never) require 
dialysis therapy. At this point, these risk factors may still be reversible, and therapies 
directed at treating hypertension, hypercholesterolaemia, smoking and lifestyle are 
likely to reduce both cardiovascular risk and progression of renal disease. This strategy 
has been adopted in the United Kingdom with the advent of initiatives aimed at 
improving management of patients with less severe degrees of chronic kidney disease in 
primary care(361). 
 
Once patients have been established on dialysis therapy randomised placebo-controlled 
clinical trial data on the efficacy of cardioprotective medications patients are sparse. 
Cice et al in a prospective trial, demonstrated the benefits of beta blockers in dialysis 
patients with dilated cardiomyopathy showing improved 2-yr survival with 
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carvedilol(362). Using angiotensin converting enzyme inhibitors, the Fosinopril in 
Dialysis (FOSIDIAL) trial however was unable to show a reduction in cardiovascular 
events with fosinopril in 397 dialysis patients(363), although a smaller Japanese trial of 
80 patients found a reduction in mortality with the angiotensin receptor blocker 
candesartan(364). Larger randomised clinical trials to assess the efficacy and safety of 
cardioprotective agents for primary prevention of cardiovascular morbidity and 
mortality (including cardiac arrest) in ESRD patients would be welcome, but their 
design and implementation may be fraught with difficulty both in terms of scale and 
logistics. Many physicians find it hard to withhold beta blockers in patients already 
considered at such high vascular risk, whilst other nephrologists point to better survival 
in centres where patients are maintained with long dialysis schedules and minimal use 
of anti-hypertensives, including beta blocking medication(19).  The evidence, where it 
exists, for lipid lowering therapy in ESRD remains unclear. Although the 4D study 
showed no benefit in treating diabetic dialysis patients with atorvastatin compared to 
placebo(36), further large prospective randomised controlled trials of lipid lowering 
therapy in advanced- or end stage renal disease, such as AURORA (A study to evaluate 
the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of 
survival and cardiovascular events) and SHARP (Study of Heart and Renal Protection) 
will report in the next two to five years(365;366). 
 
Perhaps, rather than targeting conventional cardiovascular risk factors, trialling 
therapeutic interventions at calcium-phosphate imbalance or hyperparathyroidism, may 
be a more appropriate approach in ESRD. Already, it has been demonstrated that using 
sevelamer carbonate compared to calcium containing phosphate binders results in less 
coronary calcification with a possible mortality benefit(143;148). The treatment of 
secondary hyperparathyroidism with the calcimimetic cinacalcet leads to significant 
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improvements in biochemical parameters but patient-based benefits have not yet been 
demonstrated in trials(367). Potentially this agent may yet have benefits by 
counteracting the adverse cardiovascular effects of parathyroid hormone in uraemia. 
 
Finally, in patients with a history of cardiac arrest or left ventricular systolic 
dysfunction, there is growing evidence that implantable cardiac defibrillators improve 
survival(96).  A primary prevention trial of implantable cardiac defibrillators for the 
prevention of sudden cardiac death in ESRD may be theoretically feasible, particularly 
among dialysis patients with left ventricular ejection fraction <35% who comprise a 
high-risk population for sudden death. Potentially the microwave T-wave alternans test 
may used as a method to identify high-risk patients who would require an implantable 
cardiac defibrillator and also classify a low-risk group unlikely to benefit from ICD 
therapy(368). 
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10.8 CONCLUSIONS 
• Cardiovascular disease is the leading caused of death in patients with chronic 
renal failure, both prior to commencing dialysis and on renal replacement 
therapy. The incidence is several times greater than that of age matched 
individuals from the general population 
• Increased risk of cardiovascular disease in this population is related to both 
changes in cardiac structure and function, as well as to alterations in the major 
blood vessels 
• CMR is the current optimal method for assessing cardiac morphology and 
function as well as interrogating myocardial tissue abnormalities 
• Although previous reports suggest uraemic cardiomyopathy is a combination of 
left ventricular hypertrophy, dilatation and systolic dysfunction, studies in this 
thesis suggest that there are two main forms of uraemic cardiomyopathy; left 
ventricular hypertrophy is the cardiomyopathy specific to uraemia whilst left 
ventricular systolic dysfunction reflects underlying coronary artery disease. 
Studies in this thesis have demonstrated the presence of diffuse myocardial 
fibrosis in the presence of left ventricular hypertrophy 
• Echocardiography appears to overestimate left ventricular mass compared to 
CMR in this population 
• Although uraemic cardiomyopathy does have an impact on long term survival in 
this patient cohort, conventional cardiovascular risk factors such as advanced 
age, diabetes and a history of ischaemic heart disease confer poorer survival, 
whilst receiving a renal transplant is likely to be protective for future 
cardiovascular events 
• Serum brain natriuretic peptide, whilst elevated in patients with evidence of 
uraemic cardiomyopathy does not appear to a sensitive or specific enough 
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biomarker to be used as a diagnostic aid in this patient group and conveys little 
prognostic value 
• Arterial function measured as aortic distensibilty using CMR is a powerful 
independent predictor of future cardiovascular events 
• There appears to be a link between the use of some gadolinium containing CMR 
contrast agents and development of nephrogenic systemic fibrosis, a potentially 
fatal condition, characterised by skin thickening, pain and immobility 
• Both left ventricular hypertrophy and arterial stiffness measured by CMR are 
potential targets for intervention to reduce cardiovascular risk in patients with 
ESRD. Future work to is required to assess whether it is possible to modify 
arterial stiffness in these patients in which case this parameter may be used as  a 
surrogate marker for treatments to reduce cardiovascular events in this high risk 
group 
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